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Preface
Prevention is one of the first approaches to be mentioned when public debate and policy address 
drug use and drug-related problems. Regularly, measures of prevention are presented as a means to 
overcome existing or future problems. However, evidence of ‘what works’ in practice is often 
overlooked. Similarly, research has shown examples where preventive efforts produced no or 
detrimental effects.
This publication will help steer efforts in the right direction. Using an empirically derived reference 
framework, it bridges the gaps between science, policy and practice. Based on an overview of 
existing standards in Europe and beyond, a number of highly respected experts from EU Member 
States and international organisations worked together to prepare the publication. More than 400 
national experts and stakeholders were included in a Delphi panel study and in a number of focus 
groups, which produced in-depth discussions as well as a consensus on the most important 
recommendations. The European Commission provided the funding for the original project on 
prevention standards and its results are now published within the EMCDDA Manuals series.
In this series, information, advice, and guidance are offered to professionals and practitioners. Well 
structured and with many useful tables and figures, this publication will help its users as they progress 
from a first needs assessment to the delivery of an intervention and its final evaluation. Correct 
implementation of prevention measures with evidence-based components and anchoring them within 
existing structures and services (or activities) is key to ensuring effectiveness and it helps to avoid 
unintended iatrogenic effects. This manual will provide valuable guidance in this respect and allow 
preventive interventions to reach their full potential.
Wolfgang Götz 
Director, EMCDDA
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This publication is the result of a two-year project to publish European standards in drug prevention, 
co-funded by the European Commission (EC) (60 %) and the respective project partner organisations 
(40 %). The standards were developed by the Prevention Standards Partnership, a multi-disciplinary 
and multi-sectoral collaboration of seven organisations across Europe, led by Dr Harry Sumnall and 
Angelina Brotherhood of the Centre for Public Health at Liverpool John Moores University (LJMU), 
UK, who are also the authors of this publication.
European Union (EU) policy, such as the EU drugs action plans for 2005–08 and 2009–12, has 
expressed an intention to develop and implement best practice in drug prevention, but so far has not 
been able to provide a reference framework on how to do this. Guidance on drug prevention 
interventions is available in some Member States of the EU, but it varies in terms of its content, 
methodological rigour, and its applicability to the wider European context. In response to this 
situation, this project aimed to provide a commonly agreed reference framework that could help 
improve the state of drug prevention in the EU.
Initially, available European and international drug prevention guidance was collated and reviewed. 
Quality standards matching specific selection criteria were synthesised through qualitative content 
analysis to form the first draft of the European drug prevention quality standards. In the next stage, 
the relevance, usefulness, and feasibility of these draft standards was assessed through structured 
consultations in six EU countries. Delegates provided specific feedback on the content of the 
standards but also outlined a number of challenges that would be faced during their implementation. 
Based on this feedback, the draft standards were modified several times. The final version of the 
standards incorporates input from all consultations, suggestions received at conference presentations, 
informal and formal discussions with prevention experts, and conclusions drawn at Partnership 
meetings. 
As a result, it was possible to define basic as well as expert standards for drug prevention in the EU. 
The standards will be of interest to all professionals who directly or indirectly contribute to drug 
prevention. The European drug prevention quality standards outline the necessary steps to be taken 
when planning, conducting, or evaluating drug prevention programmes. Moreover, the standards 
can be used to inform the development of prevention strategies, to assess and develop organisations 
providing prevention services, or as a reference framework in professional development. The 
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standards are a tool for self-education and self-reflection with the aim of improving drug prevention 
efforts. 
A project cycle with eight project stages forms the basis of the standards, covering: needs 
assessment; resource assessment; programme formulation; intervention design; management and 
mobilisation of resources; delivery and monitoring; final evaluations; and dissemination and 
improvement. Additionally, four standards are of relevance to each project stage, namely: 
sustainability and funding; communication and stakeholder involvement; staff development; and 
ethical drug prevention. Each project stage is divided into several components which outline what 
actions to take. Attributes constitute the third level of detail, demonstrating how each component can 
be achieved.
The standards themselves are supplemented with a detailed introduction explaining how they can be 
used in practice. Moreover, considerations regarding the real-life implementation of the standards 
are provided for each standard component, as well as in relation to the project partner countries 
(online supplement). The Appendix includes additional guidance to aid implementation and an 
extensive glossary. A self-reflection checklist is available as an online supplement to this manual.
It is anticipated that if further funding is obtained the Partnership will develop activities that will 
embed the standards in a robust framework which will include further supporting materials, training 
and education for a wide range of drug professionals, and accreditation of model programmes. 
These activities will ensure that the standards do not remain ‘on paper’, but make a real difference to 
drug prevention practice in the EU. As the standards are applied and tested in practice, it is hoped 
that new, revised versions with additional possibilities for use can be released in the future.
Publication of the standards as part of the EMCDDA Manuals series is an important first step in 
disseminating the standards. The EMCDDA has contributed greatly to the advancement of drug 
prevention in Europe. Its publications and tools, such as the Prevention and Evaluation Resource Kit 
(PERK), the guidelines for the evaluation of drug prevention and the Exchange on Drug Demand 
Reduction Action (EDDRA) database, have increased awareness of the need for quality in 
prevention. It is hoped that these standards will provide a further milestone in this progress. The 
Prevention Standards Partnership therefore wishes to express its gratitude to Marica Ferri, Rosemary 
de Sousa, Roland Simon and Marie-Christine Ashby at the EMCDDA for enabling publication of the 
standards. In particular, the Partnership would like to acknowledge Gregor Burkhart for initiating this 
project and providing strong support throughout its realisation, and for drafting the sections on 
current approaches to drug prevention and the current drug situation in Europe.
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The Prevention Standards Partnership extends its thanks to the Reitox focal points and EDDRA 
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Chapter 1 
Current approaches to drug prevention in Europe
The common view of drug prevention, particularly in lay audiences, is that it consists of informing 
(generally warning) young people about the effects (most commonly the dangers) of drug use. 
Prevention is then often equated with (mass media) campaigns. However, there is currently no 
evidence to suggest that the sole provision of information on drug effects has an impact on drug use 
behaviour, or that mass media campaigns are cost-effective. 
In reality, the challenge of prevention lies in helping young people to adjust their behaviour, 
capacities, and wellbeing in fields of multiple influences such as social norms, interaction with peers, 
living conditions, and their own personality traits. This view is also reflected in current prevention 
approaches. To provide a simplified overview, environmental prevention strategies target social 
norms, universal prevention targets skills development and interaction with peers and social life, 
selective prevention focuses on living and social conditions, and indicated prevention facilitates 
dealing and coping with individual personality traits and psychopathology.
This classification of prevention strategies (Mrazek and Haggerty, 1994), which is based on the 
overall vulnerability of the people addressed, has superseded the previously used medical paradigm 
of primary, secondary, and tertiary prevention. While this earlier classification is useful to describe the 
development of pathologies, the medical paradigm is regarded as less suitable to describe complex 
human behaviour, particularly that which is not dysfunctional or pathological. Only a relatively small 
proportion of individuals that experiment with drugs such as cannabis and cocaine progress to more 
frequent use patterns (see also online supplement on The current drug situation in Europe).
Universal, selective, and indicated prevention are consequently distinguished through the assessment 
of vulnerability (and risk). In universal prevention, all members of the population share the same 
general risk for drug use, although the risk may vary greatly between individuals. In selective 
prevention, social and demographic indicators are used that roughly indicate higher levels of 
vulnerability. This allows targeting particular groups, such as marginalised ethnic minorities, youth in 
deprived neighbourhoods, young (drug law) offenders, vulnerable families, or certain settings, like 
nightlife environments. While these indicators are useful to identify groups where drug use is more 
likely to occur, it is not possible to draw conclusions on the vulnerability of any individual in these 
groups. In indicated prevention, however, a vulnerable individual might have received screening and 
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assessment and been diagnosed by a professional to have a condition which increases the risk of 
drug use (attention deficit disorder, conduct disorder, etc.). 
Universal prevention — intervening on populations
Universal prevention strategies address an entire population (e.g. local community, pupils, 
neighbourhood). The aim of universal prevention is to deter or to delay the onset of drug use by 
providing all necessary information and skills. Universal prevention programmes are delivered to 
large groups without any prior screening for their risk of drug use and assume that all members of 
the population are at equal risk of initiating use.
School-based universal prevention is reported to take place in all European countries, although with 
varying content and levels of coverage. The overall effectiveness of school-based (universal) 
prevention has been repeatedly questioned in the past (Coggans, 2006; Gorman et al., 2007). 
Recent literature reviews show, however, that certain components of school-based prevention, such as 
the focus on normative beliefs and life skills, seem to be effective (1), and European research is 
beginning to emerge demonstrating that school-based programmes can be effective in reducing 
some types of drug use (Faggiano et al., 2010; Lammers et al., 2011). However, monitoring 
information on the contents of school-based prevention in several countries indicates that non-
evidence-based activities (e.g. stand-alone information provision about drugs, drug information days, 
external ‘expert’ visits, theatre workshops) appear to be the most common. While some evidence-
based activities (e.g. social and personal skills training) are widespread, intervention types that are 
more strongly supported by evidence (e.g. structured intervention protocols (‘programmes’), carefully 
delivered peer approaches, interventions specifically for boys) are reported only in a few countries. 
Such evidence-based interventions aim to improve communication skills, increase abilities in handling 
conflicts, stress, and frustration, or correct normative misperceptions about drug use. This so-called 
normative education is very underdeveloped despite the positive available evidence. 
Family-based prevention is another widely utilised approach in universal prevention. In 2007, 11 
European countries reported full or extensive provision of family meetings and evenings to the 
EMCDDA. However, similar to school-based prevention, current family-based prevention seems to 
focus mainly on providing information. Intensive coaching and training for families, although showing 
(1)  See the EMCDDA’s Best practice portal at: http://www.emcdda.europa.eu/best-practice and the Additional 
guidance section in the Appendix and online supplement.
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consistent efficacy across studies (Petrie et al., 2007), is offered on a limited basis, with only seven 
countries reporting the highest provision levels.
Selective prevention — intervening with (vulnerable) groups
Selective prevention serves specific subpopulations whose risk of a disorder is significantly higher 
than average, either imminently or over a lifetime. Often, this higher vulnerability to drug use stems 
from social exclusion (e.g. young offenders, school drop-outs, pupils who are failing academically). 
The main advantage of focusing on vulnerable populations is that they are already identified in many 
places and contexts. However, risk conditions of young vulnerable groups, such as young offenders, 
homeless, truant, disadvantaged, and minority youth, are rarely addressed despite increasing 
political importance.
Since 2004, an increasing number of drug policies have indicated these populations as primary 
targets for prevention, but the reported level of intervention provision has not increased during this 
period. Only a few countries report interventions addressing social disadvantage (e.g. unemployment), 
helping with criminal justice problems, or assisting marginalised families from ethnic minorities and 
families coping with mental health needs. While 13 countries report that most of their family-based 
prevention is selective, only seven report full or extensive provision of interventions targeting drug use in 
families. This is despite the proven effectiveness of interventions for vulnerable families in different 
studies (Petrie et al., 2007). Because of the difficulty of implementing experimental evaluation designs, 
evidence of the effectiveness of other types of selective prevention carried out in Europe is limited.
Available data from Member States indicates the level of provision — how much is done for a given 
(vulnerable) target population — but information about what is actually the content of preventive 
work with these target populations is currently missing because comparable monitoring systems are 
not yet in place. This is of great concern because the effectiveness of prevention differs greatly 
depending on whether evidence-based activities — targeting motivation, skills, and decision-making 
in this case — are implemented, or whether there is, for example, simply a distribution of information 
leaflets (Sussman et al., 2004). 
Indicated prevention — intervening with (vulnerable) individuals
Indicated prevention aims to identify and target individuals who are showing indicators that are 
highly correlated with an individual risk of developing drug use later in their life (such as psychiatric 
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disorder, school failure, ‘antisocial’ behaviour) or who are showing early signs of problematic drug 
use (but not clinical criteria for dependence). The aim of indicated prevention efforts is not 
necessarily to prevent the initiation of drug use but to prevent the (fast) development of dependence, 
to diminish frequency of use, or to prevent progression to more harmful patterns of drug use (e.g. 
injecting). 
Identifiers for increased individual risk can be falling school grades or alienation from parents, 
school, and positive peer groups. Children with behavioural disorders, such as coexisting attention-
deficit/hyperactivity disorder and conduct disorder, are also at high risk of developing drug use 
problems later on. Intervening with these children requires close cross-sector cooperation at 
community level between medical, social and youth services, from childhood on. This is rarely 
achieved besides isolated examples in Germany and Ireland, where counselling for parents and 
carers, concurrent medical, psychotherapeutic and psychosocial support, and educational support in 
the kindergarten or school are combined. Overall, interventions in this field are limited, with six 
countries reporting interventions for children with attention-deficit/hyperactivity disorder or disruptive 
behaviour, and 10 countries reporting early intervention and counselling to individuals who have 
started using drugs.
Nevertheless, indicated prevention programmes — despite few in numbers — tend to be better 
designed and evaluated than universal or selective approaches, and they often show high levels of 
effectiveness (EMCDDA, 2009). For instance, an intervention study conducted in the Netherlands with 
young people (aged 8–13) exhibiting disruptive behaviours showed significantly better follow-up 
outcomes on smoking and cannabis use compared to treatment as usual (Zonnevylle-Bender et al., 
2007). Indicated prevention can also consist of specific parent training in contingency management of 
children with disruptive behaviour disorders. For example, the ‘Komet för föräldrar’ method, applied in 
nearly 30 % of Sweden’s municipalities, targets parents of children showing externalising behaviour 
problems combined with difficulties in establishing positive peer relations. A randomised controlled 
trial involving 159 families showed significantly improved competences in parenting among 
participating parents and reduced behavioural problems among their children (Kling et al., 2010).
Both selective and indicated prevention may moderate the effect of an early developmental 
disadvantage, its translation into social marginalisation and subsequent progression to drug use. 
Several research studies have shown that interventions delivered during the early school years, 
aimed to improve educational environments and reduce social exclusion, also have a moderating 
effect on later drug use (Toumbourou et al., 2007), despite not being drug-specific.
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Environmental prevention strategies — intervening on societies (and systems)
Environmental strategies are aimed at altering the immediate cultural, social, physical, and economic 
environments in which people make their choices about drug use. This perspective takes into account 
that individuals do not become involved with drugs solely on the basis of personal characteristics. 
Rather, they are influenced by a complex set of factors in the environment, such as: what is expected 
or accepted in the communities in which they live; national rules or regulations and taxes; the publicity 
messages to which they are exposed; and the availability of alcohol, tobacco, and illegal drugs.
Therefore, environmental strategies often include unpopular but effective components, such as 
taxation, publicity bans, age controls, and tobacco bans. In the school setting, environmental 
strategies are delivered through school policies which may include regulations on tobacco and 
alcohol use for both pupils, staff, and adult visitors. Almost all Member States report total smoking 
bans in all schools, and a majority of countries report full or extensive provision of drug policies in 
schools. By aiming to create protective and normative social environments, such interventions can 
influence young people’s choices about drug use (Toumbourou et al., 2007). They may also be 
complemented by non-coercive measures, such as improving the design of school buildings and 
school life.
Despite targeting predominantly legal drugs at current, environmental strategies are important for the 
whole drug prevention field because early, widespread, and accepted alcohol and tobacco use is 
related to illegal drug use in many countries.
C
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Chapter 2 
Using the quality standards
What are the European drug prevention quality standards?2
Quality standards are generally accepted principles or sets of rules for the best/most appropriate way to 
implement an intervention. Frequently they refer to structural (formal) aspects of quality assurance, such 
as environment and staff composition. However, they may also refer to process aspects such as 
adequacy of content, process of the intervention or evaluation processes.
(EMCDDA online glossary: ‘Quality standards’) (2)
Quality standard: A benchmark that helps judge whether an activity, a provider, etc. represents high 
quality. Quality standards are typically based upon professional consensus. Their main focus is on 
structural and procedural aspects of quality assurance, e.g. evaluation, staff composition and 
competencies, participant safety, etc.
(Glossary for use with the European drug prevention quality standards, see Appendix)
The European drug prevention quality standards provide the first European framework on how to 
conduct high quality drug prevention. They reflect an internally consistent and long-term view on 
prevention, supporting the importance of integrated approaches to working with young people, and 
valuing and rewarding the contributions of professionals in the field. The standards outline the 
necessary steps in planning, implementing, and evaluating drug prevention activities. They help users 
of the manual to understand how people, interventions, organisations, and (governmental) strategies 
contribute to drug prevention. They encourage users to think about how existing efforts can be 
improved in order to obtain (even) better and sustainable results.
Drug prevention work in line with the standards is likely to be: relevant (focussed on fulfilling the 
needs of participants, while making reference to relevant policy); ethical (incorporating the principles 
specified in D: Ethical drug prevention, such as ensuring voluntary participation and providing real 
benefits for participants, as much as is possible given the practical circumstances of the programme); 
(2) See http://www.emcdda.europa.eu/publications/glossary2
26
European drug prevention quality standards
evidence-based (making use of the best available scientific evidence); effective (achieving set goals 
and objectives without causing harm); and feasible (achievable within available resources, and 
marked by a logical and coherent approach).
The standards represent a summary of the evidence on how to conduct drug prevention. They are in 
accordance with other major documents in the field, such as the Prevention and Evaluation Resources 
Kit (PERK) (EMCDDA, 2010) and the Declaration on the Guiding Principles of Drug Demand 
Reduction, adopted by the United Nations General Assembly at its Special Session on Drugs in 
1998 (United Nations General Assembly, 1998).
What definition of drug prevention is used?
In the standards, drug prevention is understood as any activity that is (at least partially) aimed at 
preventing, delaying or reducing drug use, and/or its negative consequences in the general 
population or subpopulations. This includes: preventing or delaying the initiation of drug use, 
promoting cessation of use, reducing the frequency and/or quantity of use, preventing the 
progression to hazardous or harmful use patterns, and/or preventing or reducing negative 
consequences of use. Consequently, the aims of drug prevention activities covered by the standards 
are in line with those listed in the EU drugs strategy 2005–12 (‘preventing people from starting to use 
drugs; preventing experimental use becoming regular use; early intervention for risky consumption 
patterns’, European Council, 2004, p. 10), but may also focus on harm reduction. To be classed as 
drug prevention activities in the context of these standards, activities must make explicit reference to 
one or more of the aims outlined above in their project documentation.
Drug prevention activities targeted by these standards may focus on any psychoactive substance, i.e. 
a substance that, if taken in sufficient dose, can alter mental and physiological processes. This 
includes legal drugs, such as alcohol or tobacco, illegal drugs (i.e. those whose production, sale, or 
use is forbidden or limited under international and national drug control laws and treaties), volatile 
substances (gases, fumes from glues, aerosols, and similar products), over-the-counter and 
prescription medicines, and new psychoactive drugs that are uncontrolled in law (e.g. ‘legal highs’). 
It is acceptable that drug prevention programmes or strategies focus on certain drugs as long as they 
specify the drugs in question; equally, drug prevention programmes or strategies may choose not to 
target specific drugs but drug use in general. Some activities may address drug use directly, while 
other activities may promote health in general and encourage people to make healthy choices, 
thereby indirectly preventing or reducing drug use.
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The standards are consequently applicable to a wide range of drug prevention activities (e.g. drug 
education, structured programmes, outreach work, brief interventions), settings (e.g. school, 
community, family, recreational settings, criminal justice), and target populations (e.g. school pupils, 
young offenders, families, ethnic groups), regardless of the duration of the programme (i.e. from one-
off to long-term activities). In line with the categorisation used by the U.S. Institute of Medicine, this 
includes universal prevention (addressing the entire population regardless of risk factors), selective 
prevention (addressing specific subpopulations with an above-average risk of drug use), and 
indicated prevention (addressing individuals who have an increased individual risk or are showing 
early signs of problematic drug use) (Mrazek and Haggerty, 1994; Springer and Phillips, 2007). 
Additionally, most standards are also relevant to environmental interventions that aim to change 
behaviours by targeting the environment in which people live and consume drugs (e.g. social norms, 
built environment, taxation).
Identifying the best means of supporting young people, particularly young drug users, and providing 
help through difficult times in their lives is one of the main objectives of contemporary drug 
prevention. Generally speaking, herein drug prevention interventions are those that promote health; 
help people make healthy and informed choices; reduce vulnerabilities and risk behaviours; and/or 
increase inclusion and social/health equity. The standards may consequently provide useful 
guidance for the wider prevention and health promotion field, for example in relation to youth work 
(e.g. violence prevention), other health behaviours (e.g. eating disorders), or addictive behaviours 
(e.g. gambling).
How can the standards be used, and what is their intended purpose? 
In comparison with other areas of drug demand reduction work, the status of prevention and the 
extent to which it has been integrated into national drugs policies, as well as the resources 
historically spent on professional development in this area, vary greatly between EU Member States. 
The European drug prevention quality standards recognise these differences and can therefore be 
used in a variety of ways that support different types of working. It is not the aim of these standards 
to standardise prevention practice across Europe, but rather to achieve a similar level of high quality 
across Europe while acknowledging diversity of practice.
The European drug prevention quality standards can be used for a range of purposes; however, 
professionals will benefit the most from the standards if using them as described in this section. 
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Table 1 shows what purposes this version of the standards should be used for, and what uses might 
be less appropriate. This information is based on consultations undertaken with drug prevention 
professionals across the EU.
Table 1: Proposed use of version 1 of the European drug prevention quality 
standards
Purpose Recommended
Information, education and guidance ü
Developing or updating quality criteria ü
Self-reflection ü
Discussion in group settings ü
Performance appraisals ü
Formal self-assessment Not yet Further work is planned to make 
the standards suitable for these 
purposes
Funding decisions Not yet
External accreditation Not yet
Substitute for outcome evaluation No, although the standards provide guidance on 
how to conduct evaluation
•  For information, education and guidance: By defining basic and expert levels of quality, the 
standards clarify what drug prevention professionals should be aiming towards. All professionals 
contributing to drug prevention can use the standards to improve their knowledge and 
understanding of good and best practice in drug prevention. The standards can also be used to 
promote better planning in prevention policy and strategy, and to promote drug prevention as a 
science on equal grounding to, for example, drug treatment. They may also serve as a reference 
framework in the training of prevention professionals. In more practical terms, the standards can 
be used as a checklist to ensure that all aspects of high quality prevention work have been 
considered, for example when applying for funding.
•  Developing or updating quality criteria: The standards are not prescriptive, but they provide a 
benchmark for the high standards of practice that target populations deserve and which can be 
achieved by all types of organisations. The standards can be used to develop own quality criteria 
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and best practice guidance, or to review and update existing criteria or guidance, in line with 
local, regional, and/or national circumstances. Funders may, for example, use the standards as a 
basis for constructing their own criteria for awarding funding or to specify criteria of what should 
be described in funding applications. 
•  For self-reflection: A top-down approach whereby standards are imposed from ‘above’ does not 
provide as strong an incentive for real development as when professionals themselves are 
convinced of their benefits. All professionals contributing to drug prevention (from government 
representatives to practitioners) are therefore encouraged to use the standards to reflect upon 
their own work and working practices, e.g. their development as practitioners, specialists or 
researchers, the structure of their prevention programme, their organisation, and/or their 
prevention strategy. The standards help professionals to understand their current position, gain 
confidence where standards are already met, and identify areas for improvement. If current 
practice does not adhere to the standards, professionals must not discontinue their work but use 
the standards to improve existing efforts. The standards can then serve as a tool to support a 
long-term process of development (3).
•  For discussion in group settings: The standards can help initiate discussion and reflection in group 
settings (e.g. during team meetings, during funding negotiations). Self-reflection as described 
above can also be carried out in a group setting. For example, one staff member could be 
appointed to read the standards in full and to conduct a draft reflection on the programme or 
organisation using the ‘self-reflection checklist’ (see online supplement). This could then be used in 
the group setting to gain consensus and more information on the position of the programme or 
organisation. In this way, the standards can inform organisational planning processes, and they 
can help establish a common understanding of what high quality drug prevention is, particularly 
in teams with a variety of professional backgrounds.
•  For performance appraisals: The standards might also be used as a reference framework in 
professional development and performance reviews, for example to identify staff training needs 
and potential for future development.
These are the recommended uses for this version of the standards. It is intended to expand this 
list in the future by developing the standards further and trialling them in practice. Tables 2 and 
(3)  A ‘self-reflection checklist’ is available as an online supplement to this manual that professionals can use to 
document their reflections on their own prevention practice in relation to the standards.
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3 provide example scenarios of how the standards could be used. The scenarios highlight that 
the standards could improve prevention practice and inform decision making in a wide variety of 
situations.
However, this version of standards may not be suitable for some purposes, including those described 
below.
The current set of standards should not be used directly to make funding decisions. Such decisions 
must take into account, for example, the applicability of the standards to local circumstances and the 
opportunity costs of choosing one programme over another. The current document does not provide 
guidance on how to make such complex decisions, and therefore using the standards for this purpose 
is discouraged. Funders may, however, use the standards as a basis for constructing their own 
criteria to award funding.
Some standards contain examples of how achievement could be evidenced in tangible terms. 
Sources of evidence may include written evidence, for example in the project plan or the description 
of the organisation, direct observations of work procedures or programme implementation, or 
interviews with staff, participants, and/or other stakeholders. However, evidence indicators are not 
provided for all standards because of the standards’ general nature. Moreover, the primary aim of 
the standards is to stimulate reflection and to improve prevention practice. It should therefore not be 
expected of organisations to demonstrate in writing how they have met the standards in order to 
receive funding. For smaller funding applications in particular, the resources required to evidence the 
standards may not be proportionate to the requested amount of funding.
For the same reasons, the current set of standards cannot be used to conduct formal self-assessment 
or as a basis for external accreditation. The main benefit of the standards lies in motivating 
professionals to reflect on their work and to align their practice with the standards. This is better 
achieved by asking professionals to engage with the document rather than focussing on quantitative 
assessment of achievement. However, future versions will include the necessary guidance to conduct 
formal assessments using the standards.
It must also be highlighted that conducting self-reflection with the standards cannot replace process 
and/or outcome evaluations. Adherence to the standards will help achieve better results on these 
evaluations; however, in order to prove effectiveness of interventions and to understand how they 
were implemented, process and outcome evaluations will still form necessary activities alongside 
using the standards. 
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Table 2: Example scenarios of how the standards could be used (part 1)
The senior management team of a large prevention 
provider uses the standards in a monthly meeting to 
discuss strengths and weaknesses of the 
organisation. A staff member highlights that there are 
insufficient measures in place to promote 
collaboration with other organisations as outlined in 
standard B: Communication and stakeholder 
involvement. She suggests organising a regional 
meeting with other providers through the regional 
drug prevention planning team.
A practitioner working for a charity reads the 
standards for general information. The standards 
under component 3.2: Using a theoretical model 
encourage him to find out more about prevention 
theories and to identify theoretical models that might 
lead to improvements in his own working approach. 
At his next professional development and 
performance review, he asks if the organisation 
would support him taking time off to pursue a part-
time university course in health promotion.
A prevention provider is preparing a project 
proposal to a funding body. The lead applicant 
consults the standards to ensure that all project 
stages have been considered sufficiently. The 
standards under A: Sustainability and funding 
encourage him to search on the Internet for projects 
that have been funded by this funding body in the 
past. He finds a description of previous projects 
which helps him develop his own funding application 
further.
A commissioner is not satisfied with the quality of 
update reports received by providers. She develops 
a standardised reporting format for use by providers 
based on the standards under component 8.2: 
Disseminating information about the programme and 
If producing a final report. This will ensure in the 
future that she receives comprehensive, well-
structured, and comparable information across 
providers.
A prevention scientist is planning an outcome 
evaluation for a drug prevention intervention. In 
doing so, she wishes to follow a standardised 
evaluation protocol. She consequently refers to 
standards 4.4: If planning final evaluations and 7.1: 
If conducting an outcome evaluation when 
developing the evaluation methodology.
A prevention policy lead wishes to review existing 
national standards for accreditation of model 
programmes. He uses the European drug prevention 
quality standards to identify major gaps in the 
existing standards. He consequently revises them and 
includes a new section on ethical drug prevention.
What can be ‘assessed’ with the standards?
The standards are based on a review of available drug prevention guidance, most of which 
concerned drug prevention interventions in general and not specific types of activities (see 
Appendix). Therefore, the standards are applicable to a wide range of drug prevention intervention 
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types, settings, and target populations. The standards give advice on how to plan, implement, and 
evaluate interventions, and they can be used to reflect on new, ongoing, or completed activities. 
However, interventions form part of a wider professional environment which is just as important in 
ensuring high quality drug prevention work. General issues (e.g. staff development, resource 
management, funding and sustainability, communication and stakeholder involvement) must be 
addressed at an organisational level. Additionally, the priorities and strategies set out by local, 
regional, national, and/or international government and funding bodies must promote good 
practice in prevention. The European drug prevention quality standards acknowledge the need for 
a good foundation upon which interventions can be delivered. Therefore, they provide guidance 
not only on specific drug prevention interventions, but also on organisational and strategic aspects 
of prevention work.
Although the standards refer to programmes, they can be used to reflect on prevention work at 
several levels of delivery, including:
•  People: individual staff members or teams. The standards can be used for professional 
development, to reflect upon current practice, and to gain a better understanding of their role 
within the wider context of prevention.
•  Activities: singular interventions or wider programmes comprising several interventions. The 
standards can be used to plan, resource, and deliver prevention activities in a consistent and high 
quality manner that provides the best chances for success.
•  Organisations: organisations involved in drug prevention, such as service providers or schools. 
The standards can be used to improve organisational configuration and strategy so that 
professionals are best supported in their work and so that target populations receive optimum 
care.
•  Strategies: priorities, action plans and tenders set out by government or funding bodies. The 
standards can be used to define policy objectives, to support thinking on the realities and 
ambitions of prevention, and to assist in funding and commissioning activities.
Not all standards are equally relevant to all these levels of delivery, but this multi-level approach 
encourages users of the document to consider the strong relationship between people, activities, 
organisations, and strategies. This wider perspective can help identify strengths and weaknesses that 
were previously invisible.
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Who should use the standards?
The standards will be of interest to all professionals working in the field of drug prevention. Although 
the standards may also inform the general public (including young people, families, and community 
members) on what to expect from drug prevention work, they are primarily targeted at drug 
prevention professionals. These professionals are likely to be involved in one or more of the following 
activities:
•  Policy- and decision-making: those who work on a strategic level, for example government 
representatives, commissioners, regional planning teams, funders. The standards provide guidance 
on how to set priorities, how to conduct needs assessments, how to coordinate prevention 
activities, and how to ensure the sustainability of drug prevention efforts. They may also help to 
better understand what prevention providers are aiming to achieve through their work, and to 
reflect on prevention strategies. The standards can also be used to develop new or review existing 
best practice guidance, and/or to develop new or update existing quality criteria (e.g. to award 
funding or model programme status). These professionals may also be interested in the evidence 
into practice briefing produced as part of the standards project (Sumnall et al., 2011).
•  Service management: those who are in charge of managing drug prevention activities at an 
organisational level within prevention providers. Typical responsibilities include planning 
activities, management of financial and human resources, and fulfilling reporting duties to 
commissioners and funders. The standards provide guidance on how to plan, manage, and 
evaluate interventions, but they also consider organisational aspects (e.g. staff development, 
health and safety). Service managers may use the standards in team meetings and to support 
their work when communicating, for example, with commissioners and funders.
•  Front-line work/work in direct contact with the target population: those who conduct, or 
contribute to, drug prevention in (direct) contact with the target population, such as psychologists, 
youth workers, social workers, outreach workers, teachers, pharmacists. The standards can inform 
their work by emphasising the need to engage with the target population, to tailor activities to 
target population needs, to ensure that delivery is of high quality, and to refer individuals to 
specialist services where required. 
•  Training: those who provide training in drug prevention. Training may be directed at practitioners 
(e.g. social workers), or it may take place in a higher education setting (i.e. university students). 
The standards can serve as a textbook outlining all aspects of high quality drug prevention work.
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•  Supervision: those who supervise and support drug prevention professionals (particularly 
practitioners). This includes line managers as well as external supervisors who are employed to 
assist with staff development. The standards can be used as a reference framework to identify 
training needs and potential for further development.
•  Programme development: those who design and develop drug prevention interventions. These 
interventions may be developed as copyrighted manualised programmes or they may be 
developed for a specific project or organisation. The standards provide general guidance on 
intervention design, but they also emphasise the need to consider conditions of real-world 
implementation when developing interventions.
•  Consultancy/evaluation/academic research: those who provide consultancy on prevention issues, 
for example with regard to effective drug prevention, prevention policy development, adaptation 
of programmes, evidence into practice translation, and/or evaluation. The standards provide a 
comprehensive checklist and reference framework, as well as benchmarks for evaluation and 
research. These professionals may also be interested in the feedback received from professionals 
during the development of the standards, which is documented in the evidence into practice 
briefing and the final project report (Sumnall et al., 2011; Brotherhood et al., 2011).
Although all professionals working in drug prevention are encouraged to engage with all standards, 
it is likely that not all standards will appear equally relevant to all. As part of the development 
process, the Partnership explored the possibility of including a table that showed which standards 
are most relevant to which professional group. However, due to differences in work practices 
between countries, sectors, and individual organisations, this was not deemed feasible. It is 
recommended that professionals obtain an initial overview of all standards, for example through the 
project cycle and list of components, before determining which standards are most relevant to their 
current professional needs. Engaging with the standards should be seen as a long-term process 
whereby professionals consult them over time to gradually develop their knowledge and work.
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Table 3: Example scenarios of how the standards could be used (part 2)
A service manager has noticed that certain clients 
are less likely to attend an intervention. She uses the 
standards under Project stage 4: Intervention design, 
component 5.4: Recruiting and retaining participants, 
and Project stage 6: Delivery and monitoring to 
review the service and to discuss potential barriers 
with clients. It becomes clear that some clients cannot 
attend the intervention regularly because of family 
commitments. The service manager consequently 
considers developing a specific outreach project for 
this client group.
A programme developer is designing a new school-
based prevention programme. He reads the 
considerations at the beginning of each component 
and notes the differences between basic and expert 
level standards to understand what the practical 
challenges of implementing the new programme 
might be. The standards encourage him to consider 
how flexibility can be built into the intervention 
design to minimise the need for unplanned deviations 
during implementation.
A commissioner refers to the standards to conduct a 
local needs assessment using Project stage 1: Needs 
assessment. The findings show that current services 
do not offer any family-based prevention 
programmes despite there being a need for them. 
She consequently ring-fences a proportion of funding 
for family-based prevention programmes and issues 
a call for tenders.
A prevention training provider is reviewing the 
feedback forms received after a course. According 
to the feedback, attendants felt there should be a 
stronger emphasis on how to respond to the 
individual needs of clients. The standards under C: 
Staff development suggest that he could amend the 
course contents to include a module on meta-
competencies.
A university lecturer uses the standards document as 
a reference book to inform students about current 
best practice in drug prevention. In particular, she 
uses some of the considerations at the beginning of 
each component to initiate discussion among 
students. The students hold a debate on the 
principles of ethical drug prevention outlined in D: 
Ethical drug prevention.
A treatment provider wishes to diversify the portfolio 
of activities by offering a prevention service to young 
people. The service manager uses the standards to 
consider how the new service can be integrated into 
the existing one. The standards under component 
2.2: Assessing internal capacities highlight that the 
organisation currently lacks staff members who are 
specialised in prevention with young people.
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How are the standards structured, and what content do they cover?
The European drug prevention quality standards are ordered chronologically in a project cycle, 
describing the development, implementation, and evaluation of drug prevention work (Figure 1).
Figure 1: The drug prevention project cycle
1 Needs assessment
2 Resource  
assessment
3 Programme 
formulation
4 Intervention design
5 Management and 
mobilisation of 
resources
6 Delivery and 
monitoring
7 Final evaluations
8 Dissemination and 
improvement
A: Sustainability 
and funding
C: Staff 
development
B: 
Communication 
and stakeholder 
involvement
D: Ethical drug 
prevention
CROSS-CUTTING 
CONSIDERATIONS
Within the cycle, the standards comprise three levels of detail.
1. Project stages
The project cycle is made up of eight stages: needs assessment; resource assessment; programme 
formulation; intervention design; management and mobilisation of resources; delivery and 
monitoring; final evaluations; and dissemination and improvement. Needs assessment and resource 
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assessment, as well as intervention design and management and mobilisation of resources, are likely 
to be conducted simultaneously and are therefore presented in the same colour. The centre of the 
cycle contains standards that are not specific to a certain project stage but should inform prevention 
work at all times.
In the standards, each project stage starts with a brief introduction indicating its position in the 
project cycle and providing a short description of the contained standards. For ease of use, the 
standards are colour-coded in line with Figure 1.
The project cycle should be understood as a simplified model of drug prevention. While the project 
cycle structure was identified as the best means of presenting a comprehensive set of quality 
standards, in reality, prevention work may be organised differently than shown in the project cycle. 
Users of the standards should carefully adapt the project cycle to the individual circumstances of their 
prevention work. Possible considerations include: which project stages have already been 
completed; which components might not be necessary in this particular project; should the order of 
the standards be changed to reflect particular circumstances (i.e. users may move from one stage to 
another in a non-chronological order)? Users can make justifiable changes to the structure of the 
project cycle, as this flexibility ensures that the standards are relevant, useful, and feasible across all 
areas of drug prevention.
It is also important to note that the standards should be considered in relation to each other. For 
example, the findings from the needs assessment will inform the programme formulation, which in 
turn will determine what resources are required. It is therefore recommended to obtain an overview 
of all standards rather than reading singular chapters in isolation. The level of detail may at first 
appear daunting, but its practical usefulness lies in providing a step-by-step guide of how to conduct 
high quality drug prevention work.
2. Components
Each project stage is divided into several components (see Table 4, page 53). They outline the 
actions which should be taken at that point in the project. Overall, there are 31 components within 
project stages and four cross-cutting considerations at the centre of the project cycle. Cross-cutting 
considerations, while perhaps not the most important aspects of prevention work as such, contain 
themes that should be reconsidered at each project stage; they were placed in the centre to reduce 
duplication between project stages.
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The number of each component is made up of the project stage and the component, while cross-
cutting considerations in the centre of the project cycle are given capital letters (A–D). The numbering 
of components does not necessarily indicate priority or chronological order. Some components are 
not always required or feasible, and the standards therein only apply if that action is taken. These 
components start with ‘If’; for example, component 4.2: If selecting an existing intervention.
In the standards, each component starts on a new page with considerations regarding its application 
in practice. The content of considerations is mostly derived from consultations with drugs 
professionals and discussions within the Partnership. The considerations typically outline the rationale 
for a certain component, discuss potential barriers to implementation of the standards in practice, as 
well as ways of overcoming these barriers, and they highlight if a component is not applicable to all 
prevention work. References to additional guidance and other components that support 
implementation of the particular component are also made. Users are encouraged to read the 
standards in conjunction with the glossary providad in the Appendix.
3. Attributes
The third level of detail contains further descriptions of the components, distinguishing between basic 
standards and expert standards (see next section). The left-hand column contains the actual 
standards (see Figure 2). If used for reflection on prevention work, these attributes define attainment 
towards the particular component. The standards are numbered in line with their relation to project 
stages and components to enable easy referencing; the numbering does not necessarily indicate 
priority or chronological order.
The right-hand column contains notes to help clarify the purpose or content of the standards, as their 
meaning may depend on the context in which they are used. The notes also indicate if a standard 
reflects basic level in certain cases (‘basic standard if’), or if there are additional considerations that 
should be taken into account. Examples show how achievement of the standards could be evidenced. 
However, examples given within the right-hand column should not necessarily be seen as the only 
appropriate ways to achieve or evidence the standards. Where there is a lot of text in the notes, it is 
displayed horizontally under the standards instead of in the right-hand column.
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Figure 2: Layout of attributes
Basic standards:
D.1 The knowledge of general policy and legislation  
is sufficient for the implementation of the programme.
i.e. staff members and participants are aware of generally binding regulations, their legal 
responsibilities, and internal rules and procedures.
Note: It depends on the particular programmes which policies and pieces of legislation are most 
important; further considerations can be found under 1.1 Knowing drug-related policy  
and legislation.
Examples of policy and legislation: equal opportunities policy, confidentiality policy, child protection 
policy, health and safety policy, laws on waster and environmental protection.
D.2 A code of ethics is defined.
Additional expert standards:
D.15 Alcohol, tobacco, and illegal drugs are banned 
in the facilities of the programme.
Basic standard if required by law.
Note: Adherence to this standard may not be 
feasible under certain circumstances, for example if 
the intervention is delivered in an external recipient 
organisation (e.g. nightclub).
D.16 The programme complies with national and 
international standards and guidelines.
Basic standard if required by existing policy and 
legislation.
Example of standards: national occupational 
standards in drug prevention, if available.
D.17 The participants’ code of rights is publicly 
posted and easy to understand.
What is the difference between basic and expert standards?
Drug prevention covers a wide range of activities that may differ, for example, in terms of their aims, 
scope of work, target population, setting, methods, duration, and/or available and required 
resources. Certain standards may therefore seem more relevant or feasible for some interventions 
than for others.
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In terms of relevance, drug prevention professionals contributing to the development of these 
standards argued that ongoing participant- and needs-led services (e.g. outreach work, drop-in 
centre, brief intervention) should be distinguished from structured long-term interventions with 
predetermined content (e.g. manualised school programme). For example, it may not always be 
possible to engage with participants over a longer period of time in participant-led services, and 
therefore those standards assuming a long-term relationship with participants might not apply (e.g. 
standards on participant retention).
In terms of feasibility, the consultations suggested that certain standards were not always feasible. 
Delegates highlighted, for example, the limitations of providing drug prevention in settings where 
providers did not have full control over implementation (e.g. schools, night-life setting). They also 
argued that the standards should be applied more rigorously to large-scale projects, while small-scale 
projects could not be expected to adhere to all standards. The distinction between large-scale and 
small-scale work refers to the size and scope of projects and organisations, for example with regard 
to how many staff members are involved, how much budget is available, the duration of projects, 
and/or the number of participants. A long-term government programme with nationwide dissemination 
would be an example of large-scale work, while a one-off intervention organised by a school for a 
small number of pupils could be classed as a small-scale project. Smaller organisations often have 
fewer capacities than larger organisations, and might therefore struggle to achieve all standards. 
However, achieving the standards should be a professional aim of all types of organisation.
The standards therefore offer three levels: ‘basic’, ‘basic if’, and ‘expert’. This distinction is based on 
the consultations that were held during the development of the standards.
•  Basic standards: these standards should be applicable to all drug prevention work, regardless of 
its particular circumstances. Basic standards provide a reference framework for those 
professionals, projects, organisations, and strategies that could not currently achieve all 
standards due to limited resources or a very basic starting point. This might include 
organisations that do not specialise primarily in prevention work, such as schools. These 
organisations would be considered to be performing very well if they achieved the basic quality 
level. However, even basic users should not simply read the basic standards, but also consider 
the relevance, usefulness, and feasibility of all expert standards. The expert standards contain 
more detailed guidance than the basic standards, and thus they may be helpful in guiding work 
at basic level. Additional basic standards (‘basic standard if’) may also apply under particular 
circumstances.
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•  Additional basic standards (‘basic standard if’): these standards are highlighted in bold font and 
reflect the basic level under particular circumstances. For example, some standards may be 
considered basic if an outcome evaluation is planned, but they would not apply if an outcome 
evaluation was not planned. Depending on how many basic standards there are, they are listed 
following the basic standards, or indicated in the right-hand column of the additional expert 
standards. Basic users of the standards should scan the expert standards to identify any 
additional standards that may reflect basic level for their project. 
•  Additional expert standards: these standards are to be seen in addition to the basic standards, 
representing a higher level of quality. Expert standards provide a reference framework for those 
professionals, projects, organisations, and strategies that have more resources available, as well 
as those smaller projects and organisations that have already achieved most basic standards. 
While adherence to all expert standards is desirable, they may not always be applicable. 
Therefore, expert users will have to determine which expert standards are relevant, useful and 
feasible with regard to their particular prevention work.
Professionals using the standards for reflection on their work can refer to this distinction to determine 
their current position, and to identify areas for improvement. Once most basic standards have been 
achieved, professionals should strive to achieve the expert standards that are relevant to their work.
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About the quality standards
Why were the standards developed?
The overall predominance of interventions in Europe that lack, or have only a weak, evidence 
base, as well as the weak implementation of prevention in general are striking. While this may be 
due to the fact that such approaches require fewer resources (e.g. less staff training), effectiveness 
can only be achieved through correct implementation of prevention activities with evidence-based 
components. Even well-intended and well-planned interventions can have harmful instead of 
preventive effects (Moos, 2005; Werch and Owen, 2002). For these reasons, standards and their 
reinforcement through funding requirements are not only needed to improve the effectiveness of 
prevention but, above all, they are ethically necessary to guarantee that no harm is done through 
preventive interventions, which in most cases have not even been asked for by the target 
population. 
The quality and evidence base of prevention is rarely subject to control or quality-conditioned 
funding. Nevertheless, the need to improve prevention is increasingly recognised in Europe, with half 
of EU Member States reporting on efforts to develop drug prevention quality standards. At the time 
of starting the European drug prevention standards project, drug prevention quality standards and 
guidelines were available only in some Member States of the EU. The available guidance varied in 
terms of its content, methodological rigour, and applicability beyond the regional or national context. 
Consequently, a common European framework on high quality drug prevention was missing. It was 
also not clear to what extent internationally available guidance was relevant to drug prevention in 
Europe, and how it could be adapted to the European context (for example, the USA Standards of 
Evidence (Flay et al., 2005)).
The need for a European drug prevention framework is also apparent in EU policy documents, such 
as the EU drugs action plans (European Council, 2005 and 2008). These have expressed an 
intention to develop and implement best practice in drug prevention, but without being able to 
provide a reference framework on how to do this.
Therefore, the aim of the standards is to improve European drug prevention practice by providing an 
empirically derived reference framework to bridge the gaps between science, policy and practice.3
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The specific objectives of the project were:
•  To develop and present a toolkit of criteria for assessment of prevention standards and guidelines 
and apply them to demonstration projects; 
•  To collate and review existing national standards of evidence and evidence-based guidelines in 
the EU and worldwide; 
•  To identify and discuss national standards and guideline implementation modifiers; 
•  To publish EU standards and guidelines in evidence-based drug prevention.
This document focuses on the standards that were produced as part of this process.
What policies do the standards support?
The standards directly support the main actions and priorities outlined in the EU drugs action plan 
(2009–12) and the EU drugs strategy (2005–12) in relation to drug demand reduction and the 
improved understanding of the drugs phenomenon, including:
•  Action 17: ‘To develop, implement and exchange good practice guidelines/quality standards for 
prevention, treatment, harm reduction and rehabilitation interventions and services’; 
•  Action 19: ‘To develop an EU consensus on minimum quality standards and benchmarks for 
prevention, treatment, harm reduction and rehabilitation interventions and services taking into 
account needs of specific groups and the work done at national and international level’; 
•  ‘A better understanding of the drugs problem and the development of an optimal response to it 
through a measurable and sustainable improvement in the knowledge base and knowledge 
infrastructure’ (European Council, 2004, p. 18; 2008, p. 13).
The standards will also support Member States in achieving the actions outlined in the United 
Nations Plan of Action adopted at the high-level segment of the fifty-second session of the 
Commission on Narcotic Drugs in 2009, such as:
•  ‘Deliver prevention programmes based on scientific evidence, both universal and targeted, in a 
range of settings (such as schools, families, the media, workplaces, communities, health and 
social services and prisons)’; 
•  ‘Ensure that drug demand reduction measures respect human rights and the inherent dignity of all 
individuals and facilitate access for all drug users to prevention services and health-care and 
social services, with a view to social reintegration’; 
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•  ‘Involve all stakeholders at the community level (including the target populations, their families, 
community members, employers and local organizations) in the planning, delivery, monitoring 
and evaluation of drug demand reduction measures’; 
•  ‘Support the development and adoption of appropriate health-care standards, as well as ongoing 
training on drug demand reduction measures’ (UNODC, 2009b, p. 24, item 18(a)).
The availability of a common framework that is adaptable to local circumstances should provide an 
incentive for EU Member States to develop local, regional, and/or national quality standards where 
these did not previously exist, or to review and update existing quality standards, and adopt these 
quality standards for their own use. Adoption of the standards will improve drug prevention practice 
and efficiency of funding, and reduce the likelihood of implementation of interventions that are 
ineffective or have iatrogenic effects. Thus, the standards will support the fulfilment of local, regional, 
national and international drugs strategies and policies.
How were the standards developed?
The European drug prevention quality standards were drafted through a review and synthesis of 
nineteen European and international documents containing drug prevention quality standards, and 
finalised through consultations with drug professionals across Europe. In developing the standards, 
the Partnership used methods that were not only valid and reliable, but that also enabled detailed 
knowledge of local professional cultures and practices (e.g. values and preferences, organisational 
structures). Figure 3 provides an overview of the development process.
Existing drug prevention guidance was identified in 2008/09 by contacting relevant representatives 
in the 27 EU Member States, i.e. the national focal points of the EMCDDA’s Reitox network, the 
European Information Network on Drugs and Drug Addiction, or the national managers responsible 
for the Exchange on Drug Demand Reduction Action (EDDRA). Additionally, prominent organisations 
working in drug prevention, such as the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), the United Nations Office on Drugs and Crime (UNODC), the Canadian Centre on 
Substance Abuse (CCSA), and the Australian National Drug Research Institute (NDRI) were contacted 
to retrieve materials. Internet and literature searches were also carried out.
In total, 77 documents were retrieved. From these, quality standards focussing on drug prevention 
with a national or, where national guidance did not exist, regional scope were selected. Materials 
were also required to be of official standing, i.e. published or recognised by government or a 
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leading agency in drug prevention. The final selection comprised 19 documents; non-English 
language materials were translated into English. The documents included in the review are listed in 
the Appendix. A first draft of the European drug prevention quality standards was produced by 
synthesising the quality standards contained in these documents.
Figure 3: Development of the standards
Synthesis of existing drug 
prevention guidance
Online Delphi survey
Focus groups
Focus groups
First draft
Second draft
Final standards
The draft standards were then refined in consultation with drug prevention professionals. Participants 
were invited from all professional levels and a wide range of professional fields contributing to drug 
prevention, namely: regional planning teams; education; health; mental health; social services; 
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criminal justice; voluntary and community sector; government; research and consultancy; and media. 
Consultations were carried out by all members of the Prevention Standards Partnership, and included 
the following countries or regions: Galicia (region of Spain); Hungary; Liguria (region of Italy); 
Lombardy (region of Italy); Poland; Romania; and the United Kingdom.
In a two-round online Delphi survey, professionals rated the priority of the draft standards from ‘high 
priority’ to ‘not a priority at all’ at component level. Across all countries and regions, 423 
professionals completed both survey rounds. In the following round of consultations, 122 
professionals attended fourteen focus group events in five countries to discuss the standards in detail, 
particularly with regard to their relevance, usefulness, and feasibility. The feedback obtained through 
the Delphi survey and focus groups was used to produce a second draft of the standards.
In the final round of consultations, 72 professionals from five countries helped define how the 
standards could be implemented in practice, and provided final suggestions for improvement. The 
final version was produced incorporating input from all consultations, suggestions received at 
conference presentations, and conclusions drawn at Partnership meetings.
Further information on the development of the standards and a list of the professionals who 
contributed to the consultations can be found in the final project report (Brotherhood et al., 2011).
What are the conditions for standards implementation, and what could be potential 
barriers?
It was clear from the onset of this project that the final standards would only become a useful tool to 
inform everyday practice if they are relevant and useful to a multitude of professionals across 
countries, and if they are applicable to a variety of settings and other circumstances. This was largely 
achieved through the consultations outlined above; it is evident in practical considerations at the 
beginning of each component and the distinction between basic and expert level standards.
However, the conversations with drug prevention professionals also indicated a range of conditions 
and potential barriers that, while required for uptake of the standards in practice, could not be 
addressed during standards development. The following paragraphs briefly describe what cultural, 
organisational, and structural changes are required to achieve widespread implementation.
•  Promote the use of quality standards: Encouragingly, the consultations suggested that many 
actions described in the standards are already common practice, even though they are often 
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not implemented to the high quality specified in the standards. Professionals could therefore 
build upon and improve existing efforts, rather than having to start from nothing. It was also 
noted that a good project would naturally end up adhering to the quality standards. However, 
it became clear that a majority of professionals may not be familiar with the concept of 
quality standards, programme certification, and professional guidelines. Even though they 
may welcome the introduction of standards, these professionals may be unsure about how to 
use them in their everyday practice. It would therefore be required to support implementation 
of the standards by providing targeted training events and educational materials. It is 
recommended that the standards, and their use, are introduced in a stepwise manner; firstly 
by introducing the field to the need for quality standards, then beginning a process of 
introducing the standards themselves, and finally familiarising potential users with their content 
in a targeted manner.
•  Develop content guidelines: The consultations indicated that there is a need for guidance on the 
content of evidence-based prevention work. The quality standards provide a consistent framework 
for the delivery of prevention, and suggest how decisions on content might be reached, but they 
are not intended to specify what activities should be delivered. In contrast to the availability of 
national prevention quality standards, only two documents containing robust guidelines were 
considered to be of relevance to the EU (NICE, 2007; UNODC, 2009a). Both of these concerned 
family-based approaches to prevention, and were biased towards the well developed prevention 
delivery structures mostly seen in west European states. The success of the standards in the future 
is likely to depend on the concurrent availability of high quality drug prevention guidelines. 
Although systematic reviews and meta-analyses present international evidence summaries, they 
lack details on implementation and local adaptation. Accessing and interpreting complex and 
often contradictory evidence is also a challenge for many professionals. It is therefore clear that 
more work needs to be conducted to allow professionals to make decisions on how best to work 
with their target populations.
•  Attract funding: The standards are designed to be challenging yet realistically achievable. 
Through the distinction between basic and expert levels, they take into account the current 
situation of drug prevention practice and resource availability in the EU. Ideally, the (basic) 
standards can be implemented by using or realigning existing resources. However, organisations 
with limited capacities may need to attract additional funding, particularly if they wish to achieve 
the expert level standards.
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•  Prioritise and support prevention: In comparison to treatment and rehabilitation, prevention 
receives relatively less (financial) attention and may therefore appear to be less important. 
Predictable and stable financial support is a condition for sustainable high quality drug 
prevention work. Adoption of the standards will promote the importance of prevention within the 
drug demand reduction framework. However, in order to improve the quality of drug prevention 
(e.g. by conducting scientific outcome evaluations), commissioners and funders must invest more 
money in prevention. The current standards do not provide detailed guidance on how to allocate 
funding, and commissioners and funders may require further training in this regard (e.g. how to 
consider opportunity costs). 
•  Establish and strengthen central prevention agencies: The consultations highlighted the 
importance of government-funded regional and national coordination bodies that implement 
drugs strategies, commission and coordinate drug prevention work, conduct needs assessments, 
promote adherence to quality standards, issue best practice guidance, organise training and 
networking events for prevention providers, facilitate collaboration between different providers, 
etc. The discussion highlighted the benefits where such structures are in place, as well as the 
problems that arise where such structures are weak or non-existent (e.g. not all countries have 
prevention policy located in one particular department or organisation), or under threat of being 
abandoned.
•  Consider differences in prevention practice: Drug prevention practice differs between countries, 
localities, and professional fields (e.g. different professional cultures between social and medical 
services). Although the standards are widely applicable, delegates questioned whether they 
could be adapted to match individual circumstances (e.g. local target population, national 
structures of delivery). This version of the standards does not contain detailed instructions on how 
to integrate them into existing systems and structures of delivery. It is intended that future versions 
of the standards will illustrate better how they can be applied in practice, based on real-life trials 
under different circumstances.
•  Create synergies: Another possible challenge relates to the lack of coordination and 
collaboration between professional groups and stakeholders in the drug prevention field. 
Delegates provided several examples, such as duplication of efforts by prevention services that 
were unaware of each other’s work, or lack of communication between researchers and 
practitioners that meant that evidence was not adapted and disseminated in a manner that was 
useful to practice. Communication can be hindered by different perceptions of the aims and 
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methods of drug prevention. Component B: Communication and stakeholder involvement targets 
this challenge specifically, recognising that better coordination would enable more targeted 
services and a better distribution of resources. However, implementation of the standards requires 
buy-in from multiple stakeholders, i.e. collaboration can only occur where several parties are 
interested in collaborating. Additionally, introduction of standards into practice will affect 
stakeholders who have not traditionally been involved in prevention work in the past, and who 
may thus be unclear about their role in contributing to drug prevention (e.g. teachers, 
pharmacists, housing officers).
•  Develop professional attitudes and skills: A further theme was the competence and willingness of 
staff to put the standards into practice. Knowledge gaps in the prevention workforce were 
reported in relation to, for example, evidence-based approaches, evaluation, adaptation, or 
strategic project planning. There appears to be a divide between the theory and practice of 
prevention (e.g. what is known to be effective versus what is actually done). The discussions also 
indicated that professionals may be hesitant to use the standards, dismissing them as ‘too 
complex’ or ‘too difficult to achieve’. Practitioners may also worry that the standards could 
devalue their professional experiences. The aim of the standards is to promote better practice, 
and therefore they cannot simply affirm current practice. Through the distinction between basic 
and expert standards and the promotion of self-reflection, the standards can become a useful tool 
if practitioners are willing to engage with them. It is important that the standards become a 
means of improving professional practice and making real changes about the way prevention is 
planned and delivered, not a bureaucratic device. While the standards could improve the 
understanding of prevention among professionals and provide important additions to 
occupational standards (e.g. C: Staff development), prevention-specific training and further 
education would also be needed. Moreover, a deep change in professional attitudes can only be 
achieved as part of a long-term process involving all relevant levels.
These considerations highlight that the standards cannot be implemented in isolation, detached from 
the realities of drug prevention. On the contrary, implementation of the standards must be 
accompanied by a process of change in the very foundations of drug prevention towards a more 
integrated and evidence-based approach. Project partners have also summarised considerations that 
are of particular relevance to their country, although it is likely that other countries may face similar 
challenges. These country considerations are available as an online supplement to this manual.
PART TWO
The standards
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Table 4: Project stages and components within the European drug prevention 
quality standards
Cross-cutting considerations
A. Sustainability and funding
B. Communication and stakeholder involvement
C. Staff development
D. Ethical drug prevention
1. Needs assessment
1.1 Knowing drug-related policy and legislation
1.2 Assessing drug use and community needs
1.3 Describing the need – Justifying the intervention
1.4 Understanding the target population
2. Resource assessment
2.1 Assessing target population and community resources
2.2 Assessing internal capacities
3. Programme formulation
3.1 Defining the target population
3.2 Using a theoretical model
3.3 Defining aims, goals, and objectives
3.4 Defining the setting
3.5 Referring to evidence of effectiveness
3.6 Determining the timeline
4. Intervention design
4.1 Designing for quality and effectiveness
4.2 If selecting an existing intervention
4.3 Tailoring the intervention to the target population
4.4 If planning final evaluations
5. Management and mobilisation of resources
5.1 Planning the programme - Illustrating the project plan
5.2 Planning financial requirements
5.3 Setting up the team
5.4 Recruiting and retaining participants
5.5 Preparing programme materials
5.6 Providing a project description
6. Delivery and monitoring
6.1 If conducting a pilot intervention
6.2 Implementing the intervention
6.3 Monitoring the implementation
6.4 Adjusting the implementation
7. Final evaluations
7.1 If conducting an outcome evaluation
7.2 If conducting a process evaluation
8. Dissemination and improvement
8.1 Determining whether the programme should be sustained
8.2 Disseminating information about the programme
8.3 If producing a final report
C
RO
SS-C
UTTIN
G
 
C
O
N
SIDERATIO
N
S
55
Cross-cutting considerations
1 Needs assessment
2 Resource  
assessment
3 Programme 
formulation
4 Intervention design
5 Management and 
mobilisation of 
resources
6 Delivery and 
monitoring
7 Final evaluations
8 Dissemination and 
improvement
A: Sustainability 
and funding
C: Staff 
development
B: 
Communication 
and stakeholder 
involvement
D: Ethical drug 
prevention
CROSS-CUTTING 
CONSIDERATIONS
There are many recurring themes that do not concern only one project stage, but the entire project 
cycle. For the purposes of these standards, four of these themes have been placed in the middle of 
the project cycle as they should be reconsidered at each project stage. 
A: Sustainability and funding — Programmes should be seen as embedded in a wider framework of 
drug prevention activities. The long-term viability of prevention work should be ensured as possible. 
Ideally, programmes can continue beyond their initial implementation and/or after external funding 
has stopped. However, sustainability depends not only upon the continued availability of funding but 
also upon the lasting commitment of staff and other relevant stakeholders to the organisation and/or 
the field of drug prevention. The standards in this component outline how sustainability can be 
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ensured by ‘anchoring’ programmes within existing systems and by developing strategies to secure 
necessary resources, particularly funding.
B: Communication and stakeholder involvement — Stakeholders are individuals, groups and 
organisations that have a vested interest in the activities and outcomes of the programme, and/or 
who are directly or indirectly affected by it, such as the target population, the community, funders, 
and other organisations working in the field of drug prevention. Relevant stakeholders should be 
contacted and involved in the programme as necessary. The support and cooperation of the target 
population will be a requirement for any programme. Other forms of stakeholder involvement may 
include establishing links with community ‘leaders’ or the local media who subsequently support the 
programme and increase its visibility. Involving other organisations working in the field is useful to 
coordinate efforts, share lessons learnt, and establish joint planning and budgeting. A 
communications strategy enables exchange between the various groups involved in the programme.
C: Staff development — This component consists of three pillars: staff training; further development; 
and professional and emotional support. Staff training needs should be assessed before 
implementation, and staff members should be trained to ensure that the programme is delivered to a 
high standard. The standards also facilitate the development of training plans. Continuous staff 
development is a means of rewarding and retaining staff members and ensuring that their knowledge 
and skills are up-to-date. During the implementation of the programme, it is important to give staff 
members the opportunity to reflect on their work and to improve on the job. 
D: Ethical drug prevention — The standards outline principles of ethical drug prevention which focus 
on: the providers’ lawful conduct; respect for participants’ rights and autonomy; real benefits for 
participants; no harms for participants; providing truthful information; obtaining consent; voluntary 
participation; ensuring confidentiality; tailoring the intervention to participants’ needs; involving 
participants as partners; and health and safety. While it may not always be possible to adhere to all 
principles of ethical drug prevention, an ethical approach must be clearly evident in every project 
stage. Consequently, protocols are developed to protect participants’ rights, and potential risks are 
assessed and mitigated.
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A: Sustainability and funding
Programmes must be designed to ensure the continuity of drug prevention activities. They should be 
part of a wider set of drug prevention activities (e.g. within an organisation or a region), and ideally, 
programmes can continue beyond their initial implementation and/or after external funding has 
stopped (e.g. they can be repeated with a new group of participants once the first group of 
participants has successfully completed the intervention). Sustainability depends upon the logical 
coherence of the programme, continued availability of necessary resources (e.g. money, staff, 
participants) (see component 5.2: Planning financial requirements), and support by relevant 
stakeholders (see B: Communication and stakeholder involvement).
The standards in this component encourage providers to consider how different activities at each 
project stage relate to each other and how they can contribute to the sustainability of the programme. 
They outline also how sustainability can be ensured by ‘anchoring’ programmes within existing systems, 
and by developing strategies to secure necessary resources. Some of these standards are likely to be 
more relevant on an organisational or strategic level than on the level of individual programmes.
Providers are encouraged to seek and apply for a variety of funding schemes. However, it may not 
always be necessary to seek external support. Funding may have already been obtained 
independently of the programme, or the nature of the intervention may not require additional 
resources. Ideally, programmes can be delivered by using or realigning existing resources. Where 
additional resources are required, sustainability can be achieved by securing external support. 
Depending on the scope of the programme, potential sources of income may vary from governmental 
funds to less formal sources, such as the community or individual donations.
The idea of active fundraising targeting a range of funding sources, as suggested in the standards, 
may seem new. Providers may feel that their abilities or opportunities to attract funding are limited. 
Funding practices differ, but local or regional government funds are often the main source of income 
for drug prevention providers. However, these funds cannot always provide the long-term support 
that programmes need. They may also be earmarked for certain activities, thus limiting providers in 
what they can do. A dedicated strategy targeting different types of governmental and non-
governmental funding maximises the chances of implementing and sustaining prevention work.
When applying for funding, the potentially long time spans between submission of the funding 
application and the receipt of respective grants should be considered, particularly with larger 
funding bodies (e.g. EU funding streams). If the programme proposal will be evaluated by a funding 
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body to determine whether the programme should be funded, applicants should consider the relevant 
external criteria.
However, it is equally important that funders and commissioners of drug prevention work ensure that 
sufficient funding is available to sustain promising and effective programmes (see component 8.1: 
Determining whether the programme should be sustained).
Further information on how to ensure the sustainability of programmes can be found, for example, in 
the handbook Guide to implementing family skills training programmes for drug abuse prevention 
(UNODC 2009a, p. 47).
Please see the glossary for definitions of key terms used in the standards.
Basic standards:
A.1 The programme promotes a long-term view on 
drug prevention.
i.e. working against cycles of ‘panic’ and 
‘indifference’ toward drug-related needs, and 
enabling continuous drug prevention.
A.2 The programme is not a fragmented short-term 
initiative.
Examples of evidence: it is embedded in a wider set 
of activities within the organisation; it contributes 
directly or indirectly to a wider strategy.
A.3 The programme is coherent in its logic and 
practical approach.
Note: the coherence of the programme should be assessed for each project stage by examining 
each element of the programme in relation to the other elements.
Purpose: to ensure and demonstrate that the programme is well designed, relevant, and practically 
feasible in the long term.
Example elements to consider: target population needs; aims, goals, and objectives; theoretical 
model; evidence base; setting; methods and activities; resources.
Example aspects to consider: are activities suitable to achieve goals and objectives? Do activities 
target relevant mediators identified in the theoretical model? Are methods correctly chosen for the 
implementation of activities? Are resources sufficient for the implementation of the programme?
Examples of evidence: the logical interrelation between the elements of the programme is presented in 
a programme logic model; connections between programme elements are described.
Additional guidance: Further guidance can be found in the Prevention and Evaluation Resources Kit 
(PERK) (EMCDDA, 2010).
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Basic standards (cont.):
A.4 The programme seeks funding from different 
sources.
Note: even if funding is already secured from a particular source, additional funding should be 
sought to allow the implementation of additional activities, e.g. a diversification of interventions (e.g. 
offering additional services) or organisational activities (e.g. staff development).
Examples of different funding sources:
•  (re-allocation of) internal resources; 
•  sharing of resources with other agencies; 
•  community resources and local government; 
•  private grants and individual donations; 
•  non-governmental and private agencies; 
•  national government and EU support.
Additional expert standards:
A.5 A clear statement of factors to assure the 
programme’s sustainability after its initial completion 
exists in writing.
A.6 The programme is linked with existing delivery 
systems.
Example of evidence: drug education is integrated 
into existing school subjects.
A.7 The drug awareness of relevant stakeholders is 
increased, where appropriate.
Purpose: to obtain ongoing support for the programme.
Examples of relevant groups: community members, family members, commissioners, staff members, 
target population.
Examples of evidence: organising an awareness-raising event, supplying relevant groups with accurate 
data on the needs of the community or target population, organising a theatre play dealing with drug 
issues.
A.8 Partnerships are established with community 
groups.
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Additional expert standards (cont.):
A.9 The organisation has obtained and/or is seeking 
independent accreditations and quality certificates.
Example of certification: International Organization 
for Standardization (ISO) certifications.
Examples of awards: European Drug Prevention Prize 
(Council of Europe Pompidou Group), Mentor Award 
(The Mentor Foundation).
Example of evidence: accreditations and quality 
certificates of the organisation are listed.
A.10 A strategy for long-term funding and attraction 
of resources exists. 
A.11 The strategy:
•  specifies a person or team for the active 
identification and attraction of funding sources; 
Example of evidence: a fundraising manager is 
appointed.
•  identifies all possible sources of funding as well 
as other organisations interested in supporting 
the programme;
Note: funding from sources that are not drug-specific 
can be attracted by taking a comprehensive view on 
drug prevention (UNODC, 2004); relevant funding 
streams may focus on, for example: reducing HIV/
AIDS, reducing crime, improving youth wellbeing.
•  considers the specific criteria for the receipt of 
funding.
Examples of resources: studying funding guidelines, 
consulting with project officer at the funding body, 
considering previously funded programmes, 
considering funding body’s strategic direction 
(UNODC, 2004).
A.12 It is considered whether the programme 
requires adaptation to fit funding criteria; and if 
necessary, the programme is adapted accordingly.
Note: when fitting a programme to funding criteria, 
the needs of the target population and the theoretical 
bases of the intervention (i.e. theoretical model) 
should not be overridden.
A.13 The programme description matches the 
requirements of the funding body.
i.e. it fulfils administrative prerequisites.
Example of evidence: presented in the required format.
A.14 Rules for the acceptance of donations are 
defined.
Examples of relevant donations: donations made by 
businesses and other private organisations.
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B: Communication and stakeholder involvement
For any drug prevention programme, there are individuals, groups and organisations that have a 
vested interest in its activities and outcomes, and/or who are directly or indirectly affected by it. 
Providers should identify these stakeholders, assess their relationship to the programme, and decide 
how and at what project stages they must be involved for a successful programme implementation. 
The standards in this component outline some key aspects of communication and stakeholder 
involvement. However, the precise nature and level of involvement will depend on the particular 
circumstances of the programme.
Involving stakeholders such as the target population, the community, or the media can be 
challenging. It may require additional resources and can slow down the process. Providers may also 
find that stakeholders are not initially interested in contributing to or supporting the programme (see 
component 2.1: Assessing target population and community resources). The standards in this 
component encourage providers to account for the requirements of stakeholder involvement when 
designing the programme. By involving the target population in the programme formulation, the 
programme will be more relevant to participants and consequently more likely to achieve its goals 
and objectives. Providing feedback to participants, for example of evaluation results, is also a 
principle of ethical drug prevention (see D: Ethical drug prevention). Support from the community and 
the media can ensure long-term sustainability (see A: Sustainability and funding). 
The consultations that informed the development of these standards indicated that providers of drug 
prevention should collaborate more, and that the level of exchange between professional groups 
should be increased (e.g. between researchers and practitioners). Communication is important to 
coordinate efforts and resources, to share lessons learnt, and to promote evidence-based 
approaches. It can be difficult to involve other organisations, which is why the standards present 
different levels of involvement from mere awareness of their existence (e.g. for referral of participants) 
up to formal collaboration (e.g. joint budgeting). Sometimes it is easier to collaborate on an 
individual level than on an institutional level, although providers should seek to establish a formal 
relationship if this is required. Local or regional drug prevention planning teams may be able to 
provide information on relevant stakeholders in the area and facilitate collaboration.
The involvement of recipient organisations, commissioners and funders is often a requirement when 
conducting drug prevention work. It is important to consider how the interests of these organisations 
relate to the needs of the target population and participants at each project stage. Commissioners 
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and funders must acknowledge the need for flexibility (e.g. tenders may need to be revised after the 
needs assessment, implementation may differ from the original plan to accommodate participants’ 
needs better). Certain parameters, such as how much flexibility is possible without seeking formal 
approval, should be negotiated as part of the grant or service agreement. Nevertheless, continuous 
two-way communication throughout implementation ensures that the programme is relevant to 
participants as well as to those commissioning or supporting it.
Finally, communication between staff members working on the programme is important to establish a 
common understanding of drug prevention in general and the programme in particular. In 
multidisciplinary teams, differences in professional background can make it difficult to maintain the 
focus on the desired outcomes (e.g. due to different problem definitions). This highlights the need for 
a common professional language and a communications strategy (see component 5.1: Planning the 
programme — Illustrating the project plan). During implementation, timely feedback helps to identify 
necessary modifications and modify the intervention accordingly (see Project stage 6: Delivery and 
monitoring).
More guidance on stakeholder involvement can be found in the Handbook Healthy Nightlife Toolbox 
(Trimbos-instituut, 2010).
Basic standards:
B.1 The multi-service nature of drug prevention is 
considered.
i.e. it is recognised that many different organisations 
and structures contribute to drug prevention: there 
are multiple providers, multiple policy drivers, 
multidisciplinary contributions, etc.
B.2 It is considered that different stakeholders may 
have different problem definitions.
Note: this could also refer to different staff members 
within the team.
Example consideration: what is the common goal 
that all stakeholders can work toward? Stakeholders 
may work toward a common goal, even if they have 
different reasons for pursuing it and/or choose 
different approaches to achieving it.
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Basic standards (cont.):
B.3 Relevant stakeholders for the programme are 
identified.
Note: stakeholders can be involved at various project 
stages, for example to consult on programme 
development, or to collaborate during 
implementation. Staff members are also stakeholders, 
but they are discussed under C: Staff development 
and component 5.3: Setting up the team.
B.4 The terms of reference for stakeholder 
involvement for a successful programme 
implementation are defined, and appropriate action 
is taken.
Example aspects to consider:
•  which groups to involve; in what form, for example consultation, collaboration; 
•  at what project stage, for example in the data collection process during needs assessment, 
programme formulation, implementation, etc., or continuously.
Examples of evidence: relevant contacts have been identified; coordination and cooperation have 
been initiated; written terms of reference.
B.5 The target population is considered as a 
stakeholder in the programme.
Note: the target population represents the group 
from which participants will be drawn. Advocates of 
participants may also need to be considered (e.g. 
parents of young people).
B.6 The organisation cooperates with other agencies 
and institutions:
Examples of agencies and institutions: local entities and administrations, government agencies, 
organisations active in health education and the promotion of young people, regional drug teams, 
youth and healthcare services, schools, police, neighbourhood and residents’ associations, NGOs.
Examples of evidence: partnerships and collaborations are listed.
•  The existence of relevant agencies and institutions 
in the area is assessed.
Note: such information may be readily available 
from local or regional prevention planning teams.
•  Staff members have information on other 
agencies’ work and use this to refer participants 
as necessary.
Example of evidence: staff members know about 
related services in the area; written information on 
referral paths is available to staff members.
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Basic standards (cont.):
•  The team communicates with other agencies. i.e. it shares its expertise and takes on information 
from others.
•  The team coordinates its efforts with other 
relevant stakeholders in the area.
Purpose: to ensure that the programme does not 
unnecessarily duplicate existing efforts unless to offer 
choice of service.
•  The team collaborates with others agencies. Purpose: to support or complement efforts.
Examples: joint action, joint budgeting, sharing of 
resources.
Examples of evidence: the team invites other 
agencies to meetings concerning the programme; the 
team asks other agencies to participate in the 
programme.
B.7 Mechanisms are in place for communication and 
regular exchange within the team.
i.e. internal coordination between all professional 
levels of staff.
Purpose: to assess progress and quality of the 
programme, for example by discussing the 
monitoring findings.
Examples of communication mechanisms: meetings, 
notification tools, discussions.
Additional basic standards if the programme is conducted for a recipient organisation:
B.8 The recipient organisation is considered as a 
stakeholder in the programme.
Examples of recipient organisation: schools, 
community centres.
B.9 The recipient organisation’s needs are assessed 
to determine if the programme is adequate.
B.10 Information provided about the programme is 
comprehensible and enables the recipient 
organisation to take an informed decision.
See also component 5.6: Providing a programme 
description.
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Additional expert standards:
B.11 Stakeholders to consider include:
•  community members; Basic standard if the programme requires community 
involvement.
Examples of relevant community members: 
community ‘leaders’, shop owners, residents.
•  representatives from other organisations; Examples of other organisations: prevention 
providers, social services, law enforcement, public 
health officials, local hospital emergency personnel, 
educationalists.
•  the funding body; Basic standard if funding is received from an external 
funding body.
•  the (local) media; 
•  any other stakeholders. Examples of other stakeholders: government, 
academic researchers.
B.12 The conditions governing relevant stakeholders’ 
work are considered.
Example of conditions: mandatory guidelines.
B.13 The target population is involved at all stages as 
a partner in the programme development.
B.14 The community relevant to the target population 
is involved:
•  The programme promotes open communication 
and dialogue with the general public.
•  The community is encouraged to participate in 
the programme, where appropriate.
•  Links are established with relevant members of 
the community.
Example of relevant community members: community 
‘leaders’.
B.15 A written service agreement or contract 
between the providing organisation and the recipient 
organisation is set up.
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Additional expert standards (cont.):
B.16 Necessary support and agreements to 
collaborate are obtained from other agencies and 
institutions.
Basic standard where these are required for a 
successful implementation of the intervention.
Examples of ‘collaborators’: school head teacher, 
teachers, administrative staff.
Example of evidence: a formal letter of participation 
and collaboration is obtained.
B.17 The organisation is represented in existing 
networks or coordinating bodies, or establishes new 
networks.
Example of coordinating body: local or regional 
drug prevention coordinating teams, prevention 
committees, expert groups.
B.18 The (local) media are involved in the 
programme, where appropriate:
•  The media are asked to promote the programme 
among the target population, or to support its 
aims.
Examples of media involvement: media advertise the 
programme, promote drug prevention values.
•  The media are asked to promote the programme 
among potential funders or donors.
Example of media involvement: media report on the 
successes of the programme.
•  The media are asked and enabled to help 
change negative attitudes towards the target 
population, where appropriate.
Example of media involvement: media avoid 
labelling the target population.
Additional resources: see Additional guidance 
section for media guides.
B.19 Obligations towards the funding body are 
adhered to.
Basic standard if funding has been provided by an 
external body.
B.20 Mechanisms are in place for communication 
and regular exchange:
•  between various agencies involved in the 
programme; 
Basic standard if several agencies are involved in the 
programme.
•  between staff members and participants.
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Additional expert standards (cont.):
B.21 Updates on the progress of the programme are 
communicated:
•  to all persons involved or interested in the 
programme; 
i.e. to all stakeholders that have been identified as 
relevant, including team members and the senior 
management of the organisation.
Note: the funding agreement may include specific 
update requirements (e.g. frequency and format of 
updates). 
•  regularly; 
•  in a user-friendly format that is adequate for the 
target audience.
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C: Staff development
Staff members are a key resource of drug prevention programmes. However, they must have the right 
set of knowledge, skills, and behaviours if the programme is to be implemented successfully. 
Competencies can be distinguished into four broad categories: basic intervention competencies (e.g. 
knowledge of effective drug prevention approaches); specific intervention competencies (e.g. 
knowledge and skills specific to the intervention); general competencies (e.g. generic social skills, 
project management); and meta-competencies which enable staff members to respond to individual 
participant needs (e.g. cultural sensitivity) (adapted from Pilling et al., 2010). The standards 
encourage professionals to consider the different requirements of, and opportunities for, staff 
development throughout the project cycle.
Staff members are sometimes expected to bring all necessary training and qualifications with them 
when they join an organisation, and staff training is consequently not always provided. However, it is 
the responsibility of providers to ensure that staff members’ competencies match the requirements of 
the programme and to reduce the likelihood that staff members (inadvertently) conduct interventions 
that are ineffective or have iatrogenic effects. Providers must consider what competencies are required 
for successful implementation, and conduct a training needs analysis with staff members (including 
volunteers). The analysis may show that staff members already have all required competencies, but 
where gaps are identified, bespoke training must be provided as necessary. The standards outline the 
content of the training as well as the competencies that staff members should meet.
While staff training is important to ensure that the programme is delivered to a high quality, the 
standards also highlight the need for further staff development. These standards are likely to be more 
relevant on an organisational or strategic level than on the level of individual programmes. Staff 
development beyond the immediate needs of the programme is a means of rewarding and retaining 
staff and of ensuring that their knowledge and skills are up-to-date with current developments in the 
field. New guidance issued by the government or other bodies may also introduce a requirement for 
additional skills training. Regular professional development and performance reviews provide staff 
members with the opportunity to discuss career plans and development needs. 
Staff training and development can be offered ‘on the job’ (for example by senior members of the 
team), by organising in-house courses, or by encouraging and supporting staff members to take 
external opportunities (e.g. nationwide training events, conferences, higher education). Some 
organisations may be hesitant to support staff members in taking part in external training, 
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particularly if attendance is not essential for the programme at hand. However, external events can 
be particularly useful in sharing experiences of best practice and establishing links with other 
organisations (see B: Communication and stakeholder involvement). A common barrier to providing 
staff training and development in any form is the perceived lack of funding for such purposes. 
Commissioners and funders should be mindful of the benefits of further staff development and ensure 
that sufficient funds are available. Ideally, they should provide or at least facilitate regional or nation-
wide training and networking events.
The third pillar within this component is professional and emotional support for staff members during 
implementation (particularly for those in direct contact with the target population). It provides an 
opportunity for staff members to reflect on their experiences of implementation and to develop their 
skills on the job, while providers benefit from identifying and fulfilling staff needs as well as 
programme needs (e.g. if staff members report problems during implementation) (see component 6.3: 
Monitoring the implementation). The level of support that staff members receive is often dependent 
upon line managers’ individual working styles and levels of personal engagement. Adherence to the 
standards will ensure a minimum level of support during implementation. Where possible, the 
adequate form of support should be determined together with staff members (e.g. whether staff 
members prefer one-on-one sessions or group discussions).
Further information on how to select, train and support staff members can be found in the Additional 
guidance section.
Note: Component 5.3 contains standards on the selection of staff members.
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Basic standards:
C.1 It is specified which competencies are required 
for a successful implementation of the programme. 
C.2 Competencies to consider include:
•  basic intervention competencies; 
i.e. general knowledge and skills relating to effective drug prevention.
Example competencies: theoretical and practical knowledge on drug use and effective responses to 
drug use (e.g. knowledge on drugs and their effects, antecedents of drug use, risk and protective 
factors, drug and alcohol issues, effective evidence-based drug education, evidence from research 
and previous evaluations on prevention, treatment, care and support, local drug situation and services, 
national drugs strategy and practice, reducing negative impacts of interventions), acting as a role 
model (e.g. drug prevention workers do not take drugs), consideration of own experiences of and 
attitudes towards drug use, open-mindedness toward participants’ views.
•  specific intervention competencies; 
i.e. specific knowledge and skills relevant to the intervention.
Example competencies: knowledge of aims, goals and objectives of the programme, identification with 
programme aims, programme rationale, core values of the programme, knowledge of the project plan, 
intervention delivery and content, theoretical model, benefits for participants, relevant stakeholders, 
services for referral of participants, knowledge of the target population (e.g. target populations’ 
perceptions and experiences of drug use).
•  general competencies; 
Example competencies: knowledge of participant-centred, interactive methods, ‘holistic’ approaches, 
interacting with participants, being non-judgemental towards participants, skills in leadership, being 
comfortable with sharing leadership, networking abilities, communication, decision making, problem 
solving, conflict resolution, creative thinking; project management (e.g. administrative tasks, long- and 
short-term planning); methodological skills (e.g. knowledge of monitoring and evaluation, importance 
of fidelity, feeling of accountability for quality of delivery), confidence, motivation, commitment to the 
programme.
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Basic standards (cont.):
•  meta-competencies.
i.e. competencies that enable staff members to respond to individual participant needs.
Example competencies: cultural sensitivity, e.g. acknowledging cultural differences, respecting 
culturally defined needs, being aware of different types of ‘culture’ (e.g. culture of poverty, exclusion, 
drug use), recognising multiple identities (e.g. high achieving drug user), recognising that cultural 
diversity increases the overall capacity; ethics, e.g. participants’ rights; needs satisfaction; how to deal 
with sensitive situations, empathy.
C.3 A training needs analysis is conducted with 
those staff members who are in direct contact with 
the target population.
i.e. their skill level is assessed to identify training 
needs.
Note: this may be conducted on a periodic basis 
rather than for each intervention.
C.4 Staff members are trained prior to 
implementation of the programme in line with the 
findings from the training needs analysis.
Note: the training needs analysis might conclude that 
there is no need for training, in which case training is 
not required.
C.5 The training is of high quality. This includes:
•  The training is appropriate for the staff. Examples: culturally sensitive, in line with staff 
members’ needs and preferences.
•  The training includes participatory methods. i.e. rather than lecture format.
•  Training providers are suitably qualified. Note: where suitable qualifications are not available, 
training providers should be suitably experienced.
•  Staff members are clear about the goals of the 
training.
C.6 Training outcomes are assessed. Purpose: to assess whether staff training needs have 
been fulfilled, and if additional training is required.
C.7 Prior to implementation, it is ensured that staff 
competencies match the required competencies for 
the programme implementation.
i.e. in line with the four categories of competencies 
outlined above.
C.8 Staff members are supported during 
implementation.
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Basic standards (cont.):
C.9 Support to staff members during implementation:
•  is delivered in a professional and appropriate 
manner; 
•  takes place on a regular and ongoing basis, 
based on staff members’ level of need and 
involvement in the programme; 
•  is equally accessible for all staff members. i.e. including volunteers, part-time staff, etc.
Additional basic standards if a staff development plan exists:
C.10 The staff development plan:
•  is in line with professional regulations and 
recommendations for further education; 
•  gives staff members the possibility to regularly 
discuss their professional career and 
opportunities for further education with their 
manager; 
Purpose: to set development goals, identify training 
needs.
Example of evidence: regular performance 
appraisals.
•  ensures equal access to further education; 
•  is reviewed regularly.
Additional expert standards:
C.11 The training needs of those who do not have 
direct contact with the target population but are in a 
position of influence are considered.
Examples of staff: administrative staff, management, 
commissioners.
Example of evidence: They are asked to attend an 
introductory session about the programme.
C.12 A defined procedure for staff training exists.
C.13 The training is nationally accredited.
C.14 The training is evaluated. Example aspects to consider: number of attending 
staff members, staff satisfaction, learning outcomes.
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Additional expert standards (cont.):
C.15 A staff development plan exists and is adhered to.
C.16 The staff development plan:
•  outlines career goals and progression paths for 
staff; 
•  encourages or obliges staff members to engage 
in further training and education; 
Example of further training: on models of drug 
dependence, developments in the field of drug 
prevention.
•  is seen as a means for rewarding and retaining 
staff members.
i.e. as an opportunity to improve qualifications, and 
a means for recognising staff’s value.
C.17 The funding for staff training and further 
development is sufficient.
C.18 Support to staff members during 
implementation includes:
•  emotional support; Example of emotional support: possibility for staff 
members to talk about their (stressful) experiences in 
a semi-structured conversation (‘debriefing’).
•  external supervision; Examples of content: checking staff members’ 
knowledge and attitudes, functioning of the team.
•  structured support between colleagues; Example of method: a member of staff presents a 
problem, and other staff members help to resolve the 
problem in a structured discussion.
•  on-the-job support. Example: peer mentoring.
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D: Ethical drug prevention
While it is relatively common to discuss the ethics of drug treatment, harm reduction, and research, it 
is less common to scrutinise the ethics of drug prevention. Drug prevention activities may not require 
physical or clinical intervention, but they represent a form of intervention in people’s lives nonetheless. 
All drug prevention programmes are underpinned by judgements about what is ‘good’ or ‘bad’ for 
participants (expressed, for example, in the programme aims). Drug prevention interventions may also 
be introduced as a result of society’s perceptions of a particular behaviour, which may not be shared 
by the target population. Moreover, prevention is typically targeted at young people, and in the case 
of targeted prevention these young people can be among the most vulnerable in society. 
Ethical questions arise therefore on a variety of levels, starting from the justification of drug 
prevention work itself. Professionals should not assume that drug prevention activities are per 
definition ethical and beneficial for participants. The principles of ethical drug prevention in the 
standards are:
•  adhering to legal requirements; 
•  respecting participants’ rights and autonomy (e.g. as defined in international frameworks on 
human rights and the rights of children — see Additional guidance section); 
•  providing real benefits for participants (i.e. ensuring that the programme is relevant and useful for 
participants) (see component 1.3: Describing the need — Justifying the intervention); 
•  causing no harm or substantial disadvantages for participants (e.g. iatrogenic effects, illness or 
injury, exclusion, stigma); 
•  providing transparent, truthful and comprehensive information (see components 5.4: Recruiting 
and retaining participants and 5.6: Providing a programme description); 
•  obtaining participants’ consent before participation; 
•  ensuring that participation is voluntary; 
•  treating participant data confidentially; 
•  tailoring the intervention to participants’ needs (see components 4.3: Tailoring the intervention to 
the target population and 6.4: Adjusting the implementation); 
•  involving participants as partners in the development, implementation, and evaluation of the 
programme (see B: Communication and stakeholder involvement); and
•  protecting participants’ and staff members’ health and safety.
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Depending on the type of programme, it may be difficult or not feasible to adhere to all principles of 
ethical drug prevention. Obtaining informed consent and ensuring voluntary participation may be a 
challenge in universal prevention programmes or, for example, in criminal justice interventions, where 
participants may be legally required to take part in such programmes. In relation to the principle of 
causing no harm, it is noteworthy that targeted prevention approaches may stigmatise participants 
(EMCDDA, 2009, p. 48). Different principles may be in conflict with each other. For example, 
participants may wish to engage in behaviours that cause them harm (e.g. drug use), or, as partners 
in the programme development, participants may ask for intervention approaches that have been 
shown to be potentially iatrogenic (e.g. talking to a former drug user or drug using peer). It can also 
be difficult to judge the ethics of the programme before it has been implemented (e.g. forecasting 
benefits and harms). Finally, all principles are, to some extent, subject to interpretation (e.g. what 
constitutes a benefit?). The standards provide an incentive for providers to verbalise and reflect on 
the underlying values and principles of their programme.
An ethical approach must be clearly evident at every project stage. Providers must consider what is 
possible within the programme (e.g. if written consent is not possible, obtaining verbal consent may 
be) and pay special attention to any specific issues arising from the programme. They should also 
take into account that different stakeholders (e.g. staff members, participants, general public, 
government) may have different viewpoints on what is ‘ethical’. However, participants should always 
be in the focus of attention. 
Basic standards:
D.1 The knowledge of general policy and legislation 
is sufficient for the implementation of the programme.
i.e. staff members and participants are aware of generally binding regulations, their legal 
responsibilities, and internal rules and procedures.
Note: It depends on the particular programme which policies and pieces of legislation are most 
important; further considerations can be found in component 1.1: Knowing drug-related policy and 
legislation.
Examples of policy and legislation: equal opportunities policy, confidentiality policy, child protection 
policy, health and safety policy, laws on waste and environmental protection.
D.2 A code of ethics is defined.
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Basic standards (cont.):
D.3 Participants’ rights are protected:
•  The programme respects and promotes human 
and other basic rights of the participants and 
members of their social network.
Examples of rights: right to information useful to 
oneself, right to equality and non-discrimination.
Example members of social network: friends, 
relatives.
•  Potential situations in which participants’ rights 
could be violated are identified, and ways to 
handle them are specified.
•  Rules on participants’ rights are established. Purpose: for example, to prevent abuse of power due 
to organisation’s or staff members’ status in relation 
to participants.
Note: this could be part of a wider strategy (e.g. 
wider school drugs policy) or specific to a particular 
intervention.
D.4 Staff obligations include:
•  adherence to a staff code of ethics; 
•  acting upon recommendations regarding 
professional or ethical conduct.
Note: particularly where complaints or cases of 
discrimination or abuse are upheld or proven.
D.5 Staff violation of participants’ rights, and 
measures taken in response, are documented in 
personnel records.
D.6 The programme has clear benefits for 
participants.
i.e. it is not a self-referential and self-promoting activity or policy in benefit of the organisation 
providing or commissioning it.
Note: the programme’s benefits can relate to individual members of the target population or to the 
target population as a community (if appropriate). Benefits need not relate directly to drug use, but 
may also include welfare and general health issues.
77
Cross-cutting considerations
Basic standards (cont.):
D.7 Potential disadvantages and risks for the target 
population and likely participants are outlined and 
considered.
Note: the nature and likelihood of disadvantages and harms should be forecast, and measures for 
their reduction and control taken; if the risks are too high or the disadvantages too severe, the 
intervention should be dismissed or suitably modified.
Examples of disadvantages: iatrogenic effects, opportunity costs, illness or injury, exclusion, 
stigmatisation, restriction of leisure activities.
Examples of situations to consider: outdoor activities, violence between participants.
D.8 The values and principles underlying the 
programme are clear.
i.e. values and principles are clear to all 
stakeholders, particularly participants.
Example of evidence: the organisation’s views on 
drug use and drug users’ rights are described in the 
programme description.
D.9 The ‘rules’ of the programme are made clear to 
participants. 
D.10 Participant data is treated confidentially. This 
includes:
•  Clear confidentiality and disclosure protocols and 
procedures are in place.
Note: this could be part of a wider strategy (e.g. 
wider school drugs policy) or specific to a particular 
intervention.
•  Participants’ confidentiality is ensured when 
collecting and handling data.
D.11 The programme reflects cultural sensitivity. i.e. demonstrates awareness of participants’ values, 
and respect for participants’ views on the 
intervention and the staff.
Example aspects to consider: importance of 
community ‘leaders’ and gatekeepers, cultural aspects 
of staff-participant interaction (e.g. what gender, age, 
ethnicity are acceptable to the target population).
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Basic standards (cont.):
D.12 The safety of staff members and participants is 
ensured:
Example of evidence: the facility is perceived as safe 
by staff members and participants.
•  Minimum rules on safety are defined. i.e. health and safety requirements are considered 
and adhered to.
Examples: appropriate level of cleaning and 
disinfection to prevent the spread of infectious 
diseases; laws on food safety are considered if 
participants want to cook or bring meals.
•  Measures and internal rules for staff protection 
exist in writing, and they are known and adhered 
to.
Example aspects to consider: adequate working 
conditions, liability insurance for volunteers.
•  Accidents, emergencies, and extraordinary 
incidents are defined, and procedures for dealing 
with them are written and known to staff 
members.
Example of evidence: defined in an organisational 
code and operational manuals.
D.13 Participants with drug-related needs that cannot 
be responded to within the programme are referred 
to specialist services.
D.14 Participants having additional drug-related 
needs feel safe and comfortable enough to ask for 
help.
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Additional expert standards:
D.15 Alcohol, tobacco, and illegal drugs are banned 
in the facilities of the programme.
Basic standard if required by law.
Note: Adherence to this standard may not be 
feasible under certain circumstances, for example if 
the intervention is delivered in an external recipient 
organisation (e.g. nightclub).
D.16 The programme complies with national and 
international standards and guidelines.
Basic standard if required by existing policy and 
legislation.
Example of standards: national occupational 
standards in drug prevention, if available.
D.17 The participants’ code of rights is publicly 
posted and easy to understand.
D.18 A complaints procedure is in place. Example of content: participants can obtain 
information about how their complaint has been 
settled.
Examples of evidence: the complaints procedure is 
known to participants and staff members; the 
complaints procedure is defined in writing.
D.19 The programme supports the relationships 
within families and communities.
D.20 A detailed programme description is provided 
to participants.
Examples of content: duration, form, and contents of 
programme, expected effects, benefits and risks, 
rules and obligations, expected participants’ 
behaviour.
See also component  5.6: Providing a programme 
description.
D.21 Participants’ access to documentation of the 
programme is defined.
D.22 Intended aims, goals, and objectives are stated 
to participants at the beginning of each session.
Note: these could be defined together with 
participants.
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Additional expert standards (cont.):
D.23 The roles and tasks as well as rights and 
responsibilities of participants and staff members are 
defined.
Example of evidence: ground rules are set for each 
session or group.
D.24 A learning contract is negotiated with 
participants.
Note: the contract could be in verbal or written form.
Example of content: participants’ expectations of the 
intervention.
D.25 The rules of the programme are fair. Example: rules apply to participants as well as staff 
members.
D.26 Participation in the programme is based on 
informed consent.
Basic standard if feasible within the intervention.
D.27 Participation in the programme is voluntary. i.e. participants are not obstructed from withdrawing 
from the programme.
Basic standard if participation is not a legal 
requirement.
Note: this standard may not apply under certain 
circumstances, for example in criminal justice 
interventions, or in the case of universal school-
based interventions.
D.28 The community or participants agree to how 
their culture is incorporated into the programme.
Example aspects to consider: use of cultural symbols 
or community knowledge.
Example of evidence: the programme is designed in 
consultation with representatives of the community or 
target population.
D.29 The programme’s structures and processes 
reflect democratic values.
Examples of evidence: participants can provide 
feedback on the programme; participants are 
consulted during the delivery of the programme.
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Additional expert standards (cont.):
D.30 Staff members are present during external 
agency involvement.
Note: this standard may not be applicable where it 
would breach participants’ confidentiality or where it 
would not be in line with programme aims.
Example of external agency involvement: external 
lecturer (e.g. police officer) talking to school class.
D.31 Responses to drug-related incidents occurring 
during programme delivery are prepared. This 
includes:
•  Drug use and other problem activities on or near 
the premises of the organisation or intervention 
are monitored.
•  Procedures are in place regarding infractions, 
complaints, and disciplinary measures.
•  The management of drug-related incidents 
corresponds to the overall aims of the 
programme.
•  A support system is in place for any participant 
having drug-related needs.
•  Assessment procedures and referral routes are 
transparent.
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CROSS-CUTTING 
CONSIDERATIONS
1 Needs assessment
Before the intervention can be planned in detail, it is important to explore the nature and extent of 
drug-related needs, as well as possible causes and contributing factors to those needs. This ensures 
that the intervention is necessary, and that it will address the correct needs and target population(s). 
Four types of needs are distinguished: policy needs; (general) community needs; needs defined by 
gaps in the provision of prevention; and (specific) target population needs.
1.1 Knowing drug-related policy and legislation: Drug-related policy and legislation should guide all 
drug prevention activities. The team must be aware of and work in correspondence with drug-related 
policy and legislation at the local, regional, national, and/or international level. Other guidance, 
such as binding standards and guidelines, should also be considered where appropriate.
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1.2 Assessing drug use and community needs: The second component in this project stage specifies 
the requirement to assess the drug situation in the general population or specific subpopulations. The 
assessment can utilise quantitative and/or qualitative methods, and should draw upon existing data 
where relevant data of high quality is already available. Other relevant issues, such as deprivation 
and inequalities, should also be assessed to account for the relationship between drug use and other 
needs. 
1.3 Describing the need — Justifying the intervention: The findings from the community needs 
assessment are documented and contextualised to justify the need for the intervention. Existing drug 
prevention programmes are analysed to gain an understanding of how the programme can 
complement the current structure of provision.
1.4 Understanding the target population: The needs assessment is then taken further by gathering 
detailed data on the prospective target population, such as information about risk and protective 
factors, and the target population’s culture and everyday life. A good understanding of the target 
population and its realities is a prerequisite for effective, cost-effective and ethical drug prevention.
This stage may be conducted at the same time as, or after, the resource assessment.
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1
1.1 Knowing drug-related policy and legislation
In order to have an impact, all drug prevention activities must strive toward the same end, albeit 
through different means. By defining the aims of drug prevention work, drug-related policy and 
legislation act as signposts guiding drug prevention activities on a local, regional, national and 
international level. It is therefore essential that all professionals — not only those working ‘at the top’ 
— are aware of relevant policy and legislation, as this enables everyone to contribute to these aims. 
Other guidance, such as binding standards and guidelines, should also be taken into consideration 
where appropriate.
It is equally important to stay up-to-date with changes in drug-related policy and legislation, as these 
may affect different aspects of the programme. For example, changed funding priorities may require 
a new strategy to ensure the programme’s sustainability (see A: Sustainability and funding); or, where 
participants receive information about drugs as part of the intervention, changes in legislation may 
require an update of the intervention content (e.g. reflecting changes in the legal status of drugs such 
as ‘legal highs’).
Moreover, by showing awareness of, and correspondence with, drug-related policy and legislation, 
providers maximise their chances of obtaining necessary support from commissioners and funders. 
In some countries, demonstrating support of relevant strategies is a criterion for obtaining 
government funding. However, these standards should not prevent programmes from addressing 
needs that are not current policy priorities. For example, the identified needs of the target 
population or community may not be explicitly targeted by existing policies and funding (see 
component 1.2: Assessing drug use and community needs). In such cases, programmes should still 
support the wider drug prevention agenda as defined by national or international strategies and 
make a case for the response to other needs.
While it is ultimately up to funders and commissioners to ascertain that programmes are in line with 
policy and legislation, all professionals should have a general level of knowledge in this area. 
Practitioners who spend a large amount of time working in direct contact with the target population 
may feel that learning about drug-related policy and legislation, and staying up-to-date with new 
developments, is beyond the remit of their work. It is the responsibility of providers to support staff 
members in achieving these standards, for example by holding in-house training events (see C: Staff 
development).
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It can be difficult to judge which policies and pieces of legislation are most relevant. Policy priorities 
can change frequently, coinciding with a new government, shifts in society’s concerns, or an 
important new piece of research. The Additional guidance section contains a selection of important 
contemporary documents in relation to international and national drug policy and legislation. 
However, the relevance of documents can depend on the type of the programme. For example, a 
local programme would be expected to prioritise local or regional documents over national and 
international ones, as these would be less relevant to the local context.
Note: Component D: Ethical drug prevention contains standards on general policy and legislation.
Basic standards:
1.1.1 The knowledge of drug-related policy and 
legislation is sufficient for the implementation of the 
programme.
Examples of policy and legislation: relevant 
legislation covering drugs, alcohol, tobacco, 
medicines, and volatile substances; health education 
policy.
1.1.2 The programme supports the objectives of 
local, regional, national, and/or international 
priorities, strategies, and policies.
Note: local/regional programmes should pay 
particular attention to local/regional policy 
documents.
Example of evidence: the programme description 
provides clear references to the most relevant 
strategies and policies, and it positions itself in 
relation to these.
Additional expert standards:
1.1.3 The programme complies with relevant local, 
regional, national, and/or international standards 
and guidelines.
Basic standard if required by existing policy and 
legislation.
Example of standards: existing standards on making 
services young-people friendly (e.g. Department of 
Health, 2007).
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1
1.2 Assessing drug use and community needs
Drug prevention programmes must respond to the needs of the target population in order to be 
ethical and effective. It is therefore not sufficient to rely on assumptions or ideology when planning 
prevention work. Instead, drug prevention programmes must be informed by an empirical assessment 
of people’s needs, regardless of whether it is a universal or targeted prevention programme. This 
assessment can target the general population or a subpopulation which is usually defined through a 
common social feature (e.g. ethnic community), a particular setting (e.g. school), or a geographic 
area (e.g. neighbourhood).
Depending on the type of organisation and programme, it may not be necessary to conduct a needs 
assessment for each individual programme, and one needs assessment may inform several different 
programmes across a defined time span. Nevertheless, as drug trends can change rapidly, it is 
important to ensure that findings are updated frequently. The assessment can be conducted by 
collecting and analysing new data using quantitative and/or qualitative methods (e.g. surveys, focus 
groups, observation), and/or by drawing upon existing (epidemiological) data to conduct a 
secondary data analysis. Basic data on drug use is often already available for the general 
population and/or subpopulations (e.g. young people, people in treatment), as it is collected as part 
of routine surveys and monitoring (see Additional guidance section). However, the potential caveats 
of existing data must be taken into account (e.g. quality, topicality, and relevance). For example, only 
national data may be available, which can be useful to interpret local data, but cannot replace local 
data. It is recommended to consult multiple and differing data sources to gain a comprehensive 
picture of the situation. Detailed guidance on how to conduct needs assessments can be found in the 
Additional guidance section.
The consultations that informed the development of these standards indicated that there was often a 
lack of communication between those who collect data on a regular basis (e.g. regional drugs 
coordination teams, public health observatories, researchers) and those who could use the data to 
develop programmes (e.g. commissioners, providers). For example, although schools are often 
researched they do not usually have access to the data in order to ensure pupils’ confidentiality. 
Consequently, existing data is not always used to inform programme development. However, even in 
the above example data may be provided to schools if several schools are included in an 
anonymised dataset with a large sample size. If needs assessments are not conducted by providers 
themselves, then structured collaboration is required to ensure that they receive the data (see B: 
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Communication and stakeholder involvement). Local or regional drugs coordination teams could be 
well suited to coordinate regional data collection and analysis to reduce duplication of efforts. 
Indeed, drugs coordination teams should consider the possibility of conducting regular needs 
assessments or consolidate data from different sources to inform the work of prevention providers in 
the area.
The standards in this component focus on the assessment of drug-related needs in order to identify 
the appropriate target population and setting for the programme. However, data on drug use alone 
is often not sufficient to design an adequate and tailored intervention. Other needs, such as health 
and social inequalities or levels of deprivation, should also be assessed to understand the complex 
nature of drug use. It is useful to consider already at this project stage which theoretical model will 
guide the programme, as it can determine what data to collect and how to interpret it. Component 
Understanding the target population in Project stage 1 presents the opportunity to conduct a more 
in-depth analysis of the target population.
Basic standards:
1.2.1 A study of the initial situation is conducted. 
1.2.2 The study utilises existing epidemiological 
knowledge.
1.2.3 The study is ethically sound. Examples of ethical soundness: the study ensures 
confidentiality and anonymity of respondents; it does 
not stigmatise or disadvantage informants.
See also: D: Ethical drug prevention.
1.2.4 Detailed and diverse information on drug use 
is gathered or reviewed. This includes:
Examples of groups to describe: general population, 
subpopulations differentiated by sex, age, ethnicity, 
vulnerability.
•  types of drugs used; Examples of drugs: legal, illegal, and medically 
controlled drugs.
•  drug use rates and trends. Examples of indicators: incidence and prevalence 
rates, use-rates in the last 30 days/last year/lifetime, 
proportion not using any drugs.
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Basic standards (cont.):
1.2.5 Other relevant needs in the community or 
setting are assessed.
Purpose: to account for the relationship between 
drug use and other needs.
Examples of needs: problems, wishes, (historical) 
prevalence of problematic behaviour, levels of socio-
economic deprivation and inequalities.
1.2.6 The study is documented, and sources of the 
data or information are indicated.
Purpose: documentation of the study is useful for the 
justification of activities and as a record.
Additional basic standards if existing data is used:
1.2.7 Existing data is: Examples of resources: local, regional, national 
datasets.
•  up-to-date; 
•  adequate for the programme scope and target 
population; 
Example of adequacy to programme scope: local 
data for local projects.
•  valid in terms of the indicators used; Example of indicators: drug use prevalence data is 
used rather than intentions to use drugs or perceived 
use in peers.
•  reliable. i.e. in regard to the data collection methodology and 
analysis.
Additional expert standards:
1.2.8 The study of the initial situation: 
•  enables knowledge of the operating environment 
within which the intervention will take place 
(‘climate’ of the environment); 
i.e. of the community or setting (e.g. recipient 
organisation) in which the intervention will take 
place.
Example aspects of environment and its culture: 
norms, goals, values, relationships, practices, 
organisational structures that are relevant within the 
local community.
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Additional expert standards (cont.):
•  is done in a systematic and rigorous manner; i.e. the study uses a recognised needs assessment 
methodology.
Example of evidence: the instruments and tools used 
to assess community needs are described.
Additional guidance: Detailed guidance on how to 
conduct needs assessments can be found in the 
Additional guidance section.
•  is done by spending time in the community; Examples of evidence: field research, discussions 
with community stakeholders.
•  seeks expert guidance on methodology, if 
needed.
Examples of ‘experts’: academics, local intelligence 
managers.
1.2.9 A team to oversee data collection and data 
analysis for this phase is assembled.
i.e. roles and responsibilities are assigned.
Examples of responsibilities: planning and 
coordinating needs assessment, data collection, 
analysis, and interpretation, writing up findings from 
the needs assessment.
1.2.10 The population size in the area or community 
is given or estimated:
Examples of data sources: statistical institutes, local 
councils, educational bulletins.
•  for the total population; Basic standard if such information is available.
Examples of total population: general population, all 
school children, all members of an ethnic community.
Example of resources: census data.
•  for the likely target population. i.e. those who are likely to be targeted by (e.g. 
participate in, exposed to) the intervention.
Basic standard if such information is available.
Example: target population estimated as a 
proportion of the total population.
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Additional expert standards (cont.):
1.2.11 Information that is gathered or reviewed 
includes:
•  drug use patterns and trends; Examples of indicators: frequency of use, situation 
and circumstance of use, functions of use, age of 
initiation, age of peak use, frequency and extent of 
occasional, regular, and/or heavy use, hazardous 
practices, populations at greater risk.
•  differentiated adverse effects of drug use; Examples of indicators: nature of harm and affected 
people, individual and community impact of drug 
prevalence, drug dependence.
•  drug-related perceptions; Examples of indicators: perceived harm of drug use, 
perceived availability of drugs, perceived 
disapproval and acceptability of drug use.
•  existence of drug markets.
1.2.12 The obtained data is compared with similar 
data from other localities or regions, or with national 
data.
Purpose: to assist with the justification of the 
intervention.
Examples of comparisons: drug use prevalence, 
analysis of drug problem at individual, institutional, 
and societal levels.
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1.3 Describing the need — Justifying the intervention
The need for the intervention is defined by drug-related policy (see component 1.1: Knowing drug-
related policy and legislation), target population and community needs (see 1.2: Assessing drug use 
and community needs and 1.4: Understanding the target population), and the existing level and 
nature of prevention provision. In this component, the findings from the previous components are 
documented and contextualised to justify the need for the intervention. 
In these standards, organisations are asked to provide an overview of the main need(s) of the 
community, point toward particular issues, explain why these issues are relevant, and identify 
necessary actions to improve the situation (or to prevent an undesirable development). This 
description will help determine whether the correct target population is chosen for consideration in 
subsequent components such as 1.4: Understanding the target population, and also inform the 
choice of programme aims (see 3.3: Defining aims, goals, and objectives). 
The justification should take into account the views of the community to ensure that the programme is 
relevant to them (see D: Ethical drug prevention, B: Communication and stakeholder involvement). It is 
therefore important to involve the community and other relevant stakeholders when describing needs; 
this is essential if the community needs assessment was based on a secondary data analysis (e.g. 
using routine data). However, communities may not be willing to accept that there is a need for an 
intervention, as this can be interpreted as admitting that there is a (drug) problem. For example, 
school head teachers may worry that the introduction of a drug prevention intervention could 
damage the reputation of their school. There may be less of a stigma if school-based drug prevention 
is a statutory part of government policy. Providers and policy makers should avoid focussing on 
‘problems’ but consider ‘needs’ instead — there can be a need for a prevention programme before a 
problem has developed.
It is likely that there are already some drug prevention programmes in operation. Existing and recent 
programmes that contribute to drug prevention are therefore analysed to gain an understanding of 
how the new programme can fit in. Local or regional drug prevention planning teams may be able to 
provide information on existing programmes in the area. The new intervention should complement 
existing efforts by filling gaps in the current provision of drug prevention. For example, low coverage 
of the target population may indicate the need for additional programmes. If the target population is 
already well covered through existing effective drug prevention programmes, providers may want to 
focus on a different target population to avoid duplication of efforts. However, they may also decide, 
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for example, to offer a different type of intervention for the same target population in order to 
increase choice and diversity of provision.
In some cases, the justification and direction of the intervention may have already been set out by a 
specific tender for projects, and providers may feel that the tender itself is the justification for the 
programme. Nevertheless, it is important that the justification of the intervention is based on factual 
information about the community, not assumption. Commissioners and funders must consequently 
acknowledge the need for flexibility (e.g. tenders may need to be revised after the needs 
assessment). Communication between providers and commissioners or funders ensures that the 
programme is relevant to the community as well as those enabling its implementation (see B: 
Communication and stakeholder involvement).
Basic standards:
1.3.1 The main needs of the population are 
described and, if possible, quantified.
Example aspects to consider: drug-related needs, 
health, policy, and social needs.
1.3.2 The description is informed by the needs 
assessment.
1.3.3 The description illustrates the potential future 
development of the needs without an intervention.
Examples of indicators to consider: rate of growth of 
illegal drug use, rate of transmission of blood-borne 
viruses.
1.3.4 The organisation is aware of existing and 
recent programmes that contribute to drug 
prevention.
Note: such information may be readily available from local or regional prevention planning teams.
Examples of programmes: existing social and health services, previous programmes for the target 
population, regional and local strategies.
Example considerations: what other organisations there are, what services they offer.
1.3.5 Existing and recent programmes that contribute 
to drug prevention are analysed according to their 
correspondence with target population and 
community needs.
Purpose: to identify gaps in service provision.
Example considerations: which target populations 
are covered, what needs are addressed by existing 
services.
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Basic standards (cont.):
1.3.6. The programme complements other health 
promotion or drug prevention programmes locally, 
regionally, and/or nationally.
Example: the programme focuses on groups that are 
not already well covered by several other 
programmes and services (e.g. targets different age 
groups).
1.3.7 The need for an intervention is justified. Example aspects to consider: the programme’s 
usefulness, expected cost-effectiveness.
Additional expert standards:
1.3.8 The description of the main needs of the 
population:
•  includes an estimate of costs associated with the 
(potential) problem; 
Examples of costs: financial, health, social, and 
community costs.
•  identifies specific subgroups or places; 
Purpose: to determine relevant subgroups or places for consideration, see 1.4: Understanding the 
target population, 3.1: Defining the target population and 3.4: Defining the setting.
Examples: identifying groups and/or places for prevention work by using incidence and prevalence 
data to establish local ages of drug use onset (target population’s age would be below the age of 
onset); identifying groups and/or places for reduction of drug use by using prevalence data to identify 
‘who’, ‘what’, and/or ‘where’ are contributing most to drug use rates (CSAP, 2002).
•  determines other factors associated with 
(potential) drug use; 
Examples of other factors: non-drug related needs of 
the community; political, structural, economic issues, 
e.g. deprivation, poverty, inequalities.
•  takes into account the views of the community or 
likely target population on the identified drug-
related needs; 
Purpose: to ensure that the intervention is relevant 
and likely to be accepted.
Example of finding: target population may not view 
drug use as a problem.
•  identifies changes necessary for an improvement 
in the situation; 
Examples of changes: policy changes, macro-level 
interventions.
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Additional expert standards (cont.):
•  differentiates between changes that are 
necessary but are beyond the programme’s 
capacities, and changes that can be covered by 
the programme.
1.3.9 Existing and recent programmes that contribute 
to drug prevention are analysed according to their:
Purpose: to identify gaps in service provision.
•  coverage of the target population; i.e. percentage of target population.
Example: if the target population is defined as ‘at-risk 
youth’, coverage can be expressed as the number of 
at-risk youth participating in existing programmes 
given as a percentage of all at-risk youth in the 
catchment area.
•  design, delivery, and impact. Examples of indicators: programme fidelity (whether 
previous programmes were implemented as 
designed), staff competency, effectiveness and 
impact of the intervention.
1.3.10 The intervention addresses needs that are:
•  urgent and important; 
•  costly and/or common; i.e. the consequences of unmet needs have high 
social and financial costs; and/or they have a high 
prevalence in society or the community.
Note: some behaviours can be uncommon but very 
costly to society, for example heroin dependence.
•  defined as drug prevention priorities by local, 
regional, national, or international agencies.
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1.4 Understanding the target population
A good understanding of the target population and its realities is a prerequisite for (cost-) effective 
and ethical drug prevention. Drug prevention must be carried out not only for people, but also with 
people, and therefore drug-related needs must also be viewed from a wider cultural and social 
perspective. The general assessment of drug-related and other needs in the general population or a 
specific subpopulation (see 1.2: Assessing drug use and community needs) indicates what the 
programme’s aims and target population could be, i.e. who the intervention should be directed 
toward, and why. However, a more in-depth analysis of the prospective target population at this 
point ensures that the design and content of the intervention are well chosen in the later project 
stages (see 4.3: Tailoring the intervention to the target population).
This component specifies the requirement to explore the target population’s culture, its position in the 
wider community, and its perspectives on drug use. This data complements the drug use data 
gathered earlier, and provides important indications for the intervention design. Where the target 
population has been chosen prior to the needs assessment (e.g. as part of a project tender), this step 
may be carried out together with the community needs assessment in 1.2: Assessing drug use and 
community needs. Apart from obtaining a general knowledge of the target population’s culture, it is 
important to understand the role of drug use in the culture (UNODC, 2004, p. 9). For example, 
certain drug use may be acceptable as part of a cultural custom (e.g. the use of alcohol to mark a 
celebration such as New Year; drug use as part of initiation rituals in certain youth cultures), while 
other forms of drug use may be sanctioned. Knowledge of drug-related cultural norms and practices 
should inform intervention design to ensure that the intervention is culturally relevant. 
Relevant factors that reduce or increase the likelihood of drug use in the target population should 
also be mapped and assessed. The findings from this analysis help define the target population (see 
3.1: Defining the target population), choose goals and objectives (3.3: Defining aims, goals, and 
objectives), and design the intervention (see Project stage 4: Intervention design). It is also possible to 
assign a risk level to the target population depending on the concurrence of risk and protective 
factors. However, the analysis of risk and protective factors is not essential for universal prevention 
programmes, as these do not single out individuals or groups with a higher risk of drug use.
In some programmes, there is a distinction between the ultimate target population (e.g. young people 
at risk of drug use) and the intermediate target population which is believed to have a strong 
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influence on the ultimate target population (e.g. parents of these young people). These interventions 
are carried out with members of the intermediate target population in order to indirectly influence the 
behaviour of the ultimate target population. In such cases, the provider must understand important 
aspects about both the intermediate and the ultimate target population, such as risk and protective 
factors relating to the ultimate target population, the intermediate target populations’ views on drug 
use, and details on the interaction between the intermediate and the ultimate target population.
Detailed information on the target population may already be available (e.g. research reports). It is 
therefore recommended to consult relevant literature to gain a better understanding of the target 
population. Additional information about the target population may also be obtained by contacting 
relevant stakeholders (e.g. regional drugs coordinating team, health and social services operating in 
the area) (see B: Communication and stakeholder involvement).
Basic standards:
1.4.1 A potential target population is chosen in line 
with the needs assessment.
Note: the final choice of the target population may depend on the findings from the analysis of 
risk and protective factors. Decisions on the target population may have already been taken 
prior to the needs assessment, for example through tenders for funding. If the needs assessment 
shows that an alternative target population would benefit more from an intervention, the 
original strategy should be developed further.
1.4.2 The target population’s culture and 
perspectives on drug use are included in the needs 
assessment.
Purpose: this will inform the design of the intervention 
as well as its tailoring to the target population.
Note: differences within the target population should 
be taken into account.
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Additional expert standards:
1.4.3 Risk and protective factors for drug use are 
explicitly mapped. This includes:
i.e. the numbers, types, and scale of main risk and 
protective factors are assessed.
Notes: the analysis of risk and protective factors is 
not as relevant to universal prevention. It is most 
relevant as a means for describing the target 
population, for example in terms of conduct 
disorders or sensation seeking.
•  Risk and protective factors are differentiated 
according to the characteristics of the target 
population.
Examples of indicators: age, sex, culture, 
vulnerability.
•  Risk and protective factors that are unique to the 
target population are identified.
Example aspects to consider: mental health issues, 
gender, sexual orientation, culture, ethnicity, 
environment.
•  The impact of broad health determinants is 
assessed.
Examples of indicators: family income, parent 
educational levels, early childhood experiences.
•  The role of the community as a risk or protective 
factor is assessed.
Examples of indicators: indices of deprivation, 
availability of drugs, structural support, community 
norms.
•  The strength of risk and protective factors is 
estimated.
i.e. they are quantified or qualified in terms of their 
relevance to drug use.
Example aspects to consider: relevance to the 
individual, the family, peer, school, workplace, 
community.
•  Similar risk factors or protective factors are 
grouped together.
Examples of categories: genetic, biological, social, 
psychological, familial, contextual, educational, 
economic, cultural.
•  Clusters of risk or protective factors that could be 
addressed together are identified.
Example: a community regeneration/ cohesion 
programme would address several community-
related factors.
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Additional expert standards (cont.):
1.4.4 Factors which can be modified are 
distinguished from factors which cannot be modified 
by the programme.
Examples: health literacy can be improved, but 
national public health policy is unlikely to be 
changed by a small-scale intervention.
1.4.5 Modifiable factors to be targeted by the 
programme are specified.
Example of evidence: presented in a logic model.
1.4.6 The risk level of the target population is 
defined.
Example of risk level definition: ‘high risk’ of early 
onset of drug use due to diagnosis of behavioural 
conduct disorder.
Example consideration: which type of intervention 
(universal, selective, indicated) is appropriate for this 
risk level? 
1.4.7 Perspectives to consider when assessing the 
target population include:
Note: differences within the target population should 
be taken into account.
•  self-perception of the target population; Example of indicators: perception of impact of drug 
use on own health and that of others.
•  cultural aspects; Example aspects to consider: general traditions and 
habits, beliefs and social rules, values.
Examples of indicators: hierarchies and types of 
relationships in the family, school, or workplace; 
beliefs about how to cope with stress.
•  general problems and needs, expectations, 
opinions and attitudes; 
Example of indicators: situation of drug use in the 
wider biography of members of the target 
population.
•  the ‘language’ of the target population; Examples of indicators: music, books, magazines, 
Internet, television programmes that the target 
population consumes; how members of the target 
population express ideas about drug use and 
prevention (e.g. youth rejection of ‘Just say NO to 
drugs’ messages).
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Additional expert standards (cont.):
•  persons and institutions that are important to the 
target population; 
Examples of persons and institutions: community 
figures, celebrities, role models, school.
•  motivations for drug use; Examples of indicators: functions of drug use, drug 
effect expectations.
•  perceptions of harms and benefits of drug use; 
•  existing knowledge, and need for information or 
education; 
Example indicator: knowledge of national laws on 
drug use.
•  views on the media and drug prevention or drug 
‘promotion’ messages in the media; 
Example indicator: media literacy skills.
•  expectations of the aims, goals, and objectives of 
drug prevention programmes; 
Examples of expectations: target population expects 
programmes that are empowering, that grant access 
to specialist services.
•  views on providers and staff members. Example of provider: drug service.
1.4.8 Relevant stakeholders are involved in 
determining target population needs.
Examples of stakeholders: family members of the 
target population (where appropriate), for example 
parents of school children.
Examples of stakeholder contributions: perspectives 
on target population’s drug use, ways of responding 
to drug use, expectations towards prevention 
providers (e.g. drug services).
1.4.9 The nature of the relationship between the 
target population and the community is included in 
the needs assessment.
Example aspects to consider: the target population’s 
perception of the community; community’s perception 
of the target population; the target population’s 
position and level of integration in the community.
Examples of indicators: levels of social/ educational/ 
economic/ service inclusion and exclusion.
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Project stage 2 
Resource assessment
A programme is not only defined by target population needs, but also by available resources. While 
the needs assessment (see Project stage 1: Needs assessment) indicates what the programme should 
aim to achieve, the resource assessment provides important information on whether and how these 
aims can be achieved. Thus, resources must be assessed to gain a realistic understanding of the 
desirable type and possible scope of the programme.
2.1 Assessing target population and community resources: Drug prevention programmes can only be 
successful if the target population, community and other relevant stakeholders are ‘ready’ to engage, 
e.g. able and willing to take part or support implementation. They may also have resources that can 
3 Programme 
formulation
4 Intervention design
5 Management and 
mobilisation of 
resources
6 Delivery and 
monitoring
7 Final evaluations
8 Dissemination and 
improvement
A: Sustainability 
and funding
C: Staff 
development
B: 
Communication 
and stakeholder 
involvement
D: Ethical drug 
prevention
CROSS-CUTTING 
CONSIDERATIONS
1 Needs assessment
2 Resource  
assessment
104
European drug prevention quality standards
be utilised as part of the programme (e.g. networks, skills). The standards in this component describe 
the requirement to assess and consider potential sources of opposition and support, as well as 
available resources of relevant stakeholders.
2.2 Assessing internal capacities: The analysis of internal resources and capacities is important, as 
the programme will only be feasible if it is in line with available staff, financial, and other resources. 
This step is carried out before programme formulation to gain an understanding of what types of 
programmes might be feasible. 
This stage may be conducted at the same time as the needs assessment, or at the beginning of the 
project before the needs assessment.
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2.1 Assessing target population and community resources
Drug prevention programmes can only be successful if they are supported by all relevant 
stakeholders, such as the target population, the community, and the recipient and referral 
organisations (where applicable). The main condition of support is that these stakeholders are ‘ready’ 
to engage with the programme, i.e. aware of the (drug-related) needs, as well as interested, willing, 
and able to support (e.g. take part in) the programme (NIDA, 2003).
The standards in this component describe the requirement to assess the level of readiness among the 
target population, the community, and any other relevant stakeholders (see B: Communication and 
stakeholder involvement). The findings of this assessment will indicate, for example, what must be 
done to obtain the necessary level of support and what difficulties might occur during implementation 
(e.g. when enrolling and retaining participants). Consequently, a more realistic estimate of the 
timeline and other necessary resources is possible. Research has identified distinct stages of 
community readiness that can help determine the current level in the target population or community 
(e.g. Plested et al., 1999).
The target population or wider community may also have resources that can be utilised in the 
programme. Some resources may facilitate implementation of the programme from a practical point 
of view (e.g. community members have good relationships with members of the target population 
and can help providers to establish contact). Other resources may be relevant and useful to the 
design and content of the intervention (e.g. providers plan intervention activities that make use of 
participants’ existing skills and talent) (see Project stage 4: Intervention design). This component 
therefore also examines existing strengths and weaknesses within the target population or 
community.
Consequently, while components 1.2: Assessing drug use and community needs and 1.4: 
Understanding the target population are about gaining a better understanding of the context within 
which drug use may occur, this component assesses the relationship between the programme itself 
and the target population or community in which it will take place.
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Basic standards:
2.1.1 Sources of opposition to, and support of, the 
programme are considered, as well as ways of 
increasing the level of support.
Note: this is not limited to the target population and 
the community, but could include other stakeholders, 
such as school head teachers, media, national 
government.
2.1.2 The ability of the target population and other 
relevant stakeholders to participate in or support the 
programme is assessed. 
i.e. their availability (e.g. time, physical presence) to participate in or support the programme.
Basic standard includes the community if community members (e.g. general public, officials) will 
be involved in the programme or where parts of the intervention are delivered in the 
community.
Note: relevant stakeholders should be identified in line with B: Communication and stakeholder 
involvement.
Example conclusions: social inclusion programmes should take place in school holidays or after 
school; brief interventions should be delivered at a suitable point in service utilisation.
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Additional expert standards:
2.1.3 The readiness of the target population and 
other relevant stakeholders for the programme is 
assessed, including their:
•  awareness of drug use and related needs; 
•  interest in the prevention programme; 
•  willingness to participate in or support the 
programme.
2.1.4 The resources of the target population and 
other relevant stakeholders are assessed.
Purpose: to inform the project plan as well as 
intervention content and design.
Example of other relevant stakeholders: community.
Examples of resources: social capital, existing 
knowledge and skills, strengths, vulnerabilities, 
material and human resources.
2.1.5 The possibility to utilise components of other 
local, regional, national, and/or international drugs 
strategies and activities is assessed.
Examples of other activities: national or regional 
drink-drive campaigns, World AIDS Day.
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2.2 Assessing internal capacities
Drug prevention programmes are only feasible if they operate within the limits of available resources, 
such as staff, competencies (e.g. skills, knowledge, experience), materials (e.g. equipment), and 
professional networks. It is therefore essential to assess what internal resources and capacities are 
currently available and/or likely to be available when the programme is implemented.
This assessment must be carried out early on in the project cycle to gain an understanding of what 
types of programme might be feasible. For example, a specialist intervention might require a staff 
member with a certain type of qualification; outreach work may require staff transport; interventions 
using information and communication technologies would require good technological skills; and 
certain settings or target populations may only be accessible if providers have already established a 
good professional relationship with relevant stakeholders. If the necessary resources are not 
available and cannot be secured, then these types of interventions are not feasible, and providers 
must modify their plans accordingly.
As the purpose of the assessment is to inform programme planning, it does not have to be ‘formal’. 
Depending on the size and nature of the organisation or programme, the assessment may consist of 
an informal discussion between staff members to identify strengths and weaknesses of the team and, 
where relevant, the wider organisation in relation to different types of resources (as outlined in this 
component). This discussion will indicate what types of interventions would (or would not) be feasible 
and what additional resources might be required. In most cases, it will not be necessary to ask an 
external organisation to carry out the assessment.
The assessment can be documented as part of the project plan (see 5.1: Planning the programme — 
Illustrating the project plan). It is also useful to include such information in funding applications.
Note: Resources are further discussed in Project stage 5: Management and mobilisation of resources.
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Basic standards:
2.2.1 Internal resources and capacities are assessed. 
Resources to consider include:
Note: the actual as well as the likely availabilities of 
these resources for the programme are assessed.
•  human resources and staff competencies; Examples of human resources: time availability, 
different types of knowledge and skills (e.g. project 
management, leadership, creativity, cultural 
sensitivity).
See also: C: Staff development; 5.3: Setting up the 
team.
•  previous experience; Example of relevant previous experience: conducting 
similar interventions in the past.
•  organisational resources; Examples of organisational resources: operating 
facilities and equipment, and their suitability for 
delivery of a wide variety of activities.
•  technological resources; Examples of technological resources: computers, 
Internet, software package to conduct evaluation; 
technical support for project management, such as a 
tracking or management information system.
•  financial resources; 
•  connections to the target population; Note: connections to the community should be 
assessed if the community could be relevant to the 
programme.
•  professional network; Example of professional network: political resources.
•  any other resources relevant for programme 
implementation.
Example of other resources: transportation.
No additional expert standards.
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Programme formulation
The programme formulation outlines the programme content and structure, and it provides the 
necessary foundation to allow targeted, detailed, coherent, and realistic planning. Based on the 
assessment of target population needs and available resources, the programme’s core elements 
should be clearly defined. These standards aim to stimulate a change in professional culture towards 
a more systematic and evidence-based approach to drug prevention work. 
3.1 Defining the target population: A good definition of the target population ensures that the 
intervention is targeted at the right people. The target population may consist of individuals, groups, 
households, organisations, communities, settings, and/or other units, as long as they are identifiable and 
clearly defined. Some programmes may need to distinguish the ultimate target population (e.g. young 
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people at risk of drug use) from the intermediate target population (e.g. parents, teachers, peers of these 
young people). The definition should be specific and appropriate for the scope of the programme.
3.2 Using a theoretical model: A theoretical model is a set of interrelated assumptions explaining 
how and why an intervention is likely to produce outcomes in the target population. Using a 
theoretical model that is suitable for the particular context of the programme increases the likelihood 
that the programme will successfully achieve its objectives. It helps identify relevant mediators of 
drug-related behaviours and determine feasible goals and objectives. All interventions should be 
based on sound theoretical models, particularly if they are newly developed. 
3.3 Defining aims, goals, and objectives: Without clear aims, goals, and objectives, there is a serious 
risk of conducting drug prevention work for its own sake, instead of for the benefit of the target 
population. The standards use a three-level structure of aims, goals, and objectives. Aims describe the 
programme’s long-term direction, general idea, purpose, or intention. Goals are clear statements on 
the programme’s outcome for participants at the completion of the intervention. Objectives describe 
the immediate or intermediate change in participants that is necessary to achieve a final goal. Finally, 
operational objectives describe the activities that are required to achieve goals and objectives.
3.4 Defining the setting: The setting is the social and/or physical environment in which the 
intervention takes place, such as family, school, workplace, nightclub, community, or society. The 
needs assessment may show that one or more settings are relevant; however, practical considerations 
(e.g. ease of access, necessary collaborations) must also be taken into account when deciding on the 
setting. A clear definition of the setting is essential so that others may understand where, and how, 
the intervention was delivered. 
3.5 Referring to evidence of effectiveness: When planning drug prevention work, it is important to be 
aware and make use of existing knowledge on ‘what works’ in drug prevention. The existing 
evidence base on effective drug prevention should be consulted, and the findings relevant to the 
programme highlighted. The evidence must be integrated with the professional experience of 
practitioners to design an intervention that is relevant to the specific programme context. Where 
evidence of effectiveness is not available, professional experiences and stakeholder expertise may 
be described instead.
3.6 Determining the timeline: A realistic timeline is essential in the planning and implementation of 
the programme (e.g. so that staff members can target and coordinate their efforts). It illustrates the 
planned schedule of activities and applicable deadlines. However, the timeline may be updated 
during the implementation of the programme to reflect its actual development.
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3.1 Defining the target population
A good definition of the target population is essential for a successful drug prevention programme to 
ensure that the intervention is targeted at the right people. The target population may consist of 
individuals, groups, households, organisations, communities, settings, and/or other units, as long as 
they are identifiable and clearly defined. A precise definition is particularly important in targeted 
prevention approaches (i.e. selective and indicated prevention). The definition of the target 
population should draw upon the information obtained in the needs assessment. How the target 
population is chosen and defined has implications for other aspects of the programme; for example, 
it determines the choice and design of the intervention (see Project stage 4: Intervention design). It 
also enables other providers, commissioners and researchers to understand for whom the intervention 
is thought to be effective. 
The definition should be specific so that it is always clear whether a person is eligible to take part in 
the intervention or not. It should be broad enough to include all persons who are eligible to take 
part, but narrow enough to exclude anyone who should not take part (e.g. by listing inclusion and 
exclusion criteria). Above all, the definition must specify a target population that can actually be 
reached within the realities of the programme. The definition may have to be reviewed during later 
project stages (e.g. when recruiting participants) to ensure that it describes the intended target 
population well. When defining the target population, possible stigmatising effects should be 
considered if, for example, membership of a certain social group is linked with an increased 
likelihood of drug use (see D: Ethical drug prevention). 
Where possible, the total size of the target population should also be given or estimated. This 
number shows how many people are (potentially) affected by the issues that the programme 
addresses, and consequently how many could benefit from taking part in it. Depending on the type 
of programme, this number may also determine how many people should be invited to take part. 
During the process evaluation, this type of information allows an understanding of how well the 
target population was covered by the intervention (i.e. whether participants represented a sufficiently 
large percentage of the target population) (see 7.2: If conducting a process evaluation).
Some programmes distinguish between the ultimate target population (e.g. young people at risk of drug 
use) and the intermediate target population which is believed to have a strong influence on the ultimate 
target population (e.g. parents, teachers, peers of these young people). These interventions are carried 
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out with the intermediate target population in order to indirectly influence the behaviour of the ultimate 
target population. In such cases, members of the ultimate target population are only indirect 
beneficiaries of the programme. Family-based programmes, peer-group, and other multiplier-centred 
programmes are all examples of such approaches (EMCDDA, 1998). For these programmes, it is 
essential to describe and, where possible, quantify both the intermediate and the ultimate target 
population. When working with the standards, organisations implementing such programmes must judge 
which target population is appropriate to consider where standards refer to ‘the target population’. For 
example, both intermediate and ultimate target populations should be considered during the needs 
assessment, but the process evaluation may focus on the intermediate target population.
Basic standards:
3.1.1 The target population of the programme is 
described.
Note: if the programme distinguishes between an 
intermediate and an ultimate target population, then 
both populations should be considered in this 
component.
3.1.2 The chosen target population can be reached.
Basic standards for targeted prevention programmes:
3.1.3 Explicit inclusion and exclusion criteria are 
provided.
Note: targeted prevention includes selective and indicated prevention.
Examples of criteria: socio-demographic (e.g. age, sex, race or ethnicity, marital status, 
religion), socio-economic (e.g. education, profession), psycho-biological (e.g. developmental 
stage (e.g. neonatal, childhood, adolescence)), setting (e.g. institution such as school or 
workplace, geography such as town or region, certain locations or social scenes).
3.1.4 Inclusion and exclusion criteria:
•  allow for clear differentiation between 
populations; 
•  define the target population appropriately; 
•  are well justified. Example of justification: according to the needs 
assessment.
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Additional expert standards:
3.1.5 Explicit inclusion and exclusion criteria are 
specified for each activity.
Basic standard if the programme targets different 
target populations.
Note: it should be considered if the programme will 
target different target populations.
3.1.6 The total size of the target population is given 
or estimated based on the needs assessment.
Example: number of young people at risk.
3.1.7 Indirect beneficiaries of the programme are 
described.
Example of indirect beneficiaries: families of young 
drug users, members of the local community, 
employers, local health services, members of the 
target population who do not participate in the 
programme, ultimate target population.
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3.2 Using a theoretical model
A theoretical model is a set of interrelated assumptions explaining how and why a drug prevention 
intervention is likely to produce outcomes in the target population, and it may also explain the causes 
of drug use. Thus, it is a way of showing ‘what works’ and ‘why’. It must not be confused with a 
summary of the needs assessment or the justification of the intervention (see Project stage 1: Needs 
assessment). Theoretical models are often presented as flowcharts or graphical representations 
(‘logic models’) that illustrate how desired outcomes are achieved by changing drug-related 
mediators in the target population (e.g. attitudes and skills that have been shown to influence drug 
use). Consequently, theoretical models clarify which mediators should be targeted by the intervention 
(see 3.3: Defining aims, goals, and objectives). They also help decide on the intervention activities, 
ensuring that needs, activities and outcomes are well interlinked. Using a theoretical model is 
therefore essential for newly developed interventions, although ideally all interventions should be 
based on sound theory.
The choice of the theoretical model is determined by the findings from the needs assessment and 
identified programme aims. Theoretical models are usually based on existing research and theory 
relating to drug use, health promotion, or human behaviour and development in general (e.g. 
psychology, sociology). Using a theoretical model is an essential aspect of taking an evidence-based 
approach, which makes use of existing knowledge in the drug prevention field. Examples of theories 
include cognitive dissonance theory, social learning theory, and normative models. However, the 
standards should not discourage professionals from developing new theories based on a review of 
the literature. Where a new theory is developed, it should be described in detail so that others can 
understand it. Further information on theories can be found, for example, in health promotion or drug 
prevention reference books.
The chosen theory must be appropriate for the programme’s particular circumstances (e.g. target 
population, patterns of drug use). Practitioners may have reservations about using theoretical models, 
perceiving them perhaps as too general, abstract or simplistic, thus not adding value to the specific 
and rich data obtained during the needs assessment. Likewise, practitioners may believe that 
theoretical models are too specific and hence not applicable to the programme’s particular 
circumstances. This highlights the importance of choosing a theory that is most appropriate for the 
context of the intervention (e.g. that matches identified needs and aims). The correct theory helps to 
understand reality better and to grasp the complexity of drug use.
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Practitioners may also feel that it is not necessary or too difficult to refer to theoretical models in 
everyday drug prevention work, as the needs assessment, the definition of goals and objectives, and/
or practical experience from previous programmes appear to be sufficient to plan activities. However, 
these concerns can be mitigated if theoretical models are understood as a means of putting the findings 
from the needs assessment in relation to the activities and outcomes of the programme.
The consultations that informed the development of these standards indicated that practitioners may 
use theoretical models without being aware that they are doing so. They may struggle to recognise 
and describe theoretical models even though they apply them implicitly in their everyday practice. 
This highlights the need for a greater emphasis on the theory behind drug prevention in the 
education, training, and further development of drug prevention professionals. It is the responsibility 
of providers to support staff members in achieving these standards, for example by holding in-house 
training events (see C: Staff development). It also highlights the need for those who develop theories 
to demonstrate how these theoretical models can be used in a range of different circumstances and 
how they can be applied in everyday practice.
Basic standards if a theoretical model is used or if a new intervention is developed:
3.2.1 The programme is based on a theoretical model.
3.2.2 The theoretical model:
•  is evidence-based; i.e. based on empirical studies.
•  based on a review of relevant literature; 
•  is (likely to be) accepted in the scientific and/or 
prevention community; 
•  allows an understanding of the specific drug-
related need and its causes; 
i.e. it is in line with the findings from the needs 
assessment.
•  allows an understanding of how the behaviour 
can be changed.
3.2.3 The theoretical model is described and 
justified.
Examples of evidence: it is presented as a ‘theory of 
change’ showing the causal mechanisms to achieve 
change; illustrated graphically as a theory logic 
model.
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Additional expert standards:
3.2.4 Adjustments are made to the initial theoretical 
model, where necessary, according to:
•  the target population; 
•  the selected intervention; 
•  the chosen setting.
3.2.5 Adjustments to the theoretical model are 
justified and documented.
Basic standard if adjustments are made.
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3.3 Defining aims, goals, and objectives
By defining aims, goals, and objectives, providers answer the most important question in drug 
prevention — what are the main benefits for participants? Without clear aims, goals, and objectives, 
there is a serious risk of conducting drug prevention work for its own sake, instead of for the benefit 
of the target population. The definition of goals and objectives is also essential in order to monitor 
the progress of the intervention during implementation and to conduct outcome and process 
evaluations after it has been implemented (see 4.4: If planning final evaluations). 
The standards use a three-level structure of aims, goals, and objectives. Aims describe the 
programme’s long-term direction, general idea, purpose, or intention. They need not be directly 
measurable or achievable within the current programme. For example, aims may be achieved several 
years after an intervention has finished, or an intervention may only partly contribute to the 
achievement of aims. However, in order to implement and evaluate programmes, precise goals and 
objectives are required. Goals are clear statements on the programme’s outcome for participants at 
the completion of the intervention. They are developed from the overall aim by translating it into more 
specific and achievable targets. For example, different goals may reflect different aspects of the 
overall aim. Each goal is then used to formulate specific objectives, and consequently each objective 
is directly related to one goal. Objectives describe the immediate or intermediate change in 
participants that is necessary to achieve a goal at the end of the intervention. Consequently, aims, 
goals, and objectives form a logical progression. Figure 4 gives an example of how an overall aim 
translates into goals and objectives.
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Figure 4: Connection between aims, goals, and objectives
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participants in adopting 
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There are two different types of objectives (see Figure 5, page 151). Specific objectives define the 
outcomes for participants (usually, the term ‘objectives’ refers to specific objectives), while 
operational objectives indicate what the provider must do to achieve these outcomes. Operational 
objectives hence describe programme outputs and necessary activities (e.g. content and delivery of 
the intervention, necessary preparations such as participant recruitment). For the purposes of 
monitoring and process evaluation, operational objectives are translated into process evaluation 
indicators with defined evaluation benchmarks (see 4.4: If planning final evaluations). The 
specification of operational objectives also helps formulate tasks in the project plan (see 5.1: 
Planning the programme — Illustrating the project plan).
Providers and commissioners may sometimes focus too much on the activities they want to carry out, 
thereby neglecting what they actually want to achieve with participants. Drug prevention 
programmes must be needs-led, not driven by output indicators (e.g. number of clients using a 
service). The choice of aims must be determined by the findings from the needs assessment. Aims 
must directly address target population needs, although they may also refer to drug-related policy 
(see Project stage 1: Needs assessment). Goals are then developed from these aims, and objectives 
are chosen by referring to the theoretical model (see 3.2: Using a theoretical model). A well chosen 
theory (i.e. one that suits the context of the intervention as defined by the needs assessment) shows 
how desired outcomes can be achieved by modifying certain mediators (e.g. participants’ 
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knowledge, skills, attitudes). Consequently, objectives should address mediators that have an 
influence on the desired outcomes (e.g. as proven by previous research).
Aims, goals, and objectives need not relate directly to drug use. For example, goals and objectives 
may not relate to drug use if the programme hopes to prevent drug use that would potentially occur 
many years after the intervention (e.g. drug prevention activities with young children). Conversely, 
aims may address wider health or social issues (e.g. social inclusion projects), meaning that drug 
prevention might form only one aspect of the programme, expressed in a drug-related goal among 
other general goals. It also depends on the scope and duration of the individual drug prevention 
programme whether a certain target constitutes an aim, a goal, or an objective. For example, 
behaviour change may be an overall aim for a short-term programme, but could represent a feasible 
objective within a long-term programme.
Where appropriate, providers should strive to agree aims, goals, and/or objectives with participants 
or members of the target population. When doing so, it must be ensured that the agreed targets are 
relevant to the programme (i.e. contribute to drug prevention) and that they do not inadvertently 
cause negative outcomes for participants (see D: Ethical drug prevention).
Basic standards:
3.3.1 It is specified what exactly is being ‘prevented’. Note: if the programme is targeting drug use, the 
drug(s) targeted should be specified. For example, 
does the programme target only illegal drugs, or are 
alcohol, tobacco, prescription medicines, and ‘legal 
highs’ also included? If the programme is targeting 
particular behaviours (e.g. risk-taking behaviours), 
they should also be defined.
3.3.2 The programme’s aims, goals, and objectives 
are specified.
i.e. it is clear which specific need is addressed by 
the programme.
3.3.3 Aims, goals, and objectives are dependent on 
each other and form a logical progression.
i.e. the general aims of the programme are translated 
into more specific goals; and each goal is connected 
to objectives that are necessary for goal 
achievement.
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Basic standards (cont.)
3.3.4 Aims, goals, and objectives are: Example of evidence: description of aims, goals, and 
objectives in the programme description is in line 
with the standards.
•  informed by the needs assessment; i.e. relevant to the target population and, for 
example, the local situation.
Note: different target populations may require 
different aims, goals, and/or objectives.
•  ‘useful’ for the target population; i.e. will improve individuals’ lives, not just satisfy 
moral concerns of public.
•  clear, understandable, and easy to identify; Note: for example, in the programme description or 
funding application.
•  formulated in terms of expected change in 
participants (‘outcomes’); 
i.e. show how participants will change over the 
course of the intervention and beyond; aims, goals, 
and specific objectives describe changes in 
participants, not planned programme activities 
(‘outputs’).
•  in accordance with professional and good ethical 
principles.
See also D: Ethical drug prevention.
3.3.5 Goals and objectives are:
•  specific; i.e. they can be related to particular activities.
•  realistic. i.e. achievable with the available resources and the 
defined target population.
Example consideration: behavioural changes may 
not be achievable within a short-term intervention.
3.3.6 Specific and operational objectives are 
distinguished.
i.e. specific objectives that refer to outcomes, and 
operational objectives that specify how outcomes 
will be achieved (activities, outputs).
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Additional basic standards if evaluations are planned:
3.3.7 Goals and objectives are:
•  temporally defined; i.e. it is described when changes are expected.
Example of application: the timeframe for 
behavioural change is described, which may also be 
beyond the programme’s lifespan.
•  measurable.
Additional expert standards:
3.3.8 Aims, goals, and objectives:
•  are in line with the theoretical model; Basic standard if a theoretical model is used.
Note: the theoretical model indicates which 
mediators should be targeted by objectives.
•  are in line with the strategic direction of the 
organisation providing the programme; 
•  are agreed with the target population; 
•  are socially desirable; i.e. the society in which the intervention is delivered 
sees the goals as positive.
Example: it is considered whether harm reduction is 
acceptable practice in this society.
•  reflect sustainable change. i.e. long-term changes in participants are preferred 
to short-term gains.
3.3.9 The targeted mediators are specified. Examples of mediators: knowledge, attitudes, 
normative beliefs.
3.3.10 Multiple mediators are targeted.
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3.4 Defining the setting
The setting is the social and/or physical environment in which the intervention takes place, such as 
family, school, workplace, nightclub, community, or society. A clear definition of the setting is 
essential so that others may understand where, and how, the intervention was delivered, and how 
the intervention setting might contribute to the outcomes obtained. If a different provider wishes to 
replicate the intervention in a different setting, they will need a description of the original setting so 
that they can adapt the intervention to the new setting.
The description of the setting may be general (e.g. schools) or specific (e.g. naming a specific 
school), depending on the type of programme. Also, depending on the needs of the target 
population, the description may not be limited to one (type of) setting; it may refer to several (types 
of) settings, i.e. a range of locations where drug prevention activities will take place. During 
implementation, it may be necessary to revise the definition of the setting, for example, to reflect 
changed habits of the target population.
As indicated above, the choice of the setting should be informed by the needs assessment (see 
Project stage 1: Needs assessment). A setting may be chosen that has great relevance to the target 
population. For example, members of the target population may spend a large amount of time there, 
and/or this setting may hold a special meaning for them. Choosing such a setting (e.g. school, 
community centre) increases the chances of reaching and retaining a greater proportion of the target 
population in comparison to settings that are not part of the target population’s everyday life (e.g. the 
providers’ own premises). However, the aims of the programme and the type and content of the 
intervention may also indicate a setting that is not part of the target population’s daily routine. For 
example, an intervention focussing on dance drugs may be best delivered in a nightclub, even 
though nightclubs may not represent a setting that individual members of the target population visit 
every day.
Practical considerations must also be taken into account when deciding on the setting. There may be 
particular implications if the intervention is delivered in a recipient organisation such as a school, 
nightclub, hospital, prison, etc. If the intervention is not commissioned by the recipient organisation, 
then access to the target population is determined by whether the recipient organisation wishes to 
collaborate with the provider or not. For example, the target population may spend a lot of time in a 
community centre that does not grant access to external visitors. Consequently, although the setting 
may be well chosen in theory, in practice it would not be feasible to carry out the intervention there. 
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Even if the recipient organisation agrees to collaborate, access to the target population may be lost if 
the organisation withdraws from participation in the programme at a later point in time. This 
highlights the need for providers to build strong professional relationships with relevant stakeholders 
(see B: Communication and stakeholder involvement).
Choosing a setting outside of providers’ premises may also limit possibilities of intervention delivery, 
for example in relation to the scope of activities, certain aspects of intervention design (see Project 
stage 4: Intervention design), fidelity of implementation (see Project stage 6: Delivery and 
monitoring), or adherence to ethical principles such as confidentiality (see D: Ethical drug 
prevention). The recipient organisation may ask the provider to respect certain rules and regulations, 
or the physical surroundings of the setting may not be suitable for all aspects of the intervention. For 
example, it may not be allowed or physically possible to make changes to a school classroom.
These considerations should not discourage providers from choosing a setting that is outside of their 
own premises if it is the most relevant and suitable one for the target population and the intervention. 
However, the potential challenges posed by implementing a programme in a recipient organisation 
should be considered, and appropriate measures taken to reduce negative impacts on the programme.
Basic standards:
3.4.1 The setting(s) for the activities is (are) 
described. 
Examples of settings: schools, peer groups, 
workplaces, family or home, social services, 
recreational settings, prisons, society.
3.4.2 The setting:
•  is most likely to produce the desired change; i.e. it is relevant to the target population.
•  matches the programme aims, goals, and 
objectives; 
•  matches the available resources. Example resources to consider: existing networks, 
funding, transportation.
3.4.3 Necessary collaborations in this setting are 
identified.
Note: the analysis may show that no collaborations 
are required in this setting (e.g. if the intervention is 
delivered on the provider’s premises).
Example of necessary collaborations: if the 
intervention is based in a school, collaboration with 
the school head teacher is likely to be necessary.
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Additional expert standards:
3.4.4 The setting:
•  matches identified risk and protective factors; Basic standard if analysis of risk and protective 
factors was carried out.
•  matches likely activities with the target 
population; 
•  makes participants feel comfortable.
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3.5 Referring to evidence of effectiveness
When planning drug prevention work, it is important to be aware and make use of existing 
knowledge on ‘what works’ in drug prevention. Drug prevention work is ‘evidence-based’ if it is 
based upon a systematic analysis of relevant professional literature (e.g. scientific journals), makes 
use of the evidence reported in the literature, and ensures correspondence with this evidence. Using 
an evidence-based approach prevents providers from pursuing activities that have already been 
shown to be ineffective or have iatrogenic effects, and it also reduces duplication of efforts (i.e. there 
is no need to ‘reinvent the wheel’). Consequently, these standards describe the requirement to consult 
the existing evidence base on effective drug prevention, and to highlight how the programme 
incorporates these findings.
Evidence of effectiveness is usually derived from scientific research trials, outcome evaluations, 
practical experience, etc. There are different levels of evidence according to how the evidence was 
produced. Critical evidence appraisals usually consider the evidence produced by randomised 
controlled trials to represent the highest level of evidence, while professional opinions (based on 
subjective accounts, unstructured observations, etc.) are usually considered to represent the lowest 
level of evidence (OCEBM, 2009; Evans, 2003). Therefore, when reviewing evidence of 
effectiveness, priority should be given to studies that represent the highest available level of 
evidence.
Practitioners may feel that they do not have the resources to consider existing literature in the 
planning and implementation of prevention work. Many organisations, such as the EMCDDA, make 
accessible evidence briefings available. The Additional guidance section contains a selection of 
databases and other web services that provide evidence updates in drug prevention. Consequently, 
practitioners are not expected to review and synthesise the evidence themselves. However, service 
managers, commissioners and funders must support these standards by acknowledging the need for 
additional time (e.g. to consult literature) and, where necessary, funding (e.g. to attend training 
events and conferences on evidence-based drug prevention) (see C: Staff development).
Evidence is rarely ‘clear cut’, and it can be contradictory because it is often specific to particular 
target populations, geographies, environments (e.g. social, policy, normative), etc. Therefore, the 
evidence from scientific research must inform practice, but it cannot replace the professional 
experience of practitioners. Practitioners are ‘experts by experience’, as one delegate put it during 
the consultations to inform these standards. The challenge of conducting evidence-based drug 
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prevention lies in applying the scientific evidence in a way that is suitable for the specific local 
context. It is therefore essential that practitioners integrate the findings from the scientific evidence 
review with their own professional knowledge (e.g. local situation, target population preferences, 
availability of resources, previous experiences of delivery) in order to decide upon the best course of 
action for the target population. 
Where scientific evidence of effectiveness is not available, professional experiences and stakeholder 
expertise may be described instead, and used to judge the effectiveness of previous and planned 
interventions. However, the limitations of these forms of knowledge compared to robust research 
evidence should be carefully considered. Professional opinion should not be considered scientifically 
valid (although it may be inherently valuable for some purposes). For example, it is important not to 
generalise from a small number of cases to a larger group, or to assume that personal opinion and 
experience hold wider validity. Circumstances that may have lead to bias and/or alternative 
explanations for previously observed outcomes should be identified. In addition, where scientific 
evidence is not yet available, it is recommended to conduct an outcome evaluation as part of the 
programme to contribute to the existing evidence base (see 4.4: If planning final evaluations).
Note: Evidence of effectiveness must not be confused with a summary of the needs assessment, the 
justification of the intervention (see Project stage 1: Needs assessment), or the findings from process 
evaluations.
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Basic standards:
3.5.1 Literature reviews and/or essential publications 
are consulted. 
Example aspects to consider: effectiveness and 
outcomes of interventions for the same or similar 
target population(s), in the same or similar setting(s), 
targeting the same or similar needs.
Example of evidence: references to relevant 
publications are provided.
3.5.2 The reviewed information is:
•  scientific; i.e. using validated methodologies and reaching 
justifiable conclusions.
•  up-to-date; i.e. it has not been superseded by more recent 
reviews/publications, and/or it is still relevant to 
current practice.
•  relevant to the programme; i.e. the reviewed information provides the necessary 
evidence base to plan the intervention.
Example aspects to consider: relevance for identified 
needs, target population, theoretical model, etc.
•  accepted in the scientific and/or prevention 
community.
Note: a review may be of high quality but its 
recommendations may not correspond with the ethos 
of prevention work. For example, highly punitive 
criminal justice-led strategies may not be widely 
accepted in the prevention community.
3.5.3 The review of the literature is not biased. i.e. a variety of sources is considered, including 
evidence that does not support effectiveness of 
particular approaches.
3.5.4 The main findings are used to inform 
intervention design.
No additional expert standards.
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3.6 Determining the timeline
It is essential to determine a timeline when planning a programme. The timeline allows staff members 
to work towards specified deadlines and to coordinate their work with other staff members and other 
work demands. It also defines what resources are necessary (e.g. ensuring that funding for staff 
salaries is in line with the programme duration) (see Project stage 5: Management and mobilisation 
of resources). If final evaluations are planned, the timeline will determine when process and/or 
outcome data should be collected (see 4.4: If planning final evaluations). It is also essential to have 
an original timeline that can be used to judge the progress of the programme during monitoring (e.g. 
are we behind schedule? Are modifications required?) and the final process evaluation (see 6.3: 
Monitoring the implementation and 7.2: If conducting a process evaluation). Finally, a description of 
the timeline can demonstrate to others that the programme has been well thought out. It is therefore 
essential to indicate the timeline, for example, in funding applications. 
The timeline must be realistic and, where possible, it should be agreed with the staff members who 
are likely to work on the programme (see 5.3: Setting up the team). When planning the timeline, it 
can be helpful to take into account the shortest time in which the programme could be completed (i.e. 
if everything goes according to plan) as well as the longest time in which the programme could be 
completed (i.e. if there are difficulties in recruiting participants, delays in receiving funding, etc.). In 
5.1: Planning the programme — Illustrating the project plan, contingency plans are developed that 
enable providers to deal effectively with emerging difficulties. This flexible approach is also 
necessary in relation to the timeline. Sufficient time must be allowed for activities, and if required the 
timeline must be updated during implementation to reflect the actual development of the programme. 
Project management reference books provide more in-depth information on how to estimate timelines 
and plan activities accordingly.
It may be argued that a defined timeline is most relevant for structured long-term programmes, but 
less so in the case of continuous participant- and needs-led services. Nevertheless, providers of 
participant-led services should also aim to determine a timeline, at least in approximate terms. 
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Basic standards:
3.6.1 A timeline is provided for the programme.
3.6.2 The timeline:
•  is clear and comprehensible; 
•  is coherent; 
•  is realistic; 
•  illustrates the sequence of events and actions; 
•  distinguishes between intervention activities, 
actions related to monitoring and evaluation, and 
administrative tasks; 
•  illustrates milestones in the progress of the 
programme; 
Examples of milestones: completion of different 
project stages; statutory monitoring reports and data 
submission.
•  illustrates applicable deadlines.
3.6.3 Timing, duration, and frequency of the 
activities are adequate to achieve the objectives.
Examples of adequacy: the time schedule is 
appropriate for the needs of the target population; 
the intensity of the intervention (for example, the 
number of sessions) is appropriate for the intended 
level of change.
Additional expert standards:
3.6.4 The timeline:
•  is detailed; 
•  is presented in a visual form. Examples of visual presentation: matrix, graph, bar 
chart.
3.6.5 The timeline includes a testing period. Basic standard if a pilot intervention is required. 
3.6.6 The timeline includes an adaptation period. Basic standard if selecting an existing intervention.
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Project stage 4 
Intervention design
The content of interventions is usually covered in guidelines rather than quality standards, as it is 
specific to the needs of the target population, the aims of the programme, etc. However, there are 
some formal aspects that can be generalised. These standards assist in the development of a new 
intervention as well as in the selection and adaptation of an existing intervention. The standards also 
encourage the consideration of evaluation requirements as part of the intervention design.
4.1 Designing for quality and effectiveness: After the cornerstones of the intervention have been 
outlined, its details are specified. Planning evidence-based activities that participants are likely to 
experience as engaging, interesting and meaningful is an important aspect of achieving the set goals 
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and objectives. Where possible, the intervention should be designed as a logical progression of 
activities that reflects participants’ development throughout the intervention.
4.2 If selecting an existing intervention: Before developing a new intervention, it should be 
considered whether an appropriate intervention might already exist, either in practice or in 
manualised form. Several factors need to be considered in the selection of an existing intervention 
to ensure that it is relevant to the particular circumstances of the programme (e.g. addressing the 
needs identified in the target population). The intervention is then adapted to match the specific 
situation of the programme.
4.3 Tailoring the intervention to the target population: Regardless of whether a new intervention is 
developed or an existing intervention adapted, the intervention must be tailored to the target 
population in line with the findings from the needs assessment. If an existing intervention is used, 
tailoring may be conducted as part of the adaptation process. Additionally, flexibility should be built 
into the intervention design, allowing practitioners to tailor the intervention during implementation 
without having to deviate from the original plan.
4.4 If planning final evaluations: Monitoring and final process and outcome evaluations should also 
be planned at this stage. An evaluation team should decide upon the appropriate type of evaluation 
for the programme, and define evaluation indicators in line with goals and objectives. It should be 
clarified what data will be collected, and how it will be collected (e.g. specification of timeline and 
data collection tools). Where an outcome evaluation is planned, the research design should be 
determined. Considering evaluation at this stage ensures that the data required for monitoring and 
final evaluations will be available in a satisfactory form when it is needed.
This stage may be conducted at the same time as the management and mobilisation of resources.
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4.1 Designing for quality and effectiveness
After the cornerstones of the intervention have been outlined (see Project stage 3: Programme 
formulation), the intervention itself is designed. Planning activities that participants are likely to 
experience as engaging, interesting and meaningful is an important aspect of achieving the set goals 
and objectives. Where possible, the intervention should be designed as a logical progression of 
activities that reflects participants’ development throughout the intervention. The principles of ethical 
drug prevention should also be considered in the intervention design (see D: Ethical drug prevention).
These standards assist in the development of new interventions, but should also be considered when 
selecting and adapting an existing intervention. However, their applicability depends on the type of 
the programme. For example, some standards may not be feasible within interventions where 
providers do not have the opportunity to build long-term relationships with participants (e.g. 
participant- and needs-led services, short-term programmes, brief interventions, outreach work). 
Before designing the intervention, a variety of sources should be consulted, such as systematic 
reviews on the effectiveness of interventions (see 3.5: Referring to evidence of effectiveness), outcome 
and process evaluations of previous programmes (including pilot interventions), and databases of 
model programmes (e.g. EDDRA quality levels 2 and 3, NREPP database — see Additional guidance 
section). This information will show what has worked well or not so well in the past, how results were 
achieved, and what lessons can be learnt for the intervention design. This evidence-based approach 
also prevents providers from pursuing activities that have already been shown to be ineffective or 
have iatrogenic effects. Programme developers or other providers may also be contacted to learn 
about implementation experiences of relevant programmes.
It is recommended to investigate whether an appropriate intervention is already available. If so, this 
existing intervention could be adapted instead of developing a new intervention. The standards in 
4.2: If selecting an existing intervention provide guidance on how to select an existing intervention. 
However, where appropriate interventions are not yet available, programme developers and 
providers are encouraged to design new interventions that are based on a review of the evidence 
base.
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Basic standards:
4.1.1 The content of the intervention follows 
evidence-based good practice recommendations.
4.1.2 The scientific approach used is outlined and, 
where possible, described in detail.
Example of evidence: citations are provided to prove 
the evidence base of the intervention.
4.1.3 The programme builds on positive relationships 
with the participants.
i.e. relationships between staff members and 
participants are marked by reciprocity, partnership, 
and mutual respect.
4.1.4 The programme values participants’ 
experiences and acknowledges their (difficult) 
realities.
4.1.5 The programme is respectful and inclusive of 
diversity.
Example aspects to consider: gender, culture, literacy 
requirements, disability, socio-economic differences.
4.1.6 Completion of the intervention is defined.
Note: Successful completion of the intervention would generally mean that the defined goals have 
been achieved with participants. However, goals may not always be achieved, and it is thus important 
to establish other means by which the provider and participants will know that the intervention has 
been completed. Success should therefore also be defined on a delivery level (i.e. the intervention has 
been carried out as planned). Moreover, goals may not relate to individual participants, but to the 
group of participants (e.g. to decrease the number of young people reporting cocaine use). It is 
therefore also important to define completion of the intervention at the level of the individual 
participant (e.g. if participants are to receive a certificate of participation). The definition of 
completion must be appropriate to the type of the intervention (e.g. participant- and needs-led services 
would require a different definition than structured manualised programmes).
Example aspects to consider:
•  how many sessions can be missed at the beginning of the intervention (e.g. participants must start 
the intervention no later than at the third session of the intervention); 
•  how many sessions participants need to attend to complete the intervention; and how many 
absences will be tolerated; 
•  if and how participants can compensate absences (e.g. through additional homework assignments, 
staff visits); 
•  if there are any mandatory elements in the intervention (UNODC, 2009a: 37).
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Additional expert standards:
4.1.7 The programme reflects a comprehensive 
approach towards health and social functioning. It:
i.e. it accounts for the biopsychosocial nature of 
drug-related needs.
•  targets different aspects of an individual’s life, 
and works across multiple life domains; 
Example aspects to consider: mental wellbeing, 
social behaviours.
Examples of life domains: school, family, community.
•  consists of several components, and utilises a 
variety of methodologies; 
Examples of different components: information 
provision, development of social and emotional skills, 
structural change (e.g. laws), service provision (e.g. 
counselling).
•  is integrated in the community, where 
appropriate.
4.1.8 The programme reflects progression. It:
•  is designed as a continuous long-term process; i.e. it follows participants over a longer period of 
their lives.
Example of evidence: indicates progression paths 
building on participants’ growing repertoire of skills 
and knowledge.
•  gradually increases its intensity; i.e. more significant changes are achieved over time.
•  offers different interventions or versions, as 
participants progress, and the progression 
through different phases reflects consistency, 
continuity, and logic; 
Example of application: different interventions as 
children mature.
•  identifies further learning opportunities for 
participants after the intervention; 
•  is repeated with the participants after a set 
period.
Basic standard if evidence base suggests that 
repetition is important for effectiveness.
Example: booster sessions in life skills training 
approaches.
138
European drug prevention quality standards
Additional expert standards (cont.):
4.1.9 The programme helps participants discover 
and realise their own resources. It:
•  is positively orientated towards participants’ 
strengths, and highlights alternatives to unhealthy 
choices; 
•  supports participants in caring for their own 
health; 
Example of corresponding goal: develop health 
literacy.
•  is set in a positive health-promoting climate; 
Note: ‘climate’ refers to how the provider (e.g. drug service) is experienced by participants and staff 
members (i.e. its ‘character’ or atmosphere). These are expressed in aspects such as prevailing norms, 
goals, values, interpersonal relationships and organisational structures (CCSA, 2009). The provider 
should aim to be, for example, friendly, open, supportive, engaging.
•  strengthens and recognises traditional cultural 
practice, where appropriate.
 
Purpose: to support the aims of drug prevention by developing participants’ confidence and 
encouraging participation in community activities (UNODC, 2004).
Note: often traditional cultural practice will promote some types of drug use while prohibiting others. 
This may be at odds with the everyday life of some participants and/or the goals of the intervention. 
The intervention should not promote drug use, but its cultural significance should be recognised and 
the intervention tailored accordingly.
4.1.10 The programme builds on positive 
relationships with the participants. This includes:
•  Staff members spend time in the field with the 
target population.
Note: The composition of the field team will depend 
on the target population (e.g. practitioners, peer-to-
peer).
•  The target population has a chance to become 
acquainted with the provider and its staff 
members.
Example of provider: drug service.
•  The approach towards the target population is 
consistent.
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Additional expert standards (cont.):
•  Participants are likely to experience the 
intervention as meaningful, productive, and 
relevant.
•  The programme acknowledges persons who are 
important to the community.
Example of important persons: community ‘leaders’.
•  Family members or persons close to the target 
population are consulted or involved in the 
activities, where appropriate.
Example of family members: parents of school 
children.
•  The programme engages excluded and/or 
marginalised groups.
•  Staff members are likely to be accepted by the 
target population.
4.1.11 Activities are likely to ensure involvement of 
participants. They:
•  are likely to be attractive and enjoyable for 
participants; 
•  are designed in an imaginative and innovative 
way; 
Example of sources for innovation: identified 
deficiencies of other activities, using models from 
outside the drug prevention field, based on 
experience.
•  balance interactive and didactic activities; 
•  provide opportunities for individual and group 
activities; 
Note: participants’ history of group work should be 
considered, and necessary group work skills should 
be trained.
•  encourage active participation; Example of participation: give participants the 
opportunity to take leadership and express opinions, 
for example by leading a discussion group, 
organising a small event, being a peer leader.
•  are orientated towards participants and flexible 
to their needs.
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4.2 If selecting an existing intervention
It is not always necessary or practically feasible to design a new intervention. Instead, it may be 
more effective and efficient to adapt an already existing intervention that addresses the identified 
needs (see Project stage 1: Needs assessment). The adaptation of existing interventions reduces 
duplication of efforts and makes use of existing knowledge about ‘what works’ in drug prevention. 
Replication is also important from a scientific point of view, as it tests whether previously found 
outcomes can be repeated. If the implementation takes place under new circumstances, it also tests 
whether statements about the intervention’s effectiveness can be generalised (e.g. to a different target 
population or setting).
Providers can find out about existing interventions in databases and other collections of model 
interventions (e.g. EDDRA quality levels 2 and 3, NREPP database — see Additional guidance 
section). Online databases offer the possibility to filter interventions according to specific search 
criteria (e.g. by target population), so that those interventions that are most appropriate for the 
particular circumstances of the new programme can be identified. An existing intervention should 
only be chosen if it has a good ‘fit’ to the local circumstances of the programme. Consequently, the 
standards in this component outline what factors should be taken into account when choosing an 
existing intervention from a range of options. The selected intervention should also be in line with the 
standards in 4.1: Designing for quality and effectiveness. Additionally, it may be useful to consider 
how the proposed structure, content, and delivery of the intervention match the requirements of the 
new programme (NIDA, 2003). Furthermore, the USA Standards of Evidence can be used to 
determine the quality of existing interventions (Flay et al., 2005).
The consultations that informed the development of the standards indicated that in many countries 
there are insufficient measures in place to protect the copyright of programme developers. It was 
reported that sometimes providers use interventions without acknowledging or remunerating the 
original authors, thus infringing copyright. The standards therefore include the requirement to list the 
author(s) of the original intervention. Also, where interventions are not free of charge, providers must 
respect this and purchase the intervention licence and materials as required. Consequently, these 
costs must be considered in the financial plan and may limit the choice of affordable programmes. 
However, programme developers may be able to offer a more affordable package upon request 
(e.g. using less expensive materials) (see 5.2: Planning financial requirements and 5.5: Preparing 
programme materials).
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When using an existing intervention, there is a danger of implementing its activities and applying its 
premises (e.g. theoretical model) without accounting for the findings from the needs assessment and 
the particulars of the programme formulation. Therefore, the component outlines the need for 
adaptation. Adaptation consists of careful intentional and planned changes made to the original 
intervention before implementation to ensure that it is appropriate for the particular circumstances of 
the programme (e.g. target population needs) and to maintain or increase its effectiveness. All 
changes must be well justified and be kept to a minimum so as not to impact on the quality or 
effectiveness of the intervention. Core elements of the original intervention must be identified and 
preserved as much as possible (NIDA, 2003; CSAP, 2002). 
It may not be appropriate to use an existing intervention if relevant interventions are not yet available 
or where original approaches are to be developed and trialled. In such cases, programme 
developers and providers may design a new intervention that is based on a review of the evidence 
base (see 3.5: Referring to evidence of effectiveness; 4.1: Designing for quality and effectiveness). 
The standards in this component apply only if an existing intervention is utilised.
The standards under 4.3: Tailoring the intervention to the target population provide further guidance 
on what to consider when adapting the intervention. Further information on how to select and 
culturally adapt programmes can be found, for example, in the handbooks Achieving Outcomes 
(CSAP, 2002) and Guide to implementing family skills training programmes for drug abuse 
prevention (UNODC, 2009a), upon which these standards are also based.
Basic standards if selecting an existing intervention:
4.2.1 The following factors are considered in the 
selection of existing interventions:
•  the intervention’s benefits and disadvantages, 
including possible negative (iatrogenic) effects of 
the intervention; 
Note: the nature and risk of unwanted outcomes 
should be forecast, and the intervention dismissed if 
the risks are too high or the unwanted outcomes too 
severe.
Example aspects to consider: likely benefits and 
disadvantages for the provider, for participants, for 
any other relevant stakeholders.
See also D: Ethical drug prevention.
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Basic standards if selecting an existing intervention (cont.):
•  the balance between possible adaptation and 
fidelity; 
•  the feasibility of the intervention. i.e. whether the activities proposed in the existing 
intervention can be implemented.
Examples: the financial resources and the knowledge 
about the methods are sufficient; the methods are not 
too complex.
4.2.2 The intervention’s fit to the local circumstances 
is determined. This includes:
•  The achieved outcomes match the desired goals 
and objectives of the intended programme.
•  The existing intervention is suitable for the chosen 
setting of the intended programme.
•  The underlying conditions found in the needs 
assessment are similar.
Example: similar needs of target population, similar 
risk and protective factors.
•  The necessary resources match the available 
resources.
4.2.3 The authors of the original intervention or 
programme are listed.
4.2.4 The existing intervention is adapted:
•  systematically; 
•  by considering differences between the 
intervention’s original and the actual 
circumstances; 
•  by understanding the theoretical model 
underlying the original intervention; 
•  by considering the balance between adaptation 
and fidelity;
i.e. fidelity to the evidence-based intervention is 
ensured.
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Basic standards if selecting an existing intervention (cont.):
•  with respect to the available resources. Note: resource considerations should not override 
the importance of fidelity where resource savings 
may impact on the quality or effectiveness of the 
intervention. 
4.2.5 The level of adaptation is made explicit. i.e. it is documented what elements have been 
changed.
Additional expert standards:
4.2.6 It is considered whether a replication study of 
an existing intervention should be undertaken.
Examples of replication types: adaptation of an 
existing intervention with same or different 
conditions, such as different target populations, 
different intervention delivery agents or modes.
4.2.7 The following factors are considered in the 
selection of existing interventions:
•  the level of evidence of effectiveness; 
i.e. the effectiveness of the intervention is sufficiently proven or at least indicated.
Note: Preference should be given to the intervention with the highest level of evidence of 
effectiveness, for example with the greatest effect sizes.
Additional guidance: effectiveness can be determined using the USA Standards of Evidence 
(Flay et al., 2005).
•  whether the intervention has been accredited or 
given ‘model’ status.
i.e. preference is given to accredited or model 
interventions.
4.2.8 The theoretical models are compatible. Basic standard if a theoretical model is used.
4.2.9 A skilled evaluator is consulted in making the 
selection, where needed.
4.2.10 Previous organisations implementing the 
intervention are listed.
4.2.11 A ‘cultural adaptation’ team is set up.
4.2.12 The cultural adaptation team includes:
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Additional expert standards (cont.):
•  the programme developer (or a representative); 
•  a translator, if necessary; 
•  representatives from the evaluation team or a 
research institute; 
•  representatives from the community, where 
appropriate; 
•  representatives from the target population; 
•  staff members, where appropriate; Note: including volunteers, etc.
•  a representative from the funding body, where 
appropriate.
4.2.13 Translations are conducted by a professional 
translator.
Example: translations of intervention materials.
4.2.14 The ‘lessons learnt’ in previous similar 
programmes and adaptations are considered.
4.2.15 The existing intervention is adapted:
•  minimally at first; i.e. adaptation is undertaken in stages. For example, 
in the first stage only the language, pictures, and 
examples are adapted.
•  by identifying and retaining the core elements of 
the original intervention; 
i.e. core elements are not changed.
Basic standard if research on core elements has been conducted and is available.
Examples of possible core elements: theoretical model; number of recommended group leaders; 
number, type, and length of sessions; sequence of sessions; key messages, topics, information; 
targeted mediators; strategies.
•  in consultation with the programme developer, if 
needed.
Note: this could be done via telephone, email or 
video conferencing.
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4.3 Tailoring the intervention to the target population
Regardless of whether a new intervention is developed or an existing intervention chosen, the 
intervention must be tailored to the specific requirements of the programme. For example, intervention 
activities or materials may be modified to better suit the needs of the target population. The purpose 
of this is to maintain or increase the effectiveness of the intervention; it must not be confused with 
providing ‘special treatment’ for certain groups (UNODC, 2004). If an existing intervention is used, 
tailoring may be conducted as part of the adaptation process while maintaining the balance 
between adaptation and fidelity (see 4.2: If selecting an existing intervention).
An essential staff competency in this regard is cultural sensitivity (see C: Staff development). Cultural 
sensitivity describes the willingness and ability of staff members to understand the importance of 
culture, to appreciate cultural diversity, to respond effectively to culturally defined needs, and to 
incorporate cultural considerations into all aspects of drug prevention work. Culture, as the set of 
shared values, beliefs, behaviours, etc. that characterises a particular social group, can be relevant 
in many different ways. For example, it may refer to the different expectations of, and towards, 
people based on their age or gender, which may influence expectations towards staff members, 
beliefs about the risks of drug use, etc. It is important to recognise that there can be different types of 
culture (e.g. ethnic culture, youth culture, culture of poverty).
Cultural sensitivity ensures that the intervention is appealing to, and therefore more likely to be 
effective with, the target population. Lack of cultural sensitivity may be a barrier to recruiting and 
retaining participants (see 5.4: Recruiting and retaining participants). For example, signs within the 
venue of the intervention and intervention materials should be easily understood by the target 
population, and the content of the intervention should be culturally relevant (e.g. informed by 
knowledge of drug-related cultural norms and practices). Certain cultural practices may be in 
conflict with the principles of evidence-based and ethical drug prevention (e.g. practices that 
promote harmful patterns of drug use, discrimination and exclusion) (see D: Ethical drug 
prevention; 3.5: Referring to evidence of effectiveness). In such cases, it must be carefully 
considered how such practices can be addressed as part of the intervention. Individual differences 
within groups must also be respected. For example, ‘culture’ may not be equally important to all 
members of the target population, and an over-emphasis of culture may alienate some of them. 
Further information on how to consider ethnicity when planning programmes can be found, for 
example, in the handbook Drug abuse prevention among youth from ethnic and indigenous 
minorities (UNODC, 2004).
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When tailoring the intervention to the target population, it is not sufficient to rely on assumptions 
about the target population. The modifications must be based on the findings from the needs 
assessment (see 1.4: Understanding the target population), and where possible members of the 
target population should be actively involved in the design and adaptation of the intervention (see B: 
Communication and stakeholder involvement).
The intervention must be tailored as much as possible prior to its implementation. Additional flexibility 
should also be built into the design, allowing practitioners to tailor the intervention during 
implementation without having to deviate from the original plan (e.g. by providing a range of options 
for activities, by outlining how the order of activities may be changed to suit participants’ needs on 
the day). By incorporating this level of flexibility in the intervention design, the likelihood that 
unplanned modifications are made spontaneously during implementation can be reduced (see 6.4: 
Adjusting the implementation). 
Basic standards:
4.3.1 The programme is adequate for and tailored to 
its specific circumstances regarding:
•  participants’ needs; 
•  the chosen setting; 
•  the operating environment; i.e. the recipient organisation or community in which 
the intervention will take place.
•  participants’ age, and their developmental stage; Examples: children, young adults, older people.
•  participants’ sex; 
•  participants’ gender; 
•  participants’ culture. i.e. the programme genuinely incorporates cultural 
sensitivity.
4.3.2 The elements to tailor include:
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Basic standards (cont.):
•  the language; Note: this includes written and oral communication.
Examples: translations and interpreters are 
considered, multilingualism of staff, slang terms used 
by target population (e.g. specific name for a drug), 
information boards and signs in the facility, tools for 
monitoring and evaluation.
•  the activities and methods for delivery; 
•  the messages of the intervention; Examples: messages contained in films, discussion 
points, legal status of drugs, normative data, songs, 
stories, dances.
•  the duration, frequency, and pace of the 
intervention; 
•  the number of participants per activity.
Additional expert standards:
4.3.3 The programme is adequate for and tailored to 
its specific circumstances regarding:
•  identified risk and protective factors; Basic standard if analysis of risk and protective 
factors was undertaken.
•  participants’ norms and values; 
•  participants’ socio-economic situation; 
•  the geographical area; 
•  any other relevant characteristics of the target 
population; 
•  differences between participants.
4.3.4 The intervention materials are tailored to the 
target population.
Basic standard if intervention materials are used (e.g. 
manuals, websites).
Examples: tailoring of designs, specific symbols, 
pictures in manuals.
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4.4 If planning final evaluations
Evaluation is an integral aspect of high quality drug prevention work. Without evaluation, it is 
impossible to know whether the intervention works as intended: is it effective in producing the 
desired outcomes in participants, and does it produce any undesired outcomes? Does it achieve the 
set goals and objectives (see 3.3: Defining aims, goals, and objectives)? How do participants and 
staff members view the quality and relevance of the intervention? Providers may worry that 
evaluations will expose weaknesses in their programme. In fact, evaluation should be seen as an 
opportunity for providers to understand, improve, and promote their programme better. Evaluation 
findings help determine whether a programme should be continued and how it could be improved 
(see Project stage 8: Dissemination and improvement).
This component focuses on outcome evaluation as a means to assessing whether goals and 
objectives were achieved, and on process evaluation as a means to understanding how they were 
achieved or, in some cases, not achieved. It is important to distinguish these two types of evaluation, 
as they serve different purposes and use different types of data. There are also other types of 
evaluation that could be relevant to the programme, although these are not discussed in the 
standards (see Uhl et al., 2010). The standards on outcome evaluation research design in this 
component are based primarily upon the USA Standards of Evidence (Flay et al., 2005).
The outcome evaluation assesses how effective an intervention is in producing desired outcomes, i.e. 
changes in participants in line with goals and objectives. As a minimum, outcome data (e.g. on drug 
use) is collected from participants at the beginning (‘pre-test’) and at the end of the intervention 
(‘post-test’) (see Figure 6, page 153). The progress of the intervention is measured by comparing the 
post-test data to the pre-test data to see if there were any significant changes in participants between 
the beginning and the end of the intervention. If the evaluation is designed as a randomised 
controlled trial, it is possible to attribute observed changes to the intervention (i.e. to assume that 
changes were caused by the intervention). Different types of evaluation design can be distinguished, 
including non-experimental design, quasi-experimental design, and randomised controlled trial. 
The process evaluation documents and analyses outputs (e.g. what activities were carried out, with 
and by whom). Process data is collected throughout the implementation of the programme (e.g. as 
part of monitoring), and it is analysed following the intervention to reflect on the programme and to 
understand how it can be improved. Aspects to consider include: reach and coverage (i.e. how well 
did participants represent the target population?); acceptance of the intervention by participants (e.g. 
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suitability of content and intervention materials); fidelity (i.e. was the intervention conducted 
according to plan; if an existing intervention was chosen, was implementation sufficiently true to the 
original evidence-based intervention?); use of resources (e.g. cost-effectiveness). These aspects are 
also considered during the implementation as part of monitoring to ensure that implementation is of 
high quality (see 6.3: Monitoring the implementation).
It is currently more common to conduct process evaluations than outcome evaluations. However, 
process evaluations cannot replace outcome evaluations if the provider wishes to understand what 
effects the intervention had on participants (e.g. participant satisfaction is not a suitable indicator for 
the effectiveness of the intervention).
Even though these evaluations are not conducted until after the intervention has been completed (see 
Project stage 7: Final evaluations), it is important to plan them at this stage. By doing so, evaluation is 
integrated into the intervention design. This will ensure that all relevant data and resources for 
evaluation will be available when they are needed.
The first standard within this component states that the most appropriate kind of evaluation must be 
determined. From a scientific point of view, all interventions should be evaluated to understand what 
makes drug prevention interventions effective. However, in reality there are many barriers that can 
prevent thorough evaluations. The consultations that informed the development of these standards 
indicated that common barriers included the costs associated with good quality outcome evaluations 
(e.g. in relation to data collection and analysis), lack of financial resources (e.g. funding available 
only for the intervention but not for evaluations), lack of human resources (e.g. necessary expertise), 
lack of technical support (e.g. for data collection and analysis), and practical feasibility (e.g. 
employing experimental research designs in participant-led health and social services, conducting 
long-term follow-up measurements). Most of these barriers concern process as well as outcome 
evaluations, although some are of particular importance to outcome evaluations. Additionally, the 
shift from information-based to skills-based approaches and the subsequent focus on behavioural 
outcomes (rather than knowledge) has added to the complexity of outcome evaluations. 
Nevertheless, delegates highlighted the importance of these standards, arguing that good quality 
evaluations are urgently needed to improve the evidence base on drug prevention in Europe.
Consequently, the type of evaluation must correspond to the resources that are (likely to be) available 
to the provider. Outcome and process evaluations should always be conducted as part of large-scale 
programmes (e.g. designed to demonstrate the efficacy or effectiveness of certain approaches, 
receiving large government support or being implemented nationwide). Randomised controlled trials 
150
European drug prevention quality standards
are the preferred design for such evaluations, as they produce the highest quality evidence, and 
other forms of evaluation should only be considered if these are not feasible. In the case of small-
scale programmes with limited resources, a process evaluation should be conducted to obtain 
important information about the quality of the programme and to assess whether an outcome 
evaluation should be carried out (see 8.1: Determining whether the programme should be sustained). 
Less resource-intensive forms of outcome evaluations should also be considered (e.g. non-
experimental design with measurements before and after the intervention, simple routine evaluations 
using only a few indicators). 
It is also important to decide whether evaluations should be ‘internal’ or ‘external’, i.e. whether they 
should be conducted by a team or individual working within the organisation or for an external 
organisation (e.g. university, consultancy). There are advantages and disadvantages to both 
approaches. For example, an external evaluator may be more expensive but have more expertise 
and be able to make a more objective judgement; an internal evaluator may have better access to 
informal sources of information but lack the time and knowledge to conduct an evaluation. The use of 
internal evaluators also introduces an element of bias as the evaluator may wish to portray the 
organisation and the outcomes of its activities in a more positive light. External individuals or teams 
are generally considered more suitable to conduct outcome evaluations, while internal staff members 
may be better suited to conduct monitoring and process evaluations (EMCDDA, 2010).
Once the most appropriate form of evaluation has been decided upon, evaluation indicators and 
benchmarks are defined. Evaluation indicators clarify what specific information (outcome and/or 
process data) must be collected prior, during and after the implementation of the intervention. 
Process indicators are derived from the operational objectives and concern the implementation of the 
programme, while outcome indicators are derived from the goals and specific objectives and 
concern changes in participants (see 3.3: Defining aims, goals, and objectives). Depending on the 
defined goals and objectives, outcomes may not focus on drug use but on other aspects in line with 
the identified needs and the theoretical model (3.2: Using a theoretical model).
The chosen indicators must be valid, i.e. appropriate for the concept they intend to measure 
(‘construct validity’). For example, an instrument may accurately measure participants’ attitudes 
toward drug use; however, attitudes toward drug use may not be a valid indicator for actual drug 
use in later life. Construct validity can be established by referring to the theoretical model and the 
existing scientific literature. Moreover, because indicators are only approximations of complex 
concepts, it is common to use several indicators.
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An evaluation benchmark should also be defined for each indicator. It defines achievement on that 
indicator in numerical terms or, where that is not possible, in descriptive terms. The evaluation 
benchmark could specify, for example, that a 10 % average increase in social skills measured through 
a questionnaire would represent a successful intervention. Success can be graded by providing more 
than one evaluation benchmark, e.g. for minimum (e.g. 5 % increase), realistic (e.g. 10 %), and optimal 
(e.g. 15 %) achievement. In order to define a benchmark, it is useful to know what the current value on 
the respective indicator is (e.g. participants’ score prior to the intervention) and what achievements can 
be reasonably expected over the course of the intervention (WHO, 1998). Distinct evaluation 
benchmarks should be formulated for outcome evaluation as well as for process evaluation indicators.
Figure 5 illustrates the relations between specific and operational objectives, evaluation indicators 
and evaluation benchmarks.
Figure 5: Connection between specific and operational objectives, evaluation indicators and 
benchmarks
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Consequently, the following information should be provided for each goal and objective to facilitate 
monitoring and the outcome evaluation: timeframe within which the goal or objective will be 
achieved, target population, outcome evaluation indicator with defined benchmark, and details on 
measurement (e.g. evaluation instrument, data collection schedule). To help monitor and evaluate the 
process of the intervention, the following information should be provided for each operational 
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objective: output required to achieve specific objective, timeframe within which the operational 
objective will be achieved, process evaluation indicator with defined benchmark. The following 
examples illustrate how aims, goals, and objectives could be formulated.
Aim (example): To assist participants in adopting a healthy lifestyle.
Goal (example): To decrease the number of young people reporting cocaine use in the previous month 
by the end of the 12-month intervention. Evaluation indicator/benchmark: 25 % reduction in the number 
of participants reporting use of cocaine in the previous month compared to baseline. Data collection: 
Self-reported drug use will be measured using an existing scale at the beginning, after six months, and at 
the end of the intervention.
Specific objective (example): To increase participants’ social skills by the end of the first six months of the 
intervention. Evaluation indicator: Assertiveness and communication skills as indicators for social skills. 
Evaluation benchmarks: 10 % average increase on ‘assertiveness’ scale, and 15 % average increase on 
‘communication skills’ scale in comparison to baseline. Data collection: Questionnaires using existing 
validated scales will be administered at the beginning of the intervention, after six months, and at the 
end of the intervention.
Operational objective (example): To conduct role play exercises with participants within the first six 
months of the intervention to develop participants’ social skills. Evaluation indicator/benchmark: Six role 
play exercises to be conducted in line with project plan.
It may be useful to involve relevant stakeholders (e.g. target population) in the definition of evaluation 
indicators and benchmarks, and in choosing methods for data collection and analysis, as this will 
increase the feasibility of the evaluations (e.g. participants may prefer to discuss the intervention in a 
focus group rather than complete a questionnaire) (see B: Communication and stakeholder 
involvement).
Aims, goals, and objectives, as well as the theoretical model, determine when to expect what 
outcomes, and consequently when to conduct measurements. Changes may occur on different 
evaluation indicators at different points in time (e.g. participants’ knowledge may change before 
their behaviour). It is, however, important that the same evaluation indicators and evaluation 
instruments are used consistently throughout the programme to ensure comparability of the data. 
Figure 6 illustrates the relationships between targets, outcomes, and measurements.
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Figure 6: Connection between targets, outcomes, and measurements
Immediate and intermediate outcomes occur during the intervention, corresponding to the objectives. 
Post-intervention outcomes occur at the end of the intervention, corresponding to the goals. It is also 
common to consider longer term final outcomes which correspond to the programme’s general aims. 
Data is collected at the beginning and end of the intervention to assess the effectiveness of the 
intervention, while periodic measurements help assess the progress of the intervention during 
implementation (e.g. as part of monitoring). After the intervention, follow-up measurements are 
conducted to test how long post-intervention outcomes are sustained (e.g. if participants 
demonstrated a change in attitude or behaviour at the end of the intervention, did they fall back into 
their old behaviours and attitudes after a couple of months?). The standards suggest the following 
intervals for follow-up measurements: up to 6 months after the intervention (short-term), >6 to 12 
months after the intervention (medium-term), and >12 months after the intervention (long-term). An 
additional measurement may be conducted when the final outcomes are expected to occur. For 
example, if an intervention is carried out with very young children, final outcomes would refer to 
whether they develop harmful patterns of drug use many years after the intervention. In practice, 
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however, such longer term follow-ups can be difficult to achieve and have high resource implications. 
As a minimum, post-intervention outcomes should be assessed to establish whether the intervention 
was effective in achieving its goals. This highlights that the defined goals must be realistic and 
achievable within the course of the intervention.
Components 7.1: If conducting an outcome evaluation and 7.2: If conducting a process evaluation 
contain further standards on the analyses and documentation of findings that are conducted as part of 
final evaluations. Further information on evaluation can also be found in the Additional guidance section. 
Where final outcome and process evaluations are not deemed appropriate or feasible, monitoring 
may be an acceptable alternative to conducting more comprehensive and formal evaluations (see 
6.3: Monitoring the implementation). Consequently, the standards in this component apply only if 
final evaluations are planned.
Basic standards if any final evaluation is planned:
4.4.1 It is determined what kind of evaluation is most 
appropriate for the programme.
Example consideration: while the process evaluation 
can help determine why successful outcomes arose, 
the outcome evaluation is more important than the 
process evaluation in determining an intervention’s 
effectiveness.
4.4.2 An evaluation plan exists in writing. Examples of content: type of evaluation, research 
model, illustrating evaluation indicators, data 
collection, monitoring, final evaluations, reporting, 
time schedules.
4.4.3 The planned evaluation is realistic and 
feasible.
i.e. it acknowledges what is feasible under real-
world conditions and with available resources.
4.4.4 Evaluation is seen as an integral and important 
element in ensuring programme quality.
4.4.5 An evaluation team is designated to oversee 
the evaluation. 
Note: the ‘team’ may also only be one person.
4.4.6 The evaluation team:
•  develops the evaluation strategy and plan, the 
evaluation indicators, and data collection 
instruments; 
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Basic standards if any final evaluation is planned (cont.):
•  prepares the evaluation report; 
•  assigns relevant roles to specific persons. Examples of roles: persons responsible for data 
collection, data recording, data analysis.
4.4.7 The human resources are sufficient to conduct 
an evaluation.
i.e. the team has a sufficient number of qualified staff 
to conduct an evaluation; the knowledge of 
evaluation is sufficient.
4.4.8 Evaluation indicators are specified.
4.4.9 Evaluation indicators are:
•  clearly described; 
•  measurable in quantitative and/or qualitative 
terms; 
•  measurable using empirical techniques; Example: observations.
•  appropriate for the type of evaluation. Example of evidence: if process and outcome 
evaluations are planned, separate indicators are 
specified for process and outcome evaluation. 
4.4.10 The choice of evaluation indicators is 
informed by:
•  the goals and objectives of the programme; i.e. each goal and each objective is connected with 
one or several evaluation indicator(s).
•  the chosen activities.
4.4.11 The process for participant selection is 
described.
Note: participants should be drawn from the defined 
target population.
See also 3.1: Defining the target population and 5.4: 
Recruiting and retaining participants.
4.4.12 A timeline is specified. i.e. it is clear when the evaluation(s) will be 
conducted.
Example: brief questionnaire for staff members and 
participants after each session.
Example of evidence: measurement schedules.
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Basic standards if any final evaluation is planned (cont.):
4.4.13 The persons to collect data from are:
•  specified;
•  adequate for the purposes of the evaluation.
i.e. they are able to provide the information required for the evaluation indicators.
Example: outcome data is collected from participants or from persons who can provide good quality 
proxy data (e.g. clinical rating, school teacher report on classroom behaviour, observation and 
recording of social interactions by staff members).
4.4.14 Participants, staff members, and others feel 
comfortable enough to provide honest answers and 
opinions.
Example: they feel comfortable enough to report 
their drug use or to criticise the programme.
4.4.15 Methods and tools used for data collection 
are described.
4.4.16 Methods and tools used for data collection:
•  are adequate for the programme; i.e. the data collection method is commensurate with 
the level of the programme.
•  retrieve information relevant to the evaluation 
indicators; 
•  consist of previously tested existing tools or well-
developed new tools; 
•  are consistently used throughout the programme. i.e. the same instruments are used throughout the 
programme (e.g. for baseline and final 
measurements).
Purpose: to ensure comparability of data.
4.4.17 A system for information management is in 
place.
i.e. a set of procedures, paper and electronic 
supports, etc.
Purpose: to facilitate data collection and processing.
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Additional basic standards if an outcome evaluation is planned:
4.4.18 The outcome evaluation follows a research 
design. The evaluation:
•  enables a clear analysis of the relationship 
between the intervention and the outcomes; 
•  reflects the strongest possible research design 
given the circumstances of the intervention. 
Example: if randomisation is not practical or 
possible, alternative designs are implemented, such 
as repeated time-series design without 
randomisation, regression-discontinuity designs, 
matched control designs.
4.4.19 The necessary sample size for a good 
research design is determined.
Example consideration: what is the minimum sample 
size that is required for the planned statistical 
analyses?
4.4.20 The method for data analysis is described.
4.4.21 The persons to collect outcome data from are 
specified. 
4.4.22 Outcome data is collected from participants 
in the intervention group.
4.4.23 Outcome data is measured:
•  at the beginning of the intervention or during 
needs assessment; 
i.e. as baseline data to enable comparisons before 
and after the intervention.
•  post-intervention. i.e. at the end of the intervention.
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Additional basic standards if a controlled design is chosen:
4.4.24 At least one comparison condition (i.e. 
control group) is arranged.
4.4.25 The participant selection criteria and the 
assignment procedure are described for intervention 
and control groups.
Example of assignment procedure: self-selection.
4.4.26 Measurements are conducted in both 
intervention and control groups.
i.e. outcome data is collected from participants in the 
control group.
4.4.27 Various characteristics are analysed in the 
intervention and control groups to ensure that they 
are similar; any identified differences are controlled 
for in the data analysis.
i.e. test for pre-test differences.
Additional basic standards if a process evaluation is planned:
4.4.28 The persons to collect process data from are 
specified. 
4.4.29 The persons to collect process data from include:
•  participants in the intervention group; 
•  staff members.
Additional expert standards:
4.4.30 The final evaluations assess the programme 
process as well as the outcomes of the intervention. 
4.4.31 The evaluation embraces various viewpoints. Examples of viewpoints: evidence of effectiveness 
(outcomes), practical functioning (process), 
correspondence with best practice guidance, ethics.
4.4.32 The target population is involved at all stages 
of the evaluation.
4.4.33 Relevant stakeholders are involved in the 
design of the evaluation.
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Additional expert standards (cont.):
4.4.34 The evaluation team:
• collects, analyses, and interprets data; 
• involves a range of representatives. Examples of groups to consider: staff members, 
participants, academics.
4.4.35 Evaluation experts are consulted, where 
necessary.
Examples of experts: university and/or external 
consultants with expertise in evaluation.
4.4.36 Where possible, external evaluations are 
conducted. 
i.e. as formal assessments by an individual or group 
working for an external organisation (e.g. university, 
consultancy).
4.4.37 Evaluation indicators:
•  acknowledge participants’ development 
throughout the programme; 
i.e. different indicators are chosen to represent 
different stages of progress in the intervention.
Note: although a range of indicators is chosen to 
capture participants’ progress over time, 
measurements must be conducted with the same 
indicators and instruments throughout the 
intervention.
•  include evaluation benchmarks indicating 
minimum and optimal intended levels of change.
i.e. a specific value to be achieved on an evaluation 
indicator during or after the intervention.
Example: the programme wants to achieve at least a 
20 % decrease in drug use, and ideally (under 
perfect conditions) a 50 % decrease in drug use.
4.4.38 The choice of evaluation indicators is 
informed by the theoretical model.
Basic standard if a theoretical model is used.
Example aspects to consider: mediators and 
moderators suggested by the theoretical model.
4.4.39 The evaluation is conducted under real-world 
conditions.
Basic standard if the programme is an effectiveness 
trial (as opposed to an efficacy trial).
Example of real-world condition: teachers instead of 
researchers as deliverers of intervention.
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Additional expert standards (cont.):
4.4.40 The research design incorporates a control 
condition.
Purpose: to be able to attribute effects to the 
intervention.
4.4.41 At least one form of data collection is 
blinded.
i.e. data collectors do not know whether participants 
received the intervention or whether they were in the 
control group.
4.4.42 The research design incorporates 
randomisation. This includes:
Purpose: to avoid obtaining a biased participant 
sample.
•  Participants are randomly assigned to 
intervention and control groups (‘randomisation’).
Basic standard if a randomised design is chosen.
•  Stakeholders are involved in the randomisation 
process as necessary.
Purpose: stakeholder assistance may be required to conduct randomisation (i.e. to obtain list of 
all eligible individuals or recipient organisations). Stakeholders must also understand why 
randomisation is important and the reasons why some individuals or organisations may not 
receive the intervention. 
Example of stakeholder involvement: school head teacher assists with allocation of classes to 
intervention and control conditions.
4.4.43 Methods and tools used for data collection:
•  comprise a range of tools and measures; Examples of tools and measures: questionnaires, 
attendance registers, satisfaction scales, forms, 
checklists, independent observations.
•  are psychometrically sound in term of their 
objectivity, validity, and reliability; 
i.e. measure what they are intended to measure 
(validity); produce consistent results (reliability: 
internal consistency, test-retest, inter-rater reliability); 
produce results independently of who uses the 
instrument (objectivity).
Note: construct validity must also be considered, i.e. 
are the indicators valid measures of targeted 
behaviour following the appropriate literature?
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Additional expert standards (cont.):
•  are culturally adapted and pilot tested, where 
appropriate.
4.4.44 Guidance on the data collection methods is 
provided.
Example of guidance: analytic strategies and 
detailed guidelines for field researchers.
4.4.45 Process data is collected from:
•  participants in the control group; 
•  other relevant stakeholders, where appropriate. Examples of stakeholders: funders, other agencies, 
community members, media.
4.4.46 Certain process data is collected at the end 
of each session.
Examples of process data: participants’ satisfaction, 
feedback from staff members on the quality and 
success of the session.
4.4.47 Outcome data is measured:
•  periodically, where appropriate; 
•  short-term; i.e. within 6 months of completing the intervention.
•  medium-term; i.e. >6 to 12 months after completing the 
intervention.
•  long-term. i.e. >12 months after completing the intervention.
4.4.48 Interventions that anticipate longer term final 
outcomes incorporate data collection at an 
appropriate time when the outcome is expected. 
Example consideration: for programmes targeting 
young children, outcome data is collected when final 
outcomes are developmentally expected.
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Project stage 5 
Management and mobilisation of resources
A drug prevention programme consists not only of the actual intervention, but also requires good 
project management and detailed planning to ensure that it is feasible. Managerial, organisational, 
and practical aspects need to be considered alongside the intervention design. To start 
implementation, available resources must be activated and new resources accessed as necessary. 
Project management reference books provide in-depth information on how to plan and manage 
projects. However, together with Project stage 3: Programme formulation these standards highlight 
some of the main considerations in relation to drug prevention work.
5.1 Planning the programme — Illustrating the project plan: A dedicated procedure ensures that 
planning and implementation are conducted systematically. A written project plan documents all 
tasks and procedures that are required for the successful implementation of the programme. The 
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project plan guides implementation by providing a common framework that all staff members can 
work towards. In later project stages, the project plan is consulted to assess whether the programme 
is implemented as intended, and if any adjustments are required.
5.2 Planning financial requirements: The financial requirements (costs) and capacities (budget) of the 
programme must be determined to put necessary and available resources into context. The costs must 
not exceed the budget that is (or will be available) for the programme. If more resources are required 
than are available, the financial plan clarifies what additional funding might be required or how the 
project plan may need to be altered.
5.3 Setting up the team: The team consists of the people working on the programme (e.g. managing, 
delivering, evaluating). Staff members (including volunteers) should be chosen in correspondence 
with legal requirements and the needs of the programme. Roles and responsibilities should be 
distributed accordingly, guaranteeing that all necessary tasks have been assigned and are carried 
out by the most suitable persons.
5.4 Recruiting and retaining participants: Participants should be recruited from the defined target 
population in a methodologically correct and ethical way. Recruitment refers to the process of 
choosing eligible individuals from the target population, informing them about the programme, 
inviting them to take part, enrolling them, and ensuring that they begin the intervention, while 
retention refers to the process of ensuring that all participants remain in the intervention until it has 
finished and/or until the goals have been achieved. Barriers to participation should be identified and 
removed to ensure that participants can complete the programme.
5.5 Preparing programme materials: The materials that are required for implementation of the 
programme should be considered, including intervention materials, instruments for monitoring and 
evaluation, technical equipment, the physical environment (e.g. facilities), etc. This allows finalising 
the financial plan, and taking action to secure necessary materials. If intervention materials are used 
(e.g. manuals, films, websites), they should be of high quality and suitable for the intended users.
5.6 Providing a programme description: A written programme description provides a clear overview 
of the programme. It is produced so that interested stakeholders (e.g. target population, funders, 
other interested professionals) may obtain information about the programme. The intervention and its 
activities should be described in detail, although the level of detail will depend upon the scope of the 
programme and the likely readers of the description. If the description is used in participant 
recruitment, particular emphasis must be put on the potential risks and benefits for participants.
This stage may be conducted at the same time as the intervention design.
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5.1 Planning the programme — Illustrating the project plan
A drug prevention programme comprises not only the intervention, but also the accompanying 
research (e.g. needs assessment, evaluation) and administrative structure (e.g. project 
management, fundraising, staff training, participant recruitment, dissemination, etc.). Only a 
dedicated planning procedure can ensure that all these aspects are well coordinated, and that 
preparations for the intervention and its implementation are conducted systematically. The most 
important part in this regard is a written project plan which illustrates the main tasks and strategies 
required for the successful implementation of the programme. It is not always necessary to produce 
the project plan from scratch; it can be adapted from existing funding applications or similar 
documents. 
The project plan guides the implementation of the programme by providing a common framework 
that all staff members can work towards. During implementation, it can be used to track and 
document implementation, assess whether implementation follows the project plan, review the 
progress of the programme, and justify any changes (e.g. to the original timeline) (see Project stage 
6: Delivery and monitoring). If used in this way, it will be a crucial source of information for the 
process evaluation and the production of the final report. This highlights that the project plan is an 
important tool even if actual implementation is not in line with the original plan (e.g. if timelines 
change). Moreover, contingency plans enable providers to deal effectively with emerging difficulties.
The project plan documents the decisions taken in the earlier project stages and outlines how they 
can be put into practice. The level of detail in the project plan depends on the circumstances of the 
programme. It should be comprehensive enough to be useful to the team and not be regarded as a 
bureaucratic ‘tick-box exercise’ that has no real value to the programme. It is recommended that 
representatives from all relevant stakeholder groups are involved in the planning (e.g. target 
population, recipient organisation). This will ensure that the programme meets their needs and 
expectations, and it will also help secure their support for the later stages of the programme (see B: 
Communication and stakeholder involvement). The project plan should be consulted regularly at 
planning meetings to discuss the progress of the programme and relevant next steps (e.g. as part of 
the monitoring procedure — see component 6.3: Monitoring the implementation). 
Time spent on planning the programme may be perceived by some professionals as a luxury, or even 
as ‘unproductive’ time, because it is not time spent directly with the target population. However, 
taking time for reflection, literature review, discussion, etc. is an essential aspect of conducting high 
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quality drug prevention. Commissioners and funders must support the implementation of the 
standards by funding such time and allowing providers to include it in cost calculations. 
The project plan differs from the programme description which informs external parties (e.g. target 
population, funders) about the programme (see 5.6: Providing a programme description). For new 
funding applications, it is recommended to produce a combined document incorporating the project 
plan and the programme description.
Basic standards:
5.1.1 Time is set aside for the planning of the 
programme.
Example of evidence: resource estimate in funding 
application includes time spent on planning.
5.1.2 The programme is planned systematically. i.e. by dedicating time to planning; by considering 
necessary actions for all project stages.
5.1.3 The planning and management process is 
transparent.
Example consideration: are all staff members aware 
of how the programme is planned and managed?
5.1.4 A written project plan exists. Also called: work plan, action plan, implementation 
plan.
5.1.5 The project plan:
•  is clear and comprehensible for all; 
•  illustrates and connects the main components of 
the programme; 
Example: showing connections between target 
population needs, aims, goals, and objectives, 
evaluation indicators, evaluation benchmarks, 
activities, outcomes, and evaluations.
Example of evidence: the logical flow of programme 
activities is illustrated in a graphical representation 
(i.e. in a programme logic model).
Additional guidance: programme logic models are 
discussed in Achieving outcomes (CSAP, 2002).
•  allows tracking actual progress of the programme 
during implementation; 
•  is realistic; 
•  is accessible by all involved staff members.
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Basic standards (cont.):
5.1.6 The project plan outlines the following:
•  aims, goals, and objectives; 
•  a set of actions for each objective; 
•  the intervention; Example aspects to consider: what intervention 
activities are to be conducted with participants, by 
whom, and how.
•  a strategy for monitoring the programme quality; Example aspects to consider: fidelity, effectiveness, 
participants’ satisfaction.
•  the programme’s time schedule; i.e. planned start and end dates for different stages 
and activities.
Note: actual start and end dates should be added 
during implementation.
•  the procedure for the recruitment and retention of 
participants; 
•  staff selection procedures.
5.1.7 A contingency plan is developed, outlining:
•  rules and procedures to prevent or handle 
potential problems; 
i.e. potential scenarios that could jeopardise the 
implementation or success of the programme, as well 
as ways of preventing or handling these scenarios.
Example of scenarios: not completing activities within 
specified timeframe.
•  a solution strategy for problems with the 
organisational capacity.
Examples of scenarios: staff members leaving, 
overspending on budget.
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Additional basic standards if evaluations are planned:
5.1.8 The project plan outlines the following:
•  a strategy for data collection; i.e. who will measure what, when and how.
•  deadlines for final evaluations.
Additional expert standards:
5.1.9 A working group is established. Note: this may include representatives from the 
target population and other stakeholder groups.
5.1.10 A procedure for programme planning is in 
place.
Example aspects to consider: responsibilities for 
planning, reporting arrangements, feedback, follow-
up.
5.1.11 Planning sessions are held and minuted. Example of evidence: regular meetings of the 
working group, meeting summaries available.
5.1.12 The programme takes short-term, mid-term, 
and long-term perspectives in planning and 
implementation.
5.1.13 The written project plan:
•  is systematically arranged as a step-by-step 
sequence; 
•  consists of a general project plan and more 
detailed action plans; 
•  groups tasks into work packages or stages.
5.1.14 The project plan outlines the following:
•  those activities that are most important for the 
success of the programme; 
i.e. the ‘critical’ activities.
•  a strategy to ensure the involvement of the target 
population in the programme development and 
implementation; 
•  a schedule for regular review of the project plan; 
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Additional expert standards (cont.):
•  preparatory tasks necessary to start the 
intervention; 
•  the procedure for the recruitment and retention of 
external collaborators; 
Example of external collaborator: recipient 
organisation (e.g. school).
•  staff training procedures; 
•  named persons responsible for the 
implementation of the plan; 
i.e. distribution of roles and responsibilities.
•  supervision of staff; 
•  a strategy for programme documentation; 
•  a communications strategy; Example: a process to communicate monitoring 
feedback to staff members.
•  procedures for cooperation with external persons 
and agencies.
Examples of external persons and agencies: social 
work case managers, probation officers, the media, 
police.
170
European drug prevention quality standards
5.2 Planning financial requirements
Drug prevention programmes are only feasible and sustainable in the long term if the necessary 
resources match the available resources. Funding is a key resource, as it can (indirectly) determine 
the availability of all other resources. The standards outline the requirement to produce a financial 
plan specifying the financial requirements (costs) and capacities (budget) of the programme. A clear 
financial plan helps ensure that sufficient funding is available to carry out all planned activities. 
Otherwise, prevention activities run the risk of being discontinued because funds have been 
exhausted ahead of completion.
Costs refer to the amount of money which is (likely to be) required for the programme. It is important 
to remember that costs arise not only from the implementation of the intervention. The total costs are 
calculated by considering all resources that are necessary to put the project plan into practice (e.g. 
materials, staff training, project management, evaluation). Tools such as the Drug Abuse Treatment 
Cost Analysis Program (DATCAP) (French, 2004) can help provide a realistic estimate of total costs. 
Additionally, the standards encourage the consideration of opportunity costs which may include non-
monetary items such as lost time (i.e. staff or participant time not spent on other activities). The 
analysis of opportunity costs should take into account a variety of perspectives, such as those of staff 
members, participants, and other stakeholders (CCSA, 2009).
Budget refers to the amount of money which is (likely to be) available for the programme. It also 
represents the maximum allowed spend (i.e. costs must not exceed the budget). Consequently, costs 
must be planned in line with the budget. If estimated costs are greater than the estimated budget, 
providers must either obtain additional funding (see A: Sustainability and funding) or modify the 
project plan so that the programme is achievable within the available resources. Programme 
developers may help refine costs, for example by offering an intervention version using alternative, 
less expensive materials. The pursuit of efficiency, however, must not compromise the quality or 
effectiveness of the intervention (e.g. using fewer staff members may reduce the quality of delivery). 
Where modifications made to reduce costs would threaten the quality or effectiveness of the 
intervention, commissioners and funders may need to appreciate better what the real costs of 
programmes and evaluations are, and allocate funding accordingly.
These standards apply regardless of whether funding is already available (e.g. as part of the 
organisational budget, as part of a grant that has already been received) and/or whether it is still to 
be secured externally (e.g. developing a programme in response to a specific tender for funding). By 
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providing a detailed breakdown of costs and funding streams and specifying which cost items will be 
covered by which types of budget, the budget can be earmarked for the specific programme and 
will thus be more likely to be available when it is needed.
If programme developers are designing a new intervention that is to be implemented separately by 
providers, it may not be possible or appropriate for these programme developers to estimate total 
cost and budget, as these will depend on the particular circumstances of the provider. In such cases, 
cost estimates may relate to costs of intervention materials, licence fees, etc.
Basic standards:
5.2.1 A clear and comprehensible financial plan 
exists in writing.
i.e. costs and budget are specified.
5.2.2 A clear cost estimate for the programme is 
provided.
5.2.3 The cost estimate is realistic for the envisaged 
programme.
5.2.4 A realistic estimate of the total budget 
available to the programme is provided.
5.2.5 The funding entities and other sources of 
income are stated.
5.2.6 The available budget is adequate for the 
envisaged programme.
5.2.7 Costs and available budget/funds are linked.
5.2.8 It is clear who is responsible for control of the 
budget.
5.2.9 Accounting is clear and transparent.
5.2.10 The budgeting complies with legal and 
general requirements.
Example of legal requirements: accounting 
procedures, such as how long invoices have to be 
archived.
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Additional expert standards:
5.2.11 A detailed and comprehensive breakdown of 
costs is provided.
Examples of items to be costed:
•  staff costs and time, including volunteers; 
•  opportunity costs; 
•  manuals and other materials; 
•  overheads, such as rent, facility space, technical equipment; 
•  project management and administration; 
•  staff training; 
•  participant recruitment and retention; 
•  data collection, monitoring, and final evaluations; 
•  dissemination of information about the programme.
5.2.12 A detailed and comprehensive breakdown of 
the available budget is provided.
i.e. outlining different funding streams.
Examples of funding streams: charitable 
contributions, internal resources.
See also A: Sustainability and funding.
5.2.13 The financial requirements are reviewed in the 
implementation phase according to emerging new 
priorities or developments.
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5.3 Setting up the team
A drug prevention programme can only be successful if is carried out by the right people. Staff 
members (including volunteers) must be chosen in correspondence with legal requirements and the 
needs of the programme. Roles and responsibilities must be distributed accordingly, ensuring that all 
tasks have been assigned and will be carried out by the most suitable persons.
The type and scope of the programme will define what qualifications and competencies (e.g. 
knowledge, skills, attitudes) are required for a successful implementation of the programme. 
Component C: Staff development contains standards on staff competencies and the training, 
development, and support of staff prior to and during implementation.
If these standards are used during the planning of a programme, their practical meaning will depend 
on whether staff members are yet to be hired for the programme and/or whether existing staff 
members can be allocated to the programme. In either case, these standards specify what criteria to 
consider when assembling the team to work on the programme. 
Basic standards:
5.3.1 There is a written procedure for staff selection 
and hiring.
5.3.2 Staff selection and hiring is in line with legal 
requirements.
5.3.3 The structure and management of the 
organisation are defined in writing.
Note: in large organisations, a description of the 
specific department responsible for the programme 
may be sufficient.
5.3.4 The form of employment is clear and 
corresponds to national legislation.
Examples of evidence: working contracts include 
details on staff rights and benefits, accident 
insurance, unemployment insurance, overtime 
premium, salary, and other forms of compensation.
5.3.5 The staff required for the successful 
implementation of the programme is defined.
Note: staff may include professional staff, volunteers, 
interns, external contributors, etc.
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Basic standards (cont.):
5.3.6 The specification takes into account:
•  required type of roles; Examples of roles: outreach worker, alcohol nurse 
specialist, administrative staff.
•  required number of staff; Example of evidence: staff-task ratio.
•  required staff qualifications; Examples of qualifications: university degree in a 
relevant field, training in prevention and health 
promotion.
•  required staff competencies.
i.e. as outlined under C: Staff development.
Note: It is likely that there will be an overlap between different roles, i.e. the same individual(s) 
may have different functions.
Examples of roles to consider: 
•  leadership of the programme, i.e. sufficient knowledge and understanding of project work; 
•  project management; 
•  intervention delivery; 
•  monitoring of the programme’s quality and effectiveness; 
•  administration and business tasks (e.g. book keeping, purchasing); 
•  external coordination, i.e. building relationships and preparing cooperation, publicity.
5.3.7 The set-up of the team is appropriate for the 
target population.
Example: ethnicity and diversity of staff members are 
(likely to be) acceptable for the target population.
5.3.8 Tasks and functions are distributed 
appropriately among staff members.
Note: the distribution of tasks and functions should consider staff members’ qualifications, their 
level of experience, and their workload balance.
Example consideration: Specialised tasks are carried out by staff members with corresponding 
qualifications and licences (e.g. chartered psychologist status); if necessary, external specialist 
staff is sought.
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Basic standards (cont.):
5.3.9 Required staff resources are (likely to be) 
available.
Example aspects to consider: time availability, 
availability of required roles and staff numbers.
Example of evidence: existing staff members or 
networks.
5.3.10 Staff members are (likely to be) ready to 
engage in the programme.
Example of staff readiness: teachers accept the need 
for a school intervention.
5.3.11 Staff members are (likely to be) clear about 
their responsibilities and roles.
Example of evidence: the division of tasks is defined 
in writing for each project stage.
5.3.12 Staff members are selected according to the 
needs of the programme.
Note: this may to refer to the allocation of existing 
staff members to the programme as well as to the 
selection of new staff members.
Additional expert standards:
5.3.13 The written procedure for staff selection and 
hiring specifies:
•  internal staff selection rules where the valid 
legislation is too general; 
Example aspects to consider: professional 
qualifications and/or experience, target population 
expectations towards staff members.
•  rules regarding the involvement of interns and 
volunteers in the programme; 
Basic standard if interns and/or volunteers are 
involved.
Note: for example, criminal records checks may be 
requested. 
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Additional expert standards (cont.):
•  rules regarding the involvement of staff members 
with previous or current problems.
Basic standard if, for example, former or current drug users are involved as staff members.
Note: rules should be sensible to the value of employment in the rehabilitation and social 
reintegration of, for example, former or current drug users. The involvement of former or current 
drug users who wish to gain work experience should not generally be ruled out (UKDPC, 
2008). Rules may specify staff development requirements (see C: Staff development). 
Examples of problems: previous or current problems with legal or illegal drugs, persons 
convicted of crimes, previous offences towards children.
5.3.14 The actual qualifications of existing staff 
members are described.
Examples of existing staff members: lead practitioner, 
service manager.
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5.4 Recruiting and retaining participants
Participants are those who take part in, or receive, the intervention in a direct manner (e.g. by taking 
part in an activity, by being exposed to a drug prevention message). Depending on the type of 
programme, participants are drawn from the ultimate target population (e.g. young people at risk of 
drug use) or an intermediate target population (e.g. family, peers, teachers) (see 3.1: Defining the 
target population). 
Recruitment refers to the process of choosing eligible individuals from the target population, 
informing them about the programme, inviting them to take part, enrolling them, and ensuring that 
they begin the intervention (e.g. attend the first session). Various means can be used to promote 
participation in the programme, e.g. outreach, word of mouth, advertisements, referral through other 
agencies (UNODC, 2009a). When recruiting participants, the principles of ethical drug prevention 
should be observed by providing, where possible, transparent, truthful and comprehensive 
information about participation in the programme and obtaining participants’ consent (see D: Ethical 
drug prevention; 5.6: Providing a programme description).
The participant sample should be representative of the defined target population (i.e. mirror its 
characteristics), so that findings can be generalised to the wider target population. This requirement 
is essential where the intervention is part of a scientific research trial. In such cases, participants must 
be recruited in a methodologically correct way to avoid bias. This is best achieved by drawing a 
random sample so that each individual or natural group (e.g. school class) has the same probability 
of being selected into the sample. Random selection can be conducted, for example, by using a 
computer-generated list of random numbers. Furthermore, the participant sample should be large 
enough to enable a range of statistical analyses (i.e. to achieve sufficient statistical power). Where 
the intervention is not part of a scientific research trial (e.g. continuous participant-led services), other 
methods may be used for participant selection. It is then essential to document how participants are 
drawn from the target population, so that others may understand the procedure.
Retention refers to the process of ensuring that all participants remain in the intervention until it has 
finished and/or until the goals have been achieved (whichever is more appropriate) (refer also to the 
definition of ‘completion’ under 4.1: Designing for quality and effectiveness). Retention of participants 
is essential to ensure that the intervention is effective (i.e. participants cannot achieve goals if they 
drop out unplanned beforehand). Retention is particularly important where an outcome evaluation is 
planned (see 4.4: If planning final evaluations; 7.1: If conducting an outcome evaluation). If post-
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intervention outcome data is not available for all participants, then a reduced sample size may mean 
that it is not be possible to conduct all intended statistical analyses. In such cases, analyses should be 
used which take into account withdrawal or dropout from an intervention (e.g. Intention-to-Treat (ITT) 
analysis). If the findings of the evaluation are to be generalised to the wider target population, it must 
also be considered how participants who dropped out differ from those that remained. 
Consequently, financial requirements must be planned so that sufficient funding is available to ensure 
that all participants can complete the intervention (see 5.2: Planning financial requirements).
The likelihood of successfully recruiting and retaining participants can be increased by taking special 
measures to make participation in the programme more attractive. An important aspect is to identify 
and remove potential barriers to participation. These may be practical (e.g. inconvenient location or 
timing, family responsibilities, illiteracy) or of a more subtle nature (e.g. risk of stigma for participants, 
programme is not culturally acceptable, intervention perceived as irrelevant). It is also possible to 
offer additional conveniences and incentives (e.g. paying for transportation, offering child care, 
offering a ‘prize’ for completion of the intervention). When intending to offer financial incentives, the 
potential advantages and disadvantages must be taken into account. Vouchers (e.g. to spend at 
supermarkets) are preferable over cash payments if there is a concern that participants will spend the 
incentive on drugs. Access can also be widened, for example, by making a special effort to include 
‘hard-to-reach’ populations.
Retention rates can sometimes be regarded as an indicator for the overall quality of the programme 
(i.e. if participants ‘like’ the programme, they will take part). Even though participants with more severe 
needs may be more likely to drop out, retention can also depend on the programme itself. For example, 
aspects of staff composition and staff behaviour may have an impact on retention rates (see 5.3: 
Setting up the team; C: Staff development), or the content and delivery of the intervention. The 
consultations held to inform the development of these standards suggested that tailoring the intervention 
to the target population was an important factor in assuring retention (see 4.3: Tailoring the intervention 
to the target population). In certain cases, providers may choose to tailor the intervention while it is 
being delivered. For example, a practitioner may decide to conduct an interactive session in a school 
class full of tired pupils instead of the planned lecture to increase their level of engagement. However, 
such modifications must be well justified so that they do not have a negative impact on the fidelity and 
effectiveness of the intervention (see 6.4: Adapting the intervention); ideally, this level of flexibility is 
already included in the intervention design (e.g. by outlining how the order of activities may be 
changed to suit participants’ needs on the day). 
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However, the pursuit of high retention rates must not override the principles of ethical drug 
prevention. Where participation is not a legal requirement, participation should be voluntary, and 
providers should respect participants’ rights, including their right to withdraw their participation at 
any time without giving a reason. Participants should be treated as free individuals and not forced to 
remain in the programme if they wish to discontinue their participation. 
It may not be possible or necessary to recruit and retain participants in all prevention activities as 
described above. For example, in outreach work, while observing the principles underlying this 
component, it may be necessary to take a less formal approach to recruitment. In other cases, 
recruitment and retention may refer to a larger unit (e.g. the recipient organisation) instead of 
individuals. For example, in universal school-based activities children may not have to be formally 
recruited and retained if drug education is part of curriculum requirements. Recruitment and retention 
would then refer to the schools themselves (e.g. informing schools about the programme and 
ensuring their continued collaboration) (see B: Communication and stakeholder involvement). 
Further information on how to recruit and retain participants can be found, for example, in the 
handbook Guide to implementing family skills training programmes for drug abuse prevention 
(UNODC, 2009a), upon which these standards are primarily based.
Basic standards:
5.4.1 It is clear how participants are drawn from the 
defined target population.
i.e. it is clear how participants are selected from all 
members of the target population.
5.4.2 The mechanisms used to recruit participants 
are defined.
i.e. it is clear how members of the target population 
are invited to take part in the intervention.
Example of recruitment mechanism: posters 
displayed in sexual health clinics.
5.4.3 Specific measures are taken to maximise 
recruitment and retention of participants. The 
programme:
•  is affordable for the target population; i.e. low-cost or free of charge.
•  offers adequate timetables and locations for the 
target population; 
•  ensures confidentiality; 
•  avoids labelling participants or the wider target 
population.
Purpose: ensures that participants are not ashamed 
to take part in the programme.
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Additional basic standards if information about the programme is provided to 
participants as part of the recruitment procedure:
5.4.4 Information about the programme: See also 5.6: Providing a programme description.
•  corresponds to reality and is up-to-date; 
•  is presented in a form that is comprehensible and 
adequate for the target population; 
•  is distributed using appropriate media and 
channels.
Additional expert standards:
5.4.5 Participants are recruited from the defined 
target population:
•  using probability sampling; Basic standard if the intervention is delivered as part 
of a randomised controlled trial (RCT).
•  using existing networks and through other 
activities; 
Examples: existing school or community networks, 
outreach work.
•  at relevant transition points in their lives (‘points 
of vulnerability’).
Examples of transition points: expected events, such 
as move from primary to secondary school 
education; unexpected events, such as parents’ 
divorce (UNODC, 2009a, p. 24).
5.4.6 Participation in the programme is open to all 
members of the target population.
i.e. certain members of the target population are not discriminated against.
Note: if there are justifiable reasons to exclude certain members of the target population, the 
definition of the target population may need to be revised.
Example aspects to consider: equal access to the programme regardless of sex, age, race, or 
religious beliefs.
5.4.7 The person recruiting potential participants is 
chosen appropriately.
Example: successful previous participant rather than 
university research staff.
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Additional expert standards (cont.):
5.4.8 Members of the target population are informed 
about the programme.
5.4.9 Information about the programme is publicly 
available.
5.4.10 In order to maximise recruitment and retention 
of participants, the programme:
•  is accessible without unnecessary delay; Example: the gap between enrolment and the first 
session of the intervention is as short as possible.
•  identifies potential practical barriers for 
participants, and takes measures to reduce these; 
Example of barriers: illiteracy.
Examples of measures to take: discuss issues with 
participants in the first session, brainstorm to find 
solutions.
•  offers conveniences for participants; Examples of conveniences: offering childcare, 
providing transportation and/or meals, possibility to 
bring other persons to some sessions (e.g. spouse, 
elders, employers).
•  offers participants a choice of staff members, 
including staff members from the participants’ 
own background; 
•  offers incentives for participants; Examples of incentives: small gifts or ‘lottery’, 
planning and organising graduation ceremony 
together with participants (UNODC, 2009a).
•  makes additional efforts to increase the access 
for ‘hard-to-reach’ populations.
Note: hard-to-reach populations include people who 
do not have access to programmes and services 
because of social exclusion and marginalisation of 
their lifestyle.
Example of hard-to-reach populations: pupils (and 
their families) who are excluded from school.
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5.5 Preparing programme materials
The standards in this component refer to those materials that are required for the implementation of 
the programme. This includes instruments for monitoring and evaluation (e.g. questionnaires), 
technical equipment (e.g. computers, DVD players, projectors), the physical environment (e.g. indoor 
and outdoor facilities), etc. By specifying what materials are needed, the cost estimate in the 
financial plan can be finalised (see 5.2: Planning financial requirements), and relevant action taken 
to secure the necessary materials.
A particular emphasis is put in this component on materials that are used to deliver the content of the 
intervention (‘intervention materials’), such as workbooks, DVDs, staff training manuals, presentations, 
websites, etc. The information contained therein and the type of media used must be suitable for the 
intended users. For example, intervention materials must be tailored to the specific needs and 
characteristics of the target population as identified in the needs assessment (see Project stage 1: 
Needs assessment and 4.3: Tailoring the intervention to the target population). Intervention materials 
must also correspond to the principles of ethical drug prevention, for example by providing accurate 
information and not trying to scare or manipulate participants (see D: Ethical drug prevention).
The type of media (e.g. Internet, books, films) should be chosen in line with the findings from the 
needs assessment, the theoretical model, and the scientific evidence (see Project stage 1: Needs 
assessment and 3.2: Using a theoretical model and 3.5 Referring to evidence of effectiveness). 
Although the budget may be limited, intervention materials should reflect the types of materials that 
are already used by the target population and/or that the target population is (likely to be) familiar 
with. Sometimes providers may wish to use a certain form of delivery because it is inexpensive, 
readily available, or perceived to be unique or innovative (e.g. social networking websites). 
However, such considerations must not override the requirement to choose intervention materials that 
correspond to target population needs (e.g. Internet-based drug prevention interventions may not be 
suitable for participants with low computer literacy).
Where possible, intervention materials should be tested and piloted with the intended target 
population to ensure that they are attractive, easy to comprehend, and (developmentally) appropriate 
(see 6.1: If conducting a pilot intervention). The materials should be adjusted in accordance with 
these findings.
As not all drug prevention programmes require intervention materials, the standards on intervention 
materials apply only where these are utilised. 
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Basic standards:
5.5.1 Materials necessary for implementation of the 
programme are specified.
Examples of materials: intervention materials (e.g. 
workbooks, DVDs, staff training manuals), instruments 
for monitoring and evaluation, technical equipment, 
physical environment.
Note: this specification may show that no particular 
materials are required.
Additional basic standards if intervention materials are used:
5.5.2 The information provided in the intervention 
materials is:
•  specific; 
•  relevant to the needs of the users (i.e. participants 
or staff members); 
•  up-to-date; 
•  factually correct; 
•  balanced in terms of positive and negative 
aspects of drug use; 
Purpose: to avoid distortion of information and 
manipulation of participants.
Note: for some types of intervention (e.g. illustrating 
legal consequences of drug use), positive aspects of 
drug use may not be relevant. 
See also D: Ethical drug prevention.
•  proofed. i.e. accurate, formatted, and well presented.
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Additional expert standards:
5.5.3 The costs of materials are in line with the 
available budget.
Basic standard if any materials are necessary.
Example aspects to consider: costs of materials, staff 
training needs.
5.5.4 Existing materials which could be used for the 
programme are identified and checked for suitability.
Purpose: to avoid duplication of existing efforts.
Examples of existing materials: intervention materials 
(e.g. manuals), instruments for monitoring and 
evaluation.
5.5.5 The information provided in the intervention 
materials is:
•  not oversimplified; 
•  referenced. Basic standard for staff manuals.
5.5.6 Intervention materials are available for: Examples of intervention materials: manuals, 
handouts. 
•  staff members and participants;
•  other relevant stakeholders. Examples of other relevant stakeholders: members of 
the target population that are not taking part in the 
programme, experts, teachers, general public.
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5.6 Providing a programme description
A written description of the drug prevention programme is produced so that interested parties, such 
as the target population, funders, and other relevant stakeholders, may obtain information about the 
programme while it is ongoing. Consequently, the aim of this description is to provide a clear 
overview of the programme. If the description is used to inform the target population about the 
programme (e.g. during recruitment), there should be a particular emphasis on the conditions and 
possible consequences of participation (e.g. price, benefits and risks).
The level of detail in the programme description depends upon the scope of the programme and the 
likely readers of the description. If the description is used to recruit participants, the intervention 
activities must be described in sufficient detail to allow members of the target population to take an 
informed decision about whether they wish to take part or not (see 5.4: Recruiting and retaining 
participants; D: Ethical drug prevention). However, it is possible that certain aspects of the 
programme will change during implementation, and if the description is too specific it may turn out to 
have been (inadvertently) false information. The description should therefore be general enough to 
allow a certain level of flexibility and modifications. This is particularly important when describing 
the programme as part of a funding application.
If the programme description is available for third parties during implementation (e.g. as part of a 
school drugs policy, on the provider’s website), it must be updated regularly to ensure that the 
provided information is accurate and up-to-date. If the programme will be continued with new 
participants in the future, the programme description should be updated after the initial 
implementation to provide further details (in line with the implementation experience) and to reflect 
any changes that have been made to the programme.
The programme description differs from the project plan which is an internal tool to guide 
programme implementation (see 5.1: Planning the programme — Illustrating the project plan). For 
new funding applications, it is recommended to produce a combined document incorporating the 
programme description and the project plan. The programme description also differs from the final 
report which summarises the programme once it has finished (see 8.3: If producing a final report).
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Basic standards:
5.6.1 A written programme description exists.
5.6.2 The programme description is:
•  clear and comprehensible for all intended target 
audiences; 
•  (at least partly) accessible by all intended target 
audiences; 
Examples of intended target audiences: target 
population, funders.
•  regularly reviewed to reflect changes during 
implementation.
5.6.3 The programme description outlines the 
following:
•  the rationale for the programme; Note: staff members may wish to withhold some 
information (e.g. needs assessment data on sensitive 
issues; predictions of the likely consequences in the 
population if the intervention is not delivered).
Example: findings from the needs assessment.
•  aims, goals, and objectives; 
•  definition of the target population; 
•  the intervention; 
i.e. intervention activities with participants and content of the intervention.
Example aspects to consider: duration, intensity, and frequency of activities, classification as 
universal, selective, indicated, or tiered prevention.
Examples of structure: according to the objectives, according to the setting (if several settings).
•  the programme’s time schedule; i.e. planned start and end dates.
•  benefits for participants; 
•  risks for participants; 
•  rules on participants’ confidentiality.
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Additional expert standards:
5.6.4 The logical flow of programme activities is 
illustrated in a graphical representation.
i.e. in a programme logic model.
5.6.5 The programme description outlines the 
following:
•  the theoretical model; 
•  evidence of effectiveness; Example of evidence: references to literature.
•  evaluation indicators and benchmarks; i.e. outcome and/or process measures and specific 
estimates.
•  planned adaptations of an existing intervention; 
•  the programme capacity; i.e. maximum and minimum numbers of participants.
•  a declaration on participants’ rights; 
•  minimum rules on safety; 
•  the code of ethics; 
•  the price for participation in the programme. Basic standard where participation is not free of 
charge.
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Project stage 6 
Delivery and monitoring
At this stage, the plans developed earlier are put into practice. A particular issue at this point is the 
need to maintain a balance between fidelity (i.e. adhering to the project plan) and flexibility (i.e. 
responding to emerging new developments). The components outline how this balance can be 
achieved by questioning the quality and progress of the implementation, and making controlled 
modifications to improve the programme.
6.1 If conducting a pilot intervention: In certain cases the intervention must be tested first by 
implementing it on a smaller scale. This helps identify potential practical issues and other weaknesses 
that did not emerge during the planning. Consequently, programme developers have the chance to 
make final and inexpensive adjustments before the actual implementation.
7 Final evaluations
8 Dissemination and 
improvement
A: Sustainability 
and funding
C: Staff 
development
B: 
Communication 
and stakeholder 
involvement
D: Ethical drug 
prevention
CROSS-CUTTING 
CONSIDERATIONS
1 Needs assessment
2 Resource  
assessment
3 Programme 
formulation
4 Intervention design
5 Management and 
mobilisation of 
resources
6 Delivery and 
monitoring
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6.2 Implementing the intervention: Once there is sufficient evidence to suggest that the intended drug 
prevention intervention will be effective, feasible, and ethical, the intervention is implemented as 
outlined in the project plan. To facilitate later evaluations and reporting on the programme, the 
implementation is documented in detail, including unexpected events, deviations, and failures.
6.3 Monitoring the implementation: While the programme is carried out, regular reviews of the 
progress help identify need for modification. Outcome and process data are collected and analysed 
periodically during implementation, for example with regard to the relevance of the intervention to 
participants, fidelity to the project plan, and effectiveness. Actual implementation of the intervention 
and other programme aspects is compared to what was set out in the project plan. Monitoring 
ensures that implementation is of high quality, but it also allows providers to improve prevention 
practice by identifying and responding to changed or additional requirements before these pose a 
threat to the success of the programme.
6.4 Adjusting the implementation: Implementation needs to remain flexible so that it can respond to 
emerging problems, changed priorities, etc. Where necessary and possible, implementation of the 
programme should be adjusted in line with the findings from the monitoring review. However, 
modifications must be minimal and well justified, and their potential negative impact on the 
programme must be considered. Consequently, if adjustments are made, they must be documented 
and evaluated to understand what effect they had on participants and the success of the programme.
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6.1 If conducting a pilot intervention
Even if a programme is theoretically well planned, it is possible that in practice things work out very 
differently than expected. For example, the target population may not be ready to engage with the 
intervention, intervention materials may not be accepted by participants as intended, or there may 
be other unforeseen barriers to participation (see 5.4: Recruiting and retaining participants). 
Particularly where a new programme was developed without involving representatives of the target 
population, such issues can remain invisible during the planning stage. Once implementation is fully 
under way, it can be very costly to confront such problems, and if issues cannot be resolved 
satisfactorily the delivery of the programme may be delayed or even discontinued. It is therefore 
recommended to conduct a pilot intervention, as this allows providers to make inexpensive 
adjustments to the intervention design and the project plan before the programme is rolled out on a 
larger scale.
A pilot intervention (or pilot study) is a small-scale trial of the intervention prior to its full 
implementation (e.g. with fewer participants, in only one or two locations). It aims to identify 
weaknesses of the planned intervention, for example in relation to its feasibility (e.g. is the resource 
estimate correct, is the programme overambitious?), its effectiveness (e.g. do outcomes occur as 
expected?), and the appropriateness of the content, intervention materials, evaluation instruments, 
etc. (UNODCCP, 2000). During the pilot intervention, process and (limited) outcome data are 
collected and used to perform a small-scale evaluation. The findings of this preliminary evaluation 
are then used to inform and improve the proper implementation.
The consultations held to inform the content of this component suggested that because resources are 
often scarce, the requirement for a pilot intervention should depend on the particular circumstances 
of the programme. Consequently, pilot interventions are considered essential if:
•  the intervention has never been implemented previously (i.e. it is a newly developed intervention); 
•  an existing intervention is being used but it has been modified significantly; 
•  the programme receives large financial support, for example from the government; 
•  the programme is intended for wide dissemination, for example nationwide; 
•  new intervention materials, such as manuals or a website, need to be tested; 
•  the intervention is delivered as part of scientific research, in which case the pilot intervention 
would represent an efficacy trial.
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There may be other scenarios in which a pilot intervention is essential, and the above situations 
should therefore be regarded only as the most prominent examples. Conversely, a pilot intervention 
may not be required if the programme utilises a carefully adapted existing intervention that has 
already been implemented successfully in the past (see 4.2: If selecting an existing intervention).
However, pilot interventions may not always be feasible due to practical circumstances or the 
resources required. For example, it can be difficult to conduct a small-scale trial of a programme that 
is already small in scale (e.g. targeted prevention programme in a single school). In such cases, 
monitoring the implementation is particularly important (see 6.3: Monitoring the implementation). 
Where several rounds of delivery are planned, the initial implementation of the programme should 
inform future implementation.
In other cases, the available funding may not allow a trial run of the programme. This highlights that 
commissioners and funders must make funding available where pilot interventions are strongly 
advised (in line with the examples above). However, it has also been reported that the pilot 
intervention is sometimes indeed the final intervention, as funds are not available to continue the 
programme and implement it fully after its trial run. In such cases, a strategy for sustainability can 
help sustain the programme beyond the pilot phase (see A: Sustainability and funding; 8.1: 
Determining whether the programme should be sustained).
Case study 3 in Developing and evaluating complex interventions: new guidance (MRC, 2008) 
contains two examples of how pilot interventions were carried out, and how the findings were used 
to improve the full implementation of the intervention.
Standards
The reviewed drug prevention standards did not include detailed guidance on pilot interventions, and 
therefore this component does not list explicit standards.
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6.2 Implementing the intervention
When there is sufficient evidence to suggest that the intended drug prevention intervention will be 
effective, feasible, and ethical, the intervention can be implemented in full (e.g. with many 
participants, in all locations, as a routine service) (see 3.5: Referring to evidence of effectiveness; 6.1: 
If conducting a pilot intervention and D: Ethical drug prevention).
The intervention must be conducted as outlined in the project plan (see Project stage 4: Intervention 
design; 5.1: Planning the programme — Illustrating the project plan). Fidelity describes the degree to 
which the actual implementation of an intervention corresponds to the original plan (or the carefully 
adapted intervention design). If, for example, staff members make unplanned modifications, such as 
reducing the number of sessions or changing the content, the effectiveness of the intervention can be 
affected. As a result, the intervention may become less effective, be ineffective, or have iatrogenic 
effects on participants. However, this does not mean that the project plan must be strictly adhered to 
if there is an obvious need for modifications. The standards in 6.3: Monitoring the implementation 
and 6.4: Adjusting the implementation outline how implementation must be monitored, and how 
careful adjustments can be made to ensure a balance between the need for implementation fidelity 
and flexibility.
When trying to understand how and why outcomes were (not) achieved, it is important to know what 
went on during the implementation of the intervention. It is thus essential to continuously document 
how the intervention was implemented, including an honest account of any deviations from the 
original plan, and any other noteworthy events (e.g. failures, accidents). Keeping such records 
facilitates reporting and process evaluation in the later project stages. 
If an outcome evaluation is planned, outcome data is collected at least at baseline and at the end of 
the intervention so that changes can be observed. The standards in 6.3: Monitoring the 
implementation also highlight the need to collect outcome and process data to inform monitoring.
Further information on implementation fidelity, and guidance on how to assess it, can be found in the 
Additional guidance section.
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Basic standards:
6.2.1 The intervention is implemented:
•  according to the written project plan; 
•  with high quality; i.e. with sufficient knowledge and experience in drug 
prevention and project work, and following 
methodological requirements.
•  with an orientation towards participants. Example: by taking participants’ perspective.
6.2.2 The implementation of the intervention is 
adequately documented. 
6.2.3 Documentation includes:
•  tracking implementation in line with the project 
plan developed in the planning stage; 
Example of evidence: actual completion dates for 
completed programme stages are entered.
•  failures, and how they were corrected; 
•  adjustments and changes made to the original 
project plan; 
•  extraordinary incidents, and responses to them. Examples of extraordinary incidents: accidents, 
emergencies.
Additional basic standards if an outcome evaluation is conducted:
6.2.4 Data for the outcome evaluation is collected:
•  at baseline; i.e. initial assessment of outcome evaluation 
indicators.
•  at the end of the intervention (‘post-intervention’). Example of timing: assessment of change after last 
session.
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Additional expert standards:
6.2.5 The intervention is implemented:
•  in a systematic and sequential manner; 
•  by involving participants in the implementation 
process.
Example of participant involvement: asking 
participants for feedback on the activities (this may 
also be part of the data collection for monitoring and 
process evaluation).
6.2.6 Data for the outcome evaluation is collected 
periodically during the intervention. 
Example of timing: assessment of change after each 
session.
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6.3 Monitoring the implementation
Even if a drug prevention intervention is well planned, tested, and carried out according to plan (see 
Project stage 3: Programme formulation; 6.1: If conducting a pilot intervention and 6.2: Implementing 
the intervention), there is no guarantee that implementation will run smoothly and that it will produce 
the desired outcomes. Therefore, implementation must be reviewed frequently so that emerging 
problems can be identified quickly and responded to (see 6.4: Adjusting the implementation).
The consultations held to inform the development of these standards indicated that in some countries, 
such as the United Kingdom, the term ‘monitoring’ may be associated with external quality control 
(e.g. requirement to provide regular update reports to funders) or with data collection for external 
analysis (e.g. data requested by commissioner to assess if regional targets are met). Although 
providers may use the findings from the monitoring reviews to provide update reports to 
commissioners and funders, in these standards the main purpose of monitoring is to stimulate internal 
quality control.
As part of monitoring, outcome and process data are collected and analysed periodically during 
implementation, and actual implementation is compared to what was set out in the project plan (see 
5.1: Planning the programme — Illustrating the project plan). The aim of monitoring is to understand, 
for example, if the programme is:
•  implemented as intended (e.g. as defined in the project plan); 
•  relevant to participants (e.g. does it correspond to participants’ needs? Is the adaptation 
appropriate?) (see Project stages 1: Needs assessment; 4: Intervention design); 
•  ethical (e.g. have participants made any complaints? Do staff members behave appropriately?) 
(see D: Ethical drug prevention); 
•  effective (e.g. does the intervention produce changes as expected? Is participants’ progress 
slower than expected?) (see 3.3: Defining aims, goals and objectives); and
•  feasible (e.g. will resources suffice until completion of the programme? Can goals be achieved? 
Can fidelity be upheld?).
Consequently, monitoring concerns the intervention activities as well as other programme aspects, 
such as participant needs, resources, etc.
Monitoring ensures that implementation is of high quality. Additionally, it allows providers to improve 
prevention practice by identifying and responding to changed or additional requirements before 
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these pose a threat to the success of the programme. The intervals between monitoring reviews must 
be appropriate for the duration and intensity of the intervention. If the reviews are conducted very 
frequently, the intervals may be too short to notice change and the reviews may require too many 
resources. On the other hand, if the intervals between reviews are very long, then problems may 
develop and become difficult to resolve before they are noticed.
Where final outcome and process evaluations are not deemed appropriate or feasible (see 4.4: If 
planning final evaluations), monitoring may be an acceptable alternative to conducting more 
comprehensive and formal evaluations. 
Further information on the quality of implementation can be found in the Additional guidance 
section.
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Basic standards:
6.3.1 Monitoring is seen as an integral part of the 
implementation phase.
i.e. staff members understand its usefulness.
6.3.2 A person or team responsible for monitoring 
the programme is specified. 
6.3.3 The monitoring process is specified. 
6.3.4 Outcome and process data are:
•  collected frequently during implementation; 
•  reviewed at frequent intervals during 
implementation; 
•  reviewed systematically. i.e. compared to the written project plan.
6.3.5 Items considered in the monitoring review include:
•  the project plan; i.e. whether it needs to be updated.
•  whether participants represent the defined target 
population; 
•  whether expected changes are being achieved; i.e. differences between expected outcomes (set 
objectives) and actual outcomes.
•  potential iatrogenic effects of the intervention 
(including ‘side effects’); 
Example of potential ‘side effects’: increased 
attachment to drug-using peers through contacts 
made during the programme.
•  practicability; i.e. what ‘works’ or doesn’t ‘work’ with participants.
•  the quality of delivery and implementation 
fidelity; 
i.e. whether the programme is implemented as set 
out in the project plan.
•  resources. Example aspects to consider: whether planned 
resources are actually available; whether available 
resources are sufficient for programme 
implementation; excessive or unexpected costs.
6.3.6 The conclusions indicate if and what elements 
of the programme need to be modified to complete it 
successfully.
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Additional expert standards:
6.3.7 A structure for the monitoring process is 
specified.
Examples of evidence: a clear reporting procedure 
for the monitoring process is defined (e.g. showing 
how often and when review meetings will be held).
6.3.8 Items considered in the monitoring review 
include:
•  participants’ needs; i.e. whether participants’ needs are met, and 
whether needs have changed since the initial needs 
assessment or in the course of the implementation.
•  participants’ responses to the intervention; Example aspect to consider: readiness for the 
intervention.
•  the adaptation process; Example aspects to consider: whether the (cultural) 
adaptation is appropriate for participants; how it 
contributes to or hinders programme success.
•  external input; i.e. quality of contributions made by third parties.
Basic standard if external providers are used.
•  whether the programme’s goals and objectives 
need to be adjusted; 
Example aspects to consider: according to the level 
of success achieving them, according to changing 
needs of the participants.
•  any other problems. Example aspects to consider: ethical concerns.
6.3.9 Feedback is provided to staff members on the 
findings from the monitoring.
Note: staff includes volunteers, interns, etc.
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6.4 Adjusting the implementation
If the intervention does not produce the desired outcomes, or if providers face difficulties during the 
implementation of the programme (e.g. struggling to recruit participants), then the implementation 
may need to be adjusted or, where that is not possible, discontinued (see 8.1: Determining whether 
the programme should be sustained). Emerging difficulties, changed priorities, etc. can be identified 
as part of regularly held monitoring reviews (see 6.3: Monitoring the implementation). So that the 
participants may benefit from the adjustments, these should be made as soon as possible (i.e. while 
the programme is still under way). 
Nevertheless, it is essential that the intervention is conducted according to the project plan, and 
modifications should be made only if they are required to improve the programme (see 6.2: 
Implementing the intervention). The consultations held to inform the development of these standards 
indicated that changes were often not the result of considerations on how to improve the programme, 
but were due to a lack of knowledge (e.g. not recognising the importance of adhering to the project 
plan), lack of time or money (e.g. running out of time and therefore skipping some content of the 
intervention), or simply convenience (e.g. perceiving the planned activities as too much work). This 
highlights the need for communication so that all responsible staff members (e.g. practitioners, 
external contributors) and stakeholders (e.g. recipient organisation) understand the importance of 
following the original plan (see B: Communication and stakeholder involvement).
Changes must be well justified (e.g. based upon the findings from the monitoring review), and they 
must be in line with the programme formulation (e.g. support programme aims, not pose a threat to 
the evidence base underpinning the programme) (see Project stage 3: Programme formulation). It 
must be likely that the changes will produce positive outcomes without iatrogenic effects, and that the 
principles of ethical drug prevention will not be overridden (see D: Ethical drug prevention). 
Importantly, changes must be kept to a minimum to ensure a balance between fidelity and flexibility.
Practitioners should avoid making spontaneous adjustments while they are actually delivering the 
intervention. In some cases, however, it may be justified to make spontaneous changes to tailor the 
intervention better to participants’ needs (see 4.3: Tailoring the intervention to the target population). 
For example, in a school class a practitioner may wish to conduct an interactive session instead of a 
lecture if the pupils are not willing to engage with the lecture format. During the consultations which 
informed these standards, one delegate described this as ‘flexibility within the outcome’ (i.e. the 
ability to achieve the same intended results with different methods). However, such a decision would 
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require careful consideration of how it might impact on the fidelity and effectiveness of the 
intervention. Ideally, this level of flexibility is already included in the intervention design (e.g. by 
outlining how the order of activities can be changed to suit participants’ needs on the day) or in the 
project plan (e.g. contingency plans) (see 5.1: Planning the programme — Illustrating the project 
plan). Staff members may also receive guidance on how to resolve such issues as part of their 
training and ongoing support (see C: Staff development).
Staff members should be informed of any changes to the programme; ideally, changes should be 
agreed between staff members. For example, if a session with participants did not go very well, a 
meeting may be held between staff members to discuss what went wrong and what could be done 
differently. Changes should also be agreed with other stakeholders where possible or required (e.g. 
participants, commissioners, funders). However, service managers, commissioners and funders must 
acknowledge the need for flexibility. This can be arranged, for example, by negotiating in advance 
how much flexibility is possible without the requirement to seek formal approval (e.g. as part of the 
grant or service agreement). 
Where adjustments are made, it is essential to document and evaluate these, as otherwise the impact 
of the changes will remain unknown. Process and outcome data should be collected and analysed to 
understand if the adjustments really improved the quality and effectiveness of the intervention. If that 
is the case, then these findings represent an important contribution to the evidence base for drug 
prevention and should be disseminated (see 8.2: Disseminating information about the programme). 
Monitoring and evaluation will also show if the changes affected the intervention in a negative way, 
for example by producing iatrogenic effects, and if they should therefore be reversed. 
In the case of scientific research trials, it is particularly important that implementation adheres strictly 
to the project plan. It may therefore not be allowed to adjust the implementation while the 
programme is still under way. In such cases, while the findings from the monitoring review cannot be 
used to adjust the programme in the current implementation, they form part of the process evaluation 
and are used to improve future versions of the programme.
Further information on the quality of implementation can be found in the Additional guidance 
section.
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Basic standards:
6.4.1 The implementation is flexible. i.e. modifications of the programme are possible 
during the implementation phase, if required; staff 
members are given the flexibility to make decisions 
based on participants’ individual needs and 
circumstances.
6.4.2 Implementation of the programme is adjusted 
in line with the monitoring findings, where possible.
Examples of adjustments: modification of goals and 
objectives, modification of activities, re-definition of 
needs, responses to unexpected issues, changes to 
project plan, trying a different strategy if initial 
strategy is not working, further cultural adaptation.
6.4.3 Issues and problems are dealt with in a 
manner appropriate to the programme.
i.e. adequate for the target population, for the 
programme’s aims, goals, and objectives, and in 
relation to the size of the problem.
6.4.4 Adjustments are well-justified, and reasons for 
adjustments are documented.
Note: adjustments should be in line with aims and, 
where possible, goals and objectives. The 
documentation should outline why changes were 
made and who requested changes.
Additional expert standards:
6.4.5 The programme is updated according to 
external developments.
Examples of external developments: changes in the 
local availability of drugs, changes in drug use 
patterns of the target population, new developments 
in the community, new developments in the field of 
drug prevention, emerging new evidence.
6.4.6 Participants are involved in adjusting the 
programme implementation.
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Project stage 7 
Final evaluations
After the intervention has been completed, final evaluations assess its outcomes and/or the process 
of delivering the intervention and implementing the programme. The standards in this project stage 
must be read in conjunction with component If planning final evaluations from Project stage 4, as that 
component describes evaluation in greater detail. It also highlights what preparations are necessary 
to ensure that relevant data is collected during implementation.
7.1 If conducting an outcome evaluation: All outcomes are reported as defined in the planning phase 
(i.e. in line with the defined evaluation indicators). Depending on the scale of the programme and the 
research design that was employed, statistical analyses are performed to determine the effectiveness 
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of the intervention in achieving the defined goals. Where possible, a causal statement on the 
intervention’s effectiveness summarises the findings of the outcome evaluation. 
7.2 If conducting a process evaluation: The process evaluation documents what happened during the 
implementation of the programme. Moreover, it analyses the quality and usefulness of the 
programme by considering its reach and coverage, acceptance of the intervention by participants, 
implementation fidelity, and use of resources. The findings from the process evaluation help to 
explain the findings from the outcome evaluation and to understand how the programme can be 
improved in the future.
The findings from the outcome evaluation and the process evaluation must be interpreted together in 
order to gain a thorough understanding of the success of the programme. This knowledge will inform 
the final Project stage 8: Dissemination and improvement.
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7.1 If conducting an outcome evaluation
As part of the outcome evaluation, outcome data is systematically collected and analysed in order 
to assess how effective the intervention was. The standards in this component outline what sort of 
analyses should be carried out with the outcome data that was collected earlier, how findings 
should be reported, and how effectiveness of the intervention is to be determined and 
documented.
The basic level outcome evaluation aims to understand if the intervention produced change in 
participants in line with the defined goals and objectives without causing any harms (see 3.3: 
Defining aims, goals, and objectives; D: Ethical drug prevention), while expert level evaluations 
would seek to investigate, for example, how different components of the intervention impacted on the 
effectiveness of the intervention, how they affected participants differently, and whether findings can 
be generalised.
If the programme was designed as a randomised controlled trial, it is possible to attribute observed 
changes to the intervention (i.e. to assume that changes were caused by the intervention). If 
participants were not randomly selected or not randomly allocated to intervention and control 
groups, then selection bias must be ruled out before outcomes can be attributed to the intervention. 
The possibility of bias in its many forms must be considered and accounted for at all times. Likewise, 
limitations of the research design must be acknowledged and taken into account when conducting 
the outcome evaluation, particularly when making statements about the intervention’s efficacy or 
effectiveness.
The basic standards in this component are likely to be appropriate for most outcome evaluations of 
small-scale programmes. However, large-scale programmes designed to demonstrate the efficacy or 
effectiveness of a particular intervention with a view to wider dissemination should also adhere to the 
expert standards in this component (i.e. all standards, including those marked as ‘expert’, would be 
considered basic level for these large-scale programmes). Large-scale evaluations should also adhere 
to the USA Standards of Evidence (Flay et al., 2005), upon which this component is based. However, 
the standards in this component apply only if an outcome evaluation is conducted.
The findings from the outcome evaluation must be contextualised with the findings from the process 
evaluation to understand how outcomes were (or were not) achieved (see 7.2: If conducting a process 
evaluation). This allows providers to draw conclusions regarding whether and how the programme 
should be continued and improved (see Project stage 8: Dissemination and improvement).
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Component 4.4: If planning final evaluations contains further information on the importance of, and 
differences between, outcome and process evaluations. Necessary preparations (e.g. data 
collection, specification of evaluation indicators) and possible challenges are also discussed in that 
component. 
Further information on evaluation can be found in the Additional guidance section.
Basic standards if conducting an outcome evaluation:
7.1.1. The sample size on which the outcome 
evaluation is based is given, and it is appropriate for 
the data analysis.
i.e. those participants where baseline and post-
intervention measurements are available.
7.1.2 An appropriate data analysis is conducted. It 
includes:
•  a complete-case analysis; i.e. all individuals assigned to the intervention group 
and, where applicable, control group are included in 
the analysis.
•  consideration of bias caused by attrition in 
follow-up measurements across study groups, and 
efforts to minimise this bias; 
Example of evidence: participants missing in follow-
up measurements are described, and reasons for 
their loss reported.
•  reporting and appropriate handling of missing 
data; 
i.e. extent and patterns of missing data are reported.
•  alternative explanations for observed effects. Example of alternative explanation: reported 
increase of negative behaviour may be due to an 
increased awareness of the problem behaviour.
7.1.3 The findings are reported, including:
•  baseline data; 
•  post-intervention outcomes. i.e. values on the defined evaluation indicators.
7.1.4 Findings on every measured outcome 
evaluation indicator are reported, regardless of the 
results.
i.e. positive and negative outcomes are reported, as 
well as those that are not statistically significant.
7.1.5 Changes are expressed in quantitative and/or 
qualitative terms.
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Basic standards if conducting an outcome evaluation (cont.):
7.1.6 Outcomes concerning behavioural changes are 
distinguished from other outcomes.
Example: intentions to use drugs and actual drug use 
are not considered to be equivalent.
7.1.7 The effectiveness of the intervention and the 
overall success of the programme are assessed by 
comparing the actual outcomes to:
•  the initial situation; i.e. post-intervention outcomes are compared to the 
baseline data in line with the evaluation indicators.
•  the programme’s goals and objectives; i.e. how adequate the intervention was for 
accomplishing these goals.
Example of evidence: attainment of goals and 
objectives is graded (maximally, minimally, not at 
all).
•  iatrogenic effects; i.e. no negative impacts upon participants.
Example of evidence: a risk-benefit analysis is 
conducted.
•  the intervention’s practical value and significance 
for public health.
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Additional expert standards:
7.1.8 Follow-up measurements after the intervention 
include a large percentage of the original 
participants.
Note: >80 % retention rate is considered good 
(NICE, 2009, p. 219). However, this benchmark 
might be difficult to achieve under certain conditions 
(e.g. follow-up over several years).
7.1.9 The data analysis includes:
•  sub-group analyses on the effectiveness of the 
intervention for different groups of participants; 
i.e. the different effect sizes, where the sample size is 
large enough.
•  a comparison of how the activities impact on 
their own and cumulatively; 
i.e. different activities are assessed for their 
effectiveness.
Examples of comparisons: the effects of booster 
sessions versus no booster sessions; the effects of 
multiple interventions versus singular interventions.
•  experimental dosage analyses; i.e. the relationship between the amount of the 
intervention that was received and the outcomes.
•  a statistical adjustment between intervention and 
control groups for differences caused by 
sampling error; 
Example of adjustment: ANCOVA/RANCOVA used 
in analysis.
•  adjustments for multiple comparisons; 
•  an analysis not only on individual level but also 
on the level of randomisation.
Example: if randomisation or participant selection 
was based on school classes rather than individual 
pupils, the data analysis should account for cluster 
bias.
7.1.10 Reported findings include:
•  short-term, medium-term, and/or long-term 
outcomes; 
i.e. up to 6 months, >6 to 12 months, >12 months 
after completing the intervention.
Purpose: to establish how long post-intervention 
outcomes are sustained.
•  final outcomes. i.e. outcomes corresponding to the longer term aims 
(e.g. many years after the intervention).
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Additional expert standards (cont.):
7.1.11 The effectiveness of the intervention is 
assessed by comparing the actual changes to the 
expected changes.
i.e. the programme’s success in meeting the set 
benchmarks on the defined outcome evaluation 
indicators.
7.1.12 The individual intervention is considered 
effective if:
•  at least one effect is statistically significant and 
positive in relation to the goals and objectives of 
the programme;
Note: a consistent pattern of statistically significant 
positive effects across multiple indicators is desirable.
•  there are no negative (iatrogenic) effects on 
important outcomes;
Example: the intervention does not increase drug 
use.
•  positive effects are found in the long-term follow-
up measurement and are statistically significant.
i.e. >12 months after completing the intervention.
7.1.13 The findings are compared with findings of 
other evaluation studies of the same intervention.
Note: this may not be possible where other 
evaluations of the same intervention are not yet 
available.
7.1.14 If several studies are available, the studies of 
highest quality are considered in determining 
effectiveness.
7.1.15 The intervention is considered overall effective 
if:
•  effect sizes between various trials of the 
intervention are similar;
•  consistent positive findings are available from at 
least two different high-quality studies/replicates 
with adequate statistical power;
•  positive findings are available from at least one 
replication study by independent investigators, 
i.e. not the programme developers.
7.1.16 A causal statement on the intervention’s 
efficacy/ effectiveness is provided.
i.e. ‘intervention X is efficacious/effective for 
producing Y outcomes for Z population’.
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Additional expert standards (cont.):
7.1.17 The causal statement on the intervention’s 
efficacy/ effectiveness:
•  is unambiguous; 
•  specifies the target population; 
•  specifies the outcomes; 
•  indicates the time frame within which these 
effects are expected to be maintained.
Note: this should be based on the long-term follow-
up measurement.
Example: short-term up to 6 months, medium-term >6 
to 12 months, long-term >12 months after completing 
the intervention.
7.1.18 It is clear under which conditions the 
intervention is expected to be effective.
7.1.19 The population(s) to whom the findings can be 
generalised is (are) specified.
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7.2 If conducting a process evaluation
As part of the process evaluation, process data is systematically collected and analysed in order to 
assess why outcomes were (not) achieved and how the programme can be improved in the future. 
The process evaluation documents what happened during the programme (e.g. what activities were 
carried out, with and by whom, when and for how long) (CSAP, 2002). It is then analysed why the 
programme was carried out that way and how that might have impacted on the effectiveness of the 
intervention. Aspects to consider include: reach and coverage (i.e. how well did participants 
represent the target population?); acceptance of the intervention by participants (e.g. suitability of 
content and intervention materials); fidelity (i.e. was the intervention conducted according to plan?); 
use of resources (e.g. to inform cost-effectiveness) (CCSA, 2009). The data that was collected as part 
of the ongoing monitoring as well as the results of the monitoring reviews may be used to inform the 
process evaluation (see 6.3: Monitoring the implementation).
The findings from the process evaluation help to explain the findings from the outcome evaluation 
(see 7.1: If conducting an outcome evaluation), and they can also demonstrate that fidelity was 
upheld if an existing intervention was implemented. Based on the evaluation findings, providers 
should draw conclusions regarding whether and how the programme should be continued and 
improved (see Project stage 8: Dissemination and improvement). For example, high attrition rates 
should prompt those conducting the evaluation to investigate the causes of drop out (e.g. did 
participants move away or were they not satisfied with the intervention?). This can indicate sources of 
bias to be considered in the outcome evaluation, but it may also show how the programme should be 
improved in the future to increase retention rates. The process evaluation may also indicate, for 
example, that the definition of the target population should be revised or that the capacity of the 
service should be increased if participants represented only a very small percentage of the total 
target population.
These standards apply only if a process evaluation is conducted. Component 4.4: If planning final 
evaluations contains further information on the importance of, and differences between, outcome 
and process evaluations. Necessary preparations (e.g. data collection, specification of evaluation 
indicators) and possible challenges are also discussed in that component. 
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Further information on evaluation can be found in the Additional guidance section.
Basic standards if conducting a process evaluation:
7.2.1 The process evaluation:
•  documents the programme implementation; i.e. it illustrates how the intervention was carried out.
•  explains why the programme was carried out in 
this way; 
•  is done systematically; i.e. using the written project plan and the defined 
process evaluation indicators.
•  considers differences between operational 
objectives and actual outputs.
7.2.2 The involvement of the target population is 
documented and evaluated. This includes:
•  the number of participants in the intervention; 
•  the methods for participant recruitment; 
•  whether actual participants represented the 
defined target population.
7.2.3 The activities are documented and evaluated. 
This includes:
•  a description of the activities; 
•  feedback from participants; Example aspects to consider: whether participants 
found the intervention acceptable, enjoyable, 
satisfactory.
•  feedback from other relevant stakeholders.
7.2.4 The programme delivery is documented and 
evaluated. This includes:
•  feedback from staff members on the quality of 
delivery; 
•  implementation fidelity; i.e. to which extent the intervention was conducted 
as planned.
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Basic standards if conducting a process evaluation (cont.):
•  unintended differences between planned and 
actual activities; 
•  intended changes; i.e. necessary adjustments made to the programme 
during implementation.
•  any unexpected problems and other issues, and 
how they were controlled or dealt with.
7.2.5 The use of resources is documented and 
evaluated. This includes:
Examples of resources: financial, human, and 
material resources.
•  a definition of ‘costs’; Examples of cost types: direct, indirect costs, 
opportunity costs.
•  how many financial resources were spent; 
•  costs for participant recruitment; Example aspect to consider: costs for programme 
promotion.
•  costs for data collection, monitoring, and 
evaluations; 
•  how many human resources were spent; Example aspects to consider: number of staff, 
working hours spent on the programme.
•  whether staff members felt adequately trained 
and supported; 
•  how many material resources were spent; 
•  differences between actual and planned 
timelines;
•  whether resources were sufficient to achieve the 
set goals and objectives.
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Additional expert standards:
7.2.6 The process evaluation:
•  explains how the outcomes of the intervention 
were achieved;
Basic standard if an outcome evaluation was carried 
out.
•  considers differences between expected and 
actual results on process evaluation indicators.
i.e. using the defined process evaluation 
benchmarks.
7.2.7 The involvement of the target population is 
documented and evaluated, including:
•  success in engaging participants; i.e. recruitment, attendance, and completion rates.
•  problems regarding the participants’ readiness 
for the intervention; 
•  participants’ characteristics; Examples of characteristics: socio-demographic (e.g. 
age, developmental stage, sex, race or ethnicity, 
marital status), socio-economic (e.g. education, 
profession), cultural (e.g. religion), geographical (e.g. 
town, region).
•  the (estimated) level of target population 
coverage.
7.2.8 The activities are documented and evaluated, 
including the adequacy of the intervention materials.
Basic standard if intervention materials were used.
Example aspects to consider: whether materials were 
understandable for participants, whether the content 
was adequate.
7.2.9 The programme delivery is documented and 
evaluated, including how much of the intervention 
was received by participants.
Example aspect to consider: whether all intended 
sessions took place.
7.2.10 The use of resources is documented and 
evaluated, including:
•  estimated costs experienced by participants and 
other stakeholders; 
Example of costs: opportunity costs.
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Additional expert standards (cont.):
•  the team performance; Example aspects to consider: acting according to 
roles and responsibilities, keeping to schedules.
•  whether staff members were actively involved in 
improving the programme quality;
•  the realised level of coordination and 
collaboration.
Example aspects to consider: number and type of 
participating organisations, number of meetings, 
conclusions and agreements.
7.2.11 Estimates on cost-effectiveness and cost-
benefit ratios are provided.
Additional guidance: see Miller and Hendrie, 2009.
8PRO
JEC
T STAG
E
EIG
H
T
219
88
Project stage 8 
Dissemination and improvement
In the final project stage, the future of the programme is of major concern: should the programme 
continue, and if so, how? Disseminating information about the programme can help to promote its 
continuation, but it also enables others to learn from the experiences of implementing the 
programme.
8.1 Determining whether the programme should be sustained: Ideally, a high quality drug prevention 
programme can continue beyond its initial implementation and/or after external funding has stopped. 
Using the empirical evidence produced through monitoring and final evaluations, it is possible to 
decide whether the programme is worthy of continuation. If it is determined that the programme 
should be sustained, appropriate steps and follow-up actions are specified and carried out.
A: Sustainability 
and funding
C: Staff 
development
B: 
Communication 
and stakeholder 
involvement
D: Ethical drug 
prevention
CROSS-CUTTING 
CONSIDERATIONS
1 Needs assessment
2 Resource  
assessment
3 Programme 
formulation
4 Intervention design
5 Management and 
mobilisation of 
resources
6 Delivery and 
monitoring
7 Final evaluations
8 Dissemination and 
improvement
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8.2 Disseminating information about the programme: Dissemination can benefit the programme in 
many ways, for example by gaining support from relevant stakeholders for its continuation or by 
improving the programme through feedback. It also adds to the evidence base for drug prevention, 
thus contributing to future drug policy, practice and research. In order to give other providers the 
opportunity to replicate the intervention, intervention materials and other relevant information (e.g. 
costing information) should also be made available.
8.3 If producing a final report: The final report is an example of a dissemination product. It may be 
produced as a record of the implementation, as part of a funding agreement, or simply to inform 
others about the programme. The final report will often represent a summary of the documentation 
produced during earlier project stages. It describes the scope and activities of the programme, and, 
where available, the findings from the final evaluations.
This stage may represent the beginning of a new project cycle aimed at improving and developing 
the existing programme further.
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8.1 Determining whether the programme should be sustained
Ideally, a high quality drug prevention programme can continue beyond its initial implementation 
and/or after external funding has stopped (e.g. it can be repeated with a new group of participants 
once the first group of participants has successfully completed the intervention). Component A: 
Sustainability and funding outlines some of the factors that influence the sustainability of 
programmes, and how the chances of continuation can be increased through a dedicated strategy 
for sustainability. However, once the intervention has been completed, it must be decided whether 
the programme is actually worthy of continuation. 
A programme should be continued if there is a strong evidence-based argument to support its 
continuation. Ideally, this argument is derived from an outcome evaluation, demonstrating the 
intervention’s (cost-)effectiveness in achieving positive outcomes with participants (see 7.1: If 
conducting an outcome evaluation). If the intervention was effective, the programme should be 
continued. If the intervention was ineffective or had considerable iatrogenic effects, the programme 
should be abandoned or at least not continued in its current form. 
Where an outcome evaluation is not available, the results of a process evaluation may indicate that 
a programme should be sustained, for example if completion rates were high and participants and 
other stakeholders reported high levels of satisfaction (see 7.2: If conducting a process evaluation). 
Where no final evaluations were carried out, the findings from the monitoring reviews should be used 
to determine whether the programme should be sustained (see 6.3: Monitoring the implementation). 
Consequently, an outcome evaluation is not an essential requirement to determine whether a 
programme should be sustained. If there is evidence from the monitoring and/or the process 
evaluation to suggest that the programme is of high quality (e.g. relevant, well received, ethical, 
feasible, well implemented), it should be continued. However, in order to prove the effectiveness of 
the intervention (and sustain the programme in the long term), it is strongly recommended to conduct 
an outcome evaluation as part of future implementation. If the findings from the monitoring and/or 
the process evaluation indicate that the programme was not of high quality (e.g. difficult to 
implement, low retention rates), then it should not be continued in its current form.
If the evidence suggests that a programme should be continued, appropriate steps and follow-up 
actions must be specified and carried out in line with the strategy developed under A: Sustainability 
and funding. Unfortunately, even with a dedicated strategy to secure funding, financial sustainability 
is ultimately outside of the control of providers, as funds can be discontinued or allocated elsewhere 
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by commissioners and funders. The consultations that informed the development of these standards 
indicated that effective or promising programmes were sometimes discontinued because of changes 
in the availability of funding or because they were considered too expensive in the long term (e.g. 
due to large elements of intense individualised contact with participants). Consequently, it is the 
responsibility of commissioners and funders to recognise and sustain effective or promising 
programmes.
If the evidence suggests that a programme should not be continued, then the findings from the 
monitoring and, where available, the process evaluation should be inspected closely to determine 
why outcomes were not achieved, why participants were dissatisfied, why there were problems 
during implementation, etc. They may indicate how the programme could be improved, and provide 
support to trial a modified version of the intervention.
This component may initially seem less relevant to some programmes. It may be clear from the onset 
of the programme that it will not be sustained, depending on, for example, the type of programme, 
its aims, and/or its resources. The intervention may serve a specific purpose that limits its relevance 
to a particular time span. For example, an awareness-raising campaign on the risks of cocaine use 
may be launched before New Year to target those who use the drug on ‘special occasions’; a youth 
group may decide to conduct a one-off intervention following a drug-related incident; a regional 
planning team may commission an intervention to reduce the drug use in a certain community and 
discontinue the programme once this goal has been achieved. In such cases, there may be no 
immediate need to continue the programme beyond its first implementation. Nevertheless, the 
organisation in charge of the programme should consider taking a long-term perspective on drug 
prevention (e.g. is it worth repeating this intervention again in a year? Is there a need for other drug 
prevention activities which build upon the outcomes of the first?). Even if sustainability is not 
necessary on the level of a particular intervention, it may be important at the organisational level (i.e. 
the organisation should continue to conduct drug prevention work) (see A: Sustainability and 
funding).
223
Project stage 8: Dissemination and improvement
8
Basic standards:
8.1.1 It is determined whether the programme should 
be continued (‘sustained’).
Note: this should be done by reviewing the findings 
from the monitoring, process evaluation, and/or 
outcome evaluation.
8.1.2 The lessons learnt from the initial 
implementation are used to inform future activities.
Note: based on results from monitoring and/or 
evaluations.
Examples of evidence: adjustments are made to 
improve the programme’s quality if it is continued in 
the future; recommendations for improvement are 
provided.
Additional basic standards if the programme should be continued (‘sustained’):
8.1.3 A strong evidence-based argument in favour of 
the programme exists.
Note: this argument should be based on findings 
from the monitoring, process evaluation, and/or 
outcome evaluation. Where such data is not 
available (in satisfactory form), (further) monitoring 
reviews and/or evaluations should be conducted that 
allow a decision on the programme’s future.
8.1.4 Opportunities for continuation are considered 
and documented.
Additional expert standards if the programme should be continued (‘sustained’):
8.1.5 Financial and other resources are sought. Basic standard if resources (e.g. funding) are time-
limited to the initial project lifespan.
8.1.6 Existing networks and links are utilised to 
promote programme continuation.
Examples of useful links: professional relations with 
commissioners, key agencies, members of the 
community.
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8.2 Disseminating information about the programme
Once the intervention has been completed, information about the programme, and, where available, 
evaluation findings, should be communicated to relevant stakeholders (e.g. participants, the scientific 
and/or prevention community). Providers may feel that in comparison to planning, implementation, 
and evaluation, dissemination is the least important part of the project cycle. However, this 
component highlights that dissemination of information about the programme is an equally important 
aspect of high quality drug prevention work. 
As dissemination occurs at the end of the project cycle, it is possible that all resources have been 
used up and that there is no money left to publicise the programme and disseminate its findings. It is 
therefore important to include the costs for dissemination in the financial plan (see 5.2: Planning 
financial requirements). Often, if the budget in a funding application has to be reduced, it is at the 
expense of dissemination activities. Such an approach does not consider that dissemination does not 
only benefit others, but benefits also the provider. Costs for dissemination can be reduced by 
targeting dissemination efforts (e.g. by identifying the most relevant groups). Careful planning 
ensures that the correct target audiences are supplied with relevant information in an adequate 
format. Depending on the specific purpose of dissemination, information may be communicated, for 
example, by using the Internet or producing printed leaflets, through presentations at workshops or 
scientific publications.
Disseminating information about the programme is an important aspect of starting the project cycle 
anew. It aids continuation and long-term sustainability of the programme by promoting it among 
funders, community members, and other essential stakeholders (see A: Sustainability and funding). It 
may lead to an increased interest from other organisations to contribute to or support the programme 
(e.g. joint activities with other agencies, interest from new recipient organisations such as schools) 
(see B: Communication and stakeholder involvement). It may also advertise the programme among 
the target population to increase readiness for participation and to recruit new participants for the 
next round of implementation (see 2.1: Assessing target population and community resources and 
5.4: Recruiting and retaining participants). 
Dissemination may also help to improve the programme further or gain a new perspective on it 
through feedback (e.g. from other providers, academics). Feedback can prompt providers to review 
their initial programme formulation or intervention design, the project plan, or to reinterpret the 
findings from monitoring and evaluation. Feedback can also highlight relevant new developments 
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(e.g. in policy and legislation), additional evidence, resources, or materials that were not previously 
considered. Where feedback is received, its value must be carefully assessed, as modifications to the 
programme should only be made if they are well justified (see 6.4: Adjusting the implementation). 
Moreover, dissemination of information enables others to learn from the (positive and negative) 
experiences of implementing the programme, and it adds to the evidence base for drug prevention. 
For example, if an outcome evaluation was conducted, others could refer to the evaluation findings 
when reviewing evidence of effectiveness and designing their intervention. Giving information on 
unintended negative outcomes, failures, and encountered difficulties is vital to enable others to 
understand the challenges of implementing the programme. Providers may be concerned that 
disclosing such information could damage their reputation and reduce their chances of receiving 
future funding. However, reporting negative outcomes is essential as otherwise the information may 
be misleading and have unethical implications (e.g. others might replicate the programme without 
being aware of the potential negative outcomes).
The standards also encourage providers to make the intervention available at a detail that allows 
other providers to (assess whether they wish to) replicate and adapt the programme. Such 
documentation would also include, for example, costing information, intervention materials (where 
used), etc. By allowing others to select an existing intervention instead of developing a new one, 
duplication of efforts can be significantly reduced. Replication of the intervention is also of benefit to 
the programme author, as it tests whether outcomes can be repeated in similar circumstances or 
generalised to another target population, setting, etc. If the intervention is found to be consistently 
effective, it is more likely to become a sustainable and well known programme.
The consultations that informed the development of these standards suggested that programme 
developers and providers may be hesitant to share materials (e.g. manuals) and detailed descriptions 
of ‘their’ programme. This is likely to be the case if, for example, the programme has been developed 
for a commercial purpose (i.e. it is not free of charge) or if it is essential to the provider in another 
way (e.g. exclusivity of offering a particular intervention). Programme developers and providers may 
worry that other providers would use the intervention (or certain aspects of it) without a licence or 
without asking for permission, without acknowledging or remunerating the original authors. 
Particularly in countries where there are only insufficient measures in place to protect the copyright of 
programme authors, such worries may be justified. Therefore, the legal aspects of reporting on the 
programme must be considered. If there are any concerns regarding copyright infringement, it is 
recommended to provide information at a level of detail that allows other providers to decide 
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whether they wish to use the programme but does not actually allow them to copy and implement the 
programme. Further details and materials could then be provided through a licence agreement (e.g. 
specifying under what conditions the intervention can be used) and, where necessary, against a 
licence fee.
Dissemination about the programme may not always seem useful, for example, if a programme was 
implemented poorly, if it did not produce the expected outcomes (it was ineffective or had iatrogenic 
effects), if it was developed for a specific purpose, or if there is no intention to continue 
implementation. However, as outlined above, even in these cases dissemination of information about 
the programme is important. It adds to the body of knowledge in drug prevention and can inform 
future programme development, drug research, and policy. If a programme was designed for a 
particular need or a particular target population, it may provide useful insights for another provider 
who is facing a similar situation in a different region. Even if a programme did not go well, it can still 
have a positive impact on drug prevention in the longer term by helping other providers avoid 
encountering the same problems. 
Further information on what to consider when disseminating findings can be found, for example, in 
the handbook Communicating research for evidence-based policymaking (European Commission, 
2010). Furthermore, the Additional guidance section provides guidance on how to disseminate 
evidence into practice, i.e. how the lessons learnt from the implementation of this programme can 
inform the everyday practice of (other) providers and practitioners. 
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Basic standards:
8.2.1 Information on the programme is disseminated. Note: dissemination of information may take place 
on a local, regional, national or international level.
8.2.2 An appropriate format for dissemination is 
specified.
Examples of formats: online, printed materials, 
presentations at workshops, scientific publications.
8.2.3 A person or team responsible for dissemination 
of information about the programme is specified.
Note: other responsibilities could include 
communication with stakeholders, programme 
promotion.
8.2.4 The target audiences are specified, including:
•  those involved in the programme and its 
evaluations; 
Examples of groups: staff members, senior 
management, participants.
•  other relevant stakeholders. Examples of stakeholders: funders, community, 
project partners.
8.2.5 The means of dissemination are appropriate 
for the target audiences.
Example: different ways of dissemination for 
members of the community and for academics 
working in the field of drug prevention.
8.2.6 Legal aspects of reporting on the programme 
are considered.
Example aspects to consider: intellectual property, 
potential sale of products or prohibition thereof.
8.2.7 To assist replication, dissemination products 
include:
•  details on the experience gained during the 
implementation of the programme; 
Example aspects to consider: theoretical and 
practical implications of the activities, knowledge 
and experience of innovative working.
•  details on negative and other unintended 
outcomes.
8.2.8 The level of detail in the dissemination allows 
interested parties to assess the programme.
i.e. whether the intervention should be adapted, 
replicated, implemented on a larger scale, whether it 
should be awarded model programme status, etc.
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Additional expert standards:
8.2.9 A plan for dissemination of the results exists.
8.2.10 Specified target audiences include the target 
population.
8.2.11 The timeline for dissemination is specified.
8.2.12 The success in disseminating information 
about the programme is assessed.
8.2.13 To assist replication, dissemination products 
include:
•  details on conditions and resources needed to 
support the adoption, implementation, and 
sustainability of the programme; 
Example aspects to consider: necessary financial 
and human resources, qualifications of implementing 
staff.
•  details on failures; Example aspect to consider: unrealised goals.
•  sample end products; 
•  case studies; Example consideration: illustrating the realities and 
potential outcomes of the intervention.
•  the actual tools and materials used in the 
programme, together with detailed guidelines on 
how to use them.
Examples of tools and materials: intervention 
materials (e.g. workbooks, staff training manuals), 
monitoring and evaluation tools.
8.2.14 Dissemination products are presented with a 
level of detail that allows implementation/replication.
8.2.15 Training and technical assistance are offered 
to interested parties.
Examples of evidence: incorporated as learning 
materials in existing training systems, training 
exchange with other providers.
8.2.16 Information on the programme is published. Examples of publication: in scientific journals, as a 
final report on the provider’s website.
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8.3 If producing a final report
The final report documents the scope and activities of the programme and, where available, the 
findings from the final evaluations. The standards in this component outline briefly what the final 
report should contain. Further information on dissemination can be found under 8.2: Disseminating 
information about the programme. As the final report is an example of a dissemination product, those 
standards must also be considered in its production.
When writing the final report, it is useful to draw upon documentation produced in the earlier project 
stages (see 1.3: Describing the need — Justifying the intervention; Project stage 3: Programme 
formulation; 5.1: Planning the programme — Illustrating the project plan; 5.6: Providing a programme 
description; 6.2: Implementing the intervention and Project stage 7: Final evaluations). However, the 
content and format of the final report must be suitable for the intended target audiences. Therefore, if 
existing documentation is used it should be carefully edited. For example, if the report is written for 
the general public, it may not be appropriate to describe the evidence of effectiveness in as much 
detail as in the original programme formulation. Conversely, a detailed description of the evidence 
would be essential if the report was produced for the professional community.
The consultations held to inform the development of these standards indicated that in some areas it is 
common practice that providers produce regular update reports for commissioners and funders. 
However, these reports are not usually available for the professional community, the target 
population, or the general public. Delegates suggested that these reports should be edited and made 
publicly available (e.g. on the provider website). This would showcase the work of providers, but it 
would also aid dissemination and discussion of good practice within the prevention community.
However, a final report is not always possible or required, and the standards in this section apply 
only if a final report is produced. If a final report is not produced, information about the programme 
should be disseminated through other means, for example through presentations (see 8.2: 
Disseminating information about the programme).
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Basic standards if a final report is produced:
8.3.1 A final report is produced.
8.3.2 The final report includes information on:
•  the justification for the programme; Note: this would be a summary of the needs 
assessment.
•  the target population; 
•  programme aims; 
•  the setting; 
•  the intervention and its activities; 
•  the project plan; Note: this does not have to be the detailed project 
plan developed during programme planning, but can 
be an outline summary of major programme 
activities.
•  information on the funding entities and sources of 
other income.
8.3.3. The information in the final report is:
•  clear and easy to read; i.e. understandable for a wide range of persons or, 
where a target audience has been specified, for the 
target audience.
•  logically organised and consistent.
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Additional expert standards:
8.3.4 The final report includes information on:
•  programme goals and objectives; Basic standard if report is produced for a 
professional audience.
•  the original intervention, and the level of 
adaptation; 
Basic standard if an existing intervention was used.
•  the theoretical model of the intervention; Basic standard if a theoretical model was used.
•  evidence of effectiveness; Basic standard if report is produced for a 
professional audience.
•  results of the outcome evaluation; Basic standard if an outcome evaluation was 
conducted.
•  results of the process evaluation; Basic standard if a process evaluation was 
conducted.
Note: where a process evaluation was not carried 
out, the findings from the monitoring could be 
described instead.
•  information on costs of delivery.
8.3.5 The report is later supplemented with the 
findings from the follow-up measurement(s).
Note: this should be based on the long-term follow-
up, where available.
Example: short-term up to 6 months, medium-term >6 
to 12 months, long-term >12 months after completing 
the intervention.
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Please note that an online supplement is also available to this manual at http://www.emcdda.
europa.eu.publications/manuals/prevention-standards/annex. The online supplement contains: 
•  references to additional guidance relevant to selected standards themes (e.g. staff development, 
ethical drug prevention, drug-related policy and legislation, needs and resource assessment, 
evidence-based intervention design, databases of model programes, implementation fidelity, 
evaluation, dissemination);
•  an abbreviated version of the standards in the form of a self-reflection checklist;
•  considerations and recommendations with regard to the implementation of the standards;
•  a list of organisations that participated in the structured consultations to inform the development 
of the standards; 
•  further information on the current drug situation in the EU.
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Original standards documents
The first draft of the European drug prevention quality standards was produced by synthesising 
quality criteria contained in the documents listed in this section. The documents are sorted by region 
(Europe, North America, international) and, within the region, alphabetically by country. In some 
instances, the publication year is approximate. English translations of the institutions and publication 
titles have been added where applicable. These documents are not necessarily listed again as 
Additional guidance; however, many contain not only quality criteria but offer also general drug 
prevention guidance and can therefore be read in conjunction with the Standards. 
All web pages were last accessed on 11.4.2011 unless otherwise stated.
Czech Republic
Ministerstvo školství, mládeže a tělovýchovy ČR (Czech Ministry of Education, Sport and Youth) 
(2008), Standardy odborné způsobilostiposkytovatelů programů primární prevence užívání 
návykových látek (schválená revize) (Professional Qualification Standards for Providers of Primary 
Addictive Drug Use Prevention Programmes (revised edition)). Prague: Ministerstvo školství, mládeže a 
tělovýchovy ČR.  
http://www.emcdda.europa.eu/themes/best-practice/standards/prevention 
Finland
STAKES (2006), Reaching For The Quality Star: Quality criteria for substance abuse prevention. 
National Research and Development Centre for Welfare and Health.  
http://neuvoa-antavat.stakes.fi/NR/rdonlyres/73F39AD6-6A0B-41CD-BA0C-7D18AB0A6FB3/0/
Reachingforquality.pdf 
Germany
Bundeszentrale für gesundheitliche Aufklärung (BZgA) (Federal Centre for Health Education) & 
Universitätsklinikum Hamburg-Eppendorf (n.d.), Qualität in der Prävention (Quality in Prevention).  
http://www.emcdda.europa.eu/themes/best-practice/standards/prevention 
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Ireland
Drug Education Workers Forum (DEWF) (2007), A manual in quality standards in substance use 
education. Dublin: DEWF.
A copy may be requested by sending a request to info@dewf.ie. 
Italy
Serpelloni, G. and Simeoni, E. (2002), La valutazione ex ante dei progetti di intervention contro l’uso 
di sostanze stupacenti (The ex ante evaluation of projects targeting drug consumption). In: Serpelloni, 
G., Simeoni, E. and Rampazzo, K. (eds.) (Ministry of Health) (2002), Quality Management (Gestione 
della Qualità). Indicazioni per le Aziende Socio Sanitarie e il Dipartimento delle Dipendenze 
(Quality Management: Recommendations for the Sanitary Local Agencies and the Department for 
Addictions). Edizioni La Grafica, pp. 487–498.
http://www.dronet.org/pubblicazioni/monografie_dettaglio.php?monografie=2
Serpelloni, G. and Simeoni, E (2002), Elementi di tecnica progettuale per gli interventi nelle 
dipendenze: indicazioni pratiche (Basic elements of planning techniques for actions targeting 
addictions: practical instructions). In: Serpelloni, G., Simeoni, E. and Rampazzo, K. (eds.) (Ministry of 
Health) (2002), Quality Management (Gestione della Qualità). Indicazioni per le Aziende Socio 
Sanitarie e il Dipartimento delle Dipendenze (Quality Management: Recommendations for the 
Sanitary Local Agencies and the Department for Addictions). Edizioni La Grafica, pp. 509–560.
http://www.dronet.org/pubblicazioni/monografie_dettaglio.php?monografie=2
Lithuania
Narkotikų kontrolės departamento prie Lietuvos Respublikos (Drug Control Department) (2007), 
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Additional guidance
The following list includes a selection of general resources as well as links to drug-related policy and 
legislation on EU and international levels. All web pages were last accessed on 11.04.2011 unless 
otherwise stated.
References to further resources supporting the uptake of the standards in practice can be found in the 
Additional guidance section in the online supplement. The online resource includes links to databases 
of model programmes as well as to documents specifically relating to standards topics such as staff 
development, ethical drug prevention, needs and resource assessment, evidence-based intervention 
design, implementation fidelity, evaluation, and dissemination.
The online supplement to this manual is available at   
http://www.emcdda.europa.eu/publications/manuals/prevention-standards/annex
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Drug-related policy and legislation
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http://www.emcdda.europa.eu/policy-and-law 
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This website includes information on national strategies/actions plans and legislation.
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European Council (2008), EU drugs action plan for 2009–12, Official Journal of the European 
Union, 2008/C 326/09, 20.12.2008. 
http://www.emcdda.europa.eu/html.cfm/index66221EN.html
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http://www.unodc.org/unodc/en/treaties/single-convention.html 
United Nations Convention on Psychotropic Substances of 1971.
http://www.unodc.org/unodc/en/treaties/psychotropics.html 
United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 
1988.
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March 2009. New York, United Nations.
http://www.unodc.org/documents/commissions/CND-Uploads/CND-52-RelatedFiles/V0984963-
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Glossary for use with the European drug prevention quality standards
The glossary provides brief explanations of key terms used in the standards. For ease of cross-
reference, defined terms are highlighted in italics within the glossary, and where applicable relevant 
standards are listed in bold font; and the numbering is equivalent to that used in Part 2 of this 
manual. The term ‘Standards’ refers to the European drug prevention quality standards. Definitions 
are based on the original standards included in the review as well as the glossaries listed at the end 
of this section and the documents included as Additional guidance (online annex). 
Access The extent to which people (e.g. members of the target population) are able to 
receive information, services, etc. Barriers to access may be practical (e.g. location, 
timing, child care) or of a more subtle nature (e.g. risk of stigma, cultural 
acceptability). 
Standards D: Ethical drug prevention; 5.4: Recruiting and retaining participants
Action plan see Project plan
Activity In the Standards, a generic term referring to drug prevention work, e.g. strategies, 
policies, practices, programmes. Programme activities are carried out to implement a 
programme, e.g. staff development activities, fundraising activities, intervention 
activities. Those activities that are most important for the success of the programme 
form the ‘critical’ activities. Intervention activities are a sub-set of programme 
activities, describing those elements of the intervention that are carried out with 
participants, e.g. role play, lecture, field trip. 
Adaptation Intentional and planned changes made to an intervention. Adaptations are made: 1) 
as part of a replication study to test the effectiveness of an intervention under the 
same or different circumstances (e.g. target population, setting, intensity of delivery); 
2) to tailor the intervention to specific requirements (e.g. culture of the target 
population, economic realities) in order to maintain or increase effectiveness. 
Adaptation does not include unplanned modifications, as these may compromise 
effectiveness. Adaptation is also known as reinvention (EMCDDA, 1998).
Standard 4.2: If selecting an existing intervention
Agency see Organisation
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Aim A statement on the programme’s general direction, purpose or intention. Aims can be 
formulated in less specific terms than goals and objectives, and need not be directly 
measurable or achievable within the current programme. For example, long term 
aims may be achieved several years after an intervention has finished, or an 
intervention may only partly contribute to the achievement of aims. Aims are not 
sufficient to implement and evaluate programmes; their purpose is to outline the 
general idea from which precise goals and objectives are developed.
Aims, goals, and objectives form a logical progression. Figure 4 (page 120) gives an 
example of how an overall aim translates into general goals and specific objectives.
Standard 3.3: Defining aims, goals, and objectives
Anecdotal evidence see Evidence
Attrition An unplanned reduction in the number of participants after the start of the 
intervention. It is caused by participants who drop out of the intervention or 
evaluation, i.e. they take part in the first session(s) and initial data collection, but do 
not remain until the end of the intervention and the final data collection. 
Attribute The third level of detail within the Standards. Attributes contain the most detailed 
descriptions and distinguish between basic and expert standards. The other levels of 
detail in the Standards are made up of components and project stages.
Baseline data Data that is collected from participants at the beginning of the intervention, e.g. to 
inform monitoring and evaluations. The progress of the intervention is measured by 
comparing the data collected during and at the end of the intervention to the initial 
baseline data. 
Benchmark see Evaluation benchmark
Beneficiary 1. Direct beneficiary: see Participant
2. Potential or indirect beneficiary: see Indirect beneficiary
Benefit The advantage brought by a certain activity for a certain person (e.g. participant), 
group (e.g. community) or organisation (e.g. recipient organisation).
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Bias Distortion of results. Bias can be produced intentionally or unintentionally during all 
project stages. There are many different types of bias. For example, a literature 
review may be biased if only certain types of publications are included (e.g. only 
journal publications), and a report may be biased if certain findings are not reported 
(e.g. negative findings excluded). Bias may also occur during participant recruitment, 
data collection and data analysis. A participant sample is biased if it does not 
represent the intended target population. For example, highly motivated members of 
the target population may be more likely to take part in and complete the intervention 
(selection bias, attrition bias). As a consequence, the effectiveness of the intervention 
for the total target population might be overestimated. 
Budget The amount of money which is available, e.g. for the programme. The budget also 
represents the maximum allowed spend, i.e. programme costs must not be greater 
than the budget. Budgeting describes the process of managing the budget, e.g. 
allocating budget to cost items. Estimates on budget and costs are documented in the 
financial plan.
Standard 5.2: Planning financial requirements
Capacity see Resource
Child see Young people
Competency In the Standards, the knowledge, skills, and behaviours that are required from staff 
members for a successful programme implementation. Competencies can be 
distinguished into four broad categories: basic intervention competencies (e.g. 
knowledge of effective drug prevention approaches); specific intervention 
competencies (e.g. specific knowledge and skills relevant to the intervention); general 
competencies (e.g. generic social skills, project management); and meta-
competencies which enable staff members to respond to individual participant needs 
(e.g. cultural sensitivity) (adapted from Pilling et al., 2010).
Standard C: Staff development
Comparison group see Control group
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Component 1. The second level of detail within the Standards. Components represent the actions 
to take at each project stage. Overall, there are 35 components. Four components 
are located at the centre of the project cycle and should be reconsidered at each 
project stage (‘cross-cutting considerations’). The remaining 31 components are 
allocated to specific project stages. The other two levels of detail in the Standards 
are made up of attributes and project stages.
2. One of several parts that, together, form a complete programme. A multi-
component intervention includes a range of different intervention activities.
Community 1. Group of people living and/or working in a geographically defined area (e.g. 
neighbourhood, city district), and/or who have a shared social or cultural 
background, interest, or experience (e.g. ethnic, religious, linguistic). Settings may be 
specific to certain communities (e.g. school, youth centre). Depending on the 
community, a sense of shared identity may exist to varying degrees. Often, 
individuals belong to several communities based on, for example, geography, 
occupation, leisure interests (WHO, 1998).
Standards 1.2: Assessing drug use and community needs; 2.1: Assessing target 
population and community resources
2. Professional community: The body of professionals working in a certain 
occupational field (e.g. scientific and/or prevention community).
Community 
readiness
see Readiness
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Control group A group of people who serve as a reference point to interpret changes in the 
intervention group during the outcome evaluation. The individuals in the control group 
are essentially similar to the intervention participants but do not receive the 
intervention. Instead, they may receive, for example, no intervention at all, an 
alternative intervention, or take part in a prevention-unrelated activity. Data is 
collected from the control group using the same procedures as in the intervention 
group. If changes occur only in the intervention group (assessed by statistical testing), 
it is more likely that they have been caused by the intervention. If changes occur in 
both groups, they may be unrelated to the intervention and caused by a different, 
unknown factor. Control groups are used in quasi-experimental designs and 
randomised controlled trials. Other terms indicating use of a control group include 
controlled design, control-group design, control condition. The control group is also 
known as the comparison group. 
Standard 4.4: If planning final evaluations
Cost 1. Direct/indirect cost: The amount of money which is required for the programme. 
Two cost types can be distinguished: direct costs are directly related to the duration 
of the programme (e.g. staff salaries), while indirect costs are not directly associated 
with the duration of the programme (e.g. manuals and other materials). Estimates on 
budget and costs are documented in the financial plan.
Standard 5.2: Planning financial requirements
2. Opportunity cost: The value (benefit) of the next-best alternative available to 
someone who chooses between several options. Opportunity costs are not restricted 
to financial costs, but include other aspects, such as lost time or pleasure. For 
example, participants may have to give up work or leisure time in order to take part 
in an intervention, and facilities may not be used for other activities. 
Cost-benefit-analysis The process of analysing the relationship between a programme’s costs and benefits 
on a variety of levels (e.g. individual, society). The results are expressed in monetary 
terms. See also: Cost-effectiveness-analysis.
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Cost-effectiveness-
analysis
The process of analysing the relationship between a programme’s costs and positive 
(health) effects for participants. If several effective programmes are available, a cost-
effectiveness-analysis helps identify which programme achieves, in relative terms, the 
best outcomes with fewest resources. For example, a programme may cost more than 
an alternative, but also produce much better outcomes. It could therefore be more 
cost-effective than the cheaper alternative. Cost-effectiveness must be distinguished 
from efficiency.
Coverage The extent to which an intervention reaches its intended target population. Coverage 
can be expressed in quantitative terms as the ratio of the number of actual 
participants to the number of individuals in the target population. This requires a 
precise definition of the target population and a quantitative estimate of its size.
Cultural sensitivity The willingness and ability (e.g. of staff members) to understand the importance of 
culture, to appreciate cultural diversity, to respond effectively to culturally defined 
needs, and to incorporate cultural considerations into all aspects of drug prevention 
work. Cultural sensitivity may express itself, for example, in providing translations of 
signs and materials, ensuring that the content of the intervention is culturally relevant, 
or considering cultural aspects of staff composition and behaviour. Cultural sensitivity 
is also known as cultural competence.
Standards C: Staff development; D: Ethical drug prevention; 4.3: Tailoring the 
intervention to the target population
Culture The set of shared values, attitudes, beliefs, behaviours (e.g. customs), forms of 
communication (e.g. language, arts, symbols, music), etc. that characterises a 
particular social group or organisation (see Community). The ability to integrate 
cultural considerations into prevention work is known as cultural sensitivity.
Standard 1.4: Understanding the target population
Data collection 
instrument
A device used to collect information, e.g. on the target population. Examples include 
self-report questionnaires, interview or observation protocols. Validated instruments 
are those that fulfil the criteria of objectivity, reliability, and validity. Evaluation 
instruments are data collection instruments that are used for evaluation purposes.
Delivery see Implementation
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Dissemination 1. Dissemination of information about the programme: Communicating details about 
the programme, and where available evaluation findings, to relevant target 
audiences, such as the scientific and/or prevention community, funders, and the 
target population. 
Project stage 8: Dissemination and improvement
2. Dissemination of the programme (‘going to scale’): Replicating a programme on a 
large scale, e.g. with more participants, covering a greater geographical area, etc. 
In this scenario, the programme is initially tested on a small scale for its effectiveness, 
e.g. in a limited number of schools. Once its effectiveness has been demonstrated, it 
is rolled out on a large scale, e.g. to all schools nationwide.
Determinant of 
health
Any factor that is believed to affect health, such as biological (e.g. age, sex, genetic), 
individual (e.g. lifestyle, childhood experiences), socio-economic (e.g. education, 
occupation, income), environmental (e.g. pollution, working conditions), political (e.g. 
health policy), structural (e.g. access and availability of services) and cultural factors 
(e.g. gender roles). Proximal determinants of health, such as individual behaviour, are 
directly related to health; whereas distal determinants, such as cultural norms, are 
related to health more remotely.
Drug Any psychoactive substance, i.e. a substance that, if taken in sufficient dose, can alter 
mental and physiological processes. Examples of drugs include alcohol, tobacco, 
illegal substances (i.e. those whose production, sale, or use is forbidden or limited 
under international and national drug control laws and treaties), volatile substances 
(gases, fumes from glues, aerosols, and similar products), over-the-counter and 
prescription medicines, and new psychoactive substances (e.g. ‘legal highs’). Drugs 
are also known as substances or compounds; illegal drugs are also known as 
controlled or illicit drugs. Note: Food is excluded from this definition.
Standard 3.3: Defining aims, goals, and objectives 
Drug demand 
reduction
A general term used in international drug control conventions to describe activities 
that aim to reduce consumer demand for (illegal) drugs. Drug demand reduction 
includes drug prevention, treatment and rehabilitation approaches. It differs from 
supply reduction which aims to limit the production and distribution of (illegal) drugs 
through law enforcement. In practice, drug demand reduction and supply reduction 
complement each other to form comprehensive drugs policies.
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Drug prevention Any activity that is (at least partially) aimed at preventing or reducing drug use, and/
or its negative consequences in the general population or subpopulations, including 
preventing or delaying the initiation of drug use, promoting cessation of use, 
reducing the frequency and/or quantity of use, preventing the progression to 
hazardous or harmful use patterns, and/or preventing or reducing negative 
consequences of use. Prevention activities can be carried out with different target 
populations (e.g. school pupils, young offenders), in different settings (e.g. 
community, school, family), using different methods and contents (e.g. information 
provision, life skills training), and range from one-off to long-term activities. Some 
activities address drugs directly, while other activities promote health in general and 
encourage people to make healthy choices, thereby indirectly preventing or reducing 
drug use. Depending on how the target population is defined, the following types 
can be distinguished: universal prevention; selective prevention; indicated prevention; 
tiered prevention. Environmental prevention is another type of prevention activity. A 
previously used typology distinguished primary, secondary and tertiary prevention; 
however, the categorisation by target population has superseded this typology. Drug 
prevention is also known as, for example, substance abuse prevention.
To be classed as drug prevention activities in the context of the Standards, activities 
must make explicit reference to drug prevention in their project documentation.
Drug prevention 
intervention
see Drug prevention; Intervention
Drug prevention 
programme
see Drug prevention; Programme
Drug use The consumption of a drug for purposes other than prescribed medical treatment or 
scientific investigation. Drug use can be abstinent, infrequent (experimentation), 
occasional (e.g. less than weekly) or regular (e.g. at least once per week). According 
to the World Health Organization (WHO), hazardous use describes a use pattern 
that increases the risk of harmful physical, mental, and social consequences for users 
and their social environment (e.g. family, community), while harmful use describes a 
use pattern that is already damaging the mental or physical health of users, and may 
have social consequences. Drug use is also known as drug/substance misuse/abuse. 
However, terms such as ‘misuse’ or ‘abuse’ can be considered judgemental if used to 
describe drug use in general; they are more suitable for referring to harmful use only.
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Effect 1. In evaluation research, a result, outcome, or impact of an intervention or set of 
interventions. Outcome evaluation research aims to understand the effects and the 
effectiveness of interventions. The ‘effect size’ provides a quantitative estimate of the 
effect. It can be calculated as the difference in means between the intervention group 
and the control group on a certain indicator, divided by the standard deviation of the 
control group or both groups (EMCDDA, 2011).
2. Drug effect: The mental, physiological, behavioural, etc. changes occurring in 
users as a consequence of their drug use.
Effective intervention An intervention that produces the desired outcomes without causing harm. The USA 
Society for Prevention Research has defined the characteristics of an effective 
intervention in the ‘Standards of Evidence’ (Flay et al., 2005).
Standard 7.1: If conducting an outcome evaluation
Effectiveness The extent to which an intervention produces, in practice, the desired outcomes 
without causing harm. In outcome evaluation research, effectiveness trials test 
whether interventions are effective under real-world conditions or in natural settings 
(Flay et al., 2005), e.g. when delivered by a typical classroom teacher rather than a 
specially trained professional in a research trial. They clarify under what conditions 
interventions are effective by considering the impact of variations (e.g. conditions of 
delivery, quality of implementation). Effectiveness trials are different from efficacy 
trials, which test interventions under ideal conditions.
Effect size see Effect
Efficacy In outcome evaluation research, the extent to which an intervention produces, under 
ideal conditions, the desired outcomes without causing harm, e.g. when delivered by 
the programme developer or specially trained professionals. Conditions are 
controlled to avoid any variation. Efficacy trials are different from effectiveness trials, 
which test interventions under real-world conditions and explicitly explore the impact 
of variations.
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Efficiency The optimal use of resources, i.e. a measure of the relationship between the cost and 
outcomes of a programme. A programme is inefficient if the same outcomes could be 
achieved with fewer resources (e.g. less expensive equipment, fewer staff members), 
or if the same resources could produce better outputs (e.g. engage with a greater 
number of participants). If several effective programmes are available, a cost-
effectiveness-analysis can be carried out to identify which programme achieves, in 
relative terms, the best outcomes with fewest resources. However, efficiency differs 
from effectiveness.
Environmental 
prevention
Drug prevention activities that focus on changing the environment in which people 
live. Environmental prevention covers a range of activities, depending on how the 
term ‘environment’ is understood. Activities may address social norms (e.g. attitudes 
towards drug use in the community), regulations (e.g. written policies, public tobacco 
smoking bans), availability of drugs (e.g. policing, test purchasing), the built 
environment (e.g. improved lighting, video surveillance), etc. Consequently, 
environmental prevention can serve to reduce drug demand (see Drug demand 
reduction), supply, and/or drug-related harms.
Epidemiology The study of the distribution and causes of health and disease, e.g. in relation to drug 
use. Epidemiological information provides the basis for drug prevention activities by 
indicating, for example, the prevalence of drug use and the extent and nature of 
drug-related needs in a community. Epidemiology typically employs quantitative 
study designs (e.g. prevalence surveys, cohort studies, routine statistics). Social 
sciences approaches (e.g. sociology, economics) are increasingly used to 
contextualise epidemiological findings.
Standard 1.2: Assessing drug use and community needs
Ethical drug 
prevention
In the Standards, drug prevention work that is characterised by an ethical and lawful 
conduct of the provider and orientation towards participants’ rights, autonomy, and 
needs (e.g. positive outcomes without harms). In general, ethics provide guidance on 
how people ought to act and how to make decisions on what is ‘right’ and ‘wrong’.
Standard D: Ethical drug prevention
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Evaluation The systematic collection, processing and analysis of data from the programme to 
assess whether goals and objectives have been achieved, and how. Methods can 
utilise qualitative and/or quantitative approaches. An evaluation is ‘internal’ or 
‘external’ depending on whether the individual or team conducting the evaluation 
works within the organisation being evaluated or for an external organisation (e.g. 
university, consultancy) (EMCDDA, 2010). The Standards describe monitoring as a 
means of ongoing evaluation during implementation, and outcome and process 
evaluation as more scientific forms of evaluation that are conducted following 
implementation.
Standards 4.4: If planning final evaluations; 6.3: Monitoring the implementation;  
7: Final evaluations
Evaluation 
benchmark
A criterion against which achievement of goals and (specific and operational) 
objectives can be measured. Each benchmark is linked to an evaluation indicator and 
defines achievement on that indicator in numerical terms or, where that is not 
possible, in descriptive terms. Evaluation benchmarks are also known as targets, 
performance indicators, or success indicators.
Figure 5 (page 151) illustrates the relations between specific and operational 
objectives, evaluation indicators and benchmarks.
Standard 4.4: If planning final evaluations
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Evaluation indicator A one-dimensional, substitute measure for a concept that cannot be measured or 
observed directly (EMCDDA, 1998), i.e. the specific information to be collected for 
process evaluations and outcome evaluations. Goals and objectives commonly 
address outcomes that cannot be measured directly (e.g. drug use, social skills). 
Therefore, they are translated into indicators that help assess the achievement of 
goals and objectives. Outcome indicators are derived from goals and specific 
objectives and concern the changes in participants. Examples include: self-reported 
drug use; self-reported intention to use drugs in the future; communication skills (e.g. 
questionnaire or observation). Process indicators are derived from the operational 
objectives and concern the implementation of the programme. Examples include: 
number of participants, participants’ frequency of participation, number of staff 
members involved in the programme, participant and staff feedback, fidelity of 
implementation, etc. Because indicators are only approximations of complex 
concepts, it is common to use several indicators to measure one concept. Evaluation 
indicators are also known as process and outcome measures, evaluation criteria, etc. 
Figure 5 (page 151) illustrates the relations between specific and operational 
objectives, evaluation indicators and benchmarks.
Standard 4.4: If planning final evaluations
Evaluation 
instrument
A device used to collect information for monitoring and final evaluations, e.g. self-
report questionnaire, interview or observation protocol. Validated instruments are 
those that fulfil the criteria of objectivity, reliability, and validity. The EMCDDA’s 
Evaluation Instruments Bank (EIB) is an online archive of freely available evaluation 
instruments.
Standard 4.4: If planning final evaluations
Evaluation tool Technical resources required to conduct monitoring and final evaluations, e.g. 
evaluation instruments.
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Evidence 1. Empirical information, i.e. information based on observations, experiments, etc.
2. Evidence of effectiveness: Information on the effectiveness of interventions in 
achieving outcomes. This information is typically derived from scientific research trials 
and reported in the professional literature, e.g. scientific journals. Evidence may also 
be derived from outcome evaluations that were not part of research trials, as long as 
they were conducted in a scientifically sound manner. Scientific evidence is 
distinguished from anecdotal evidence which is based upon subjective accounts, e.g. 
professional experiences, unstructured observations. Consequently, different levels of 
evidence can be distinguished according to how the evidence was produced; for 
example, in critical evidence appraisals randomised controlled trials are usually 
considered to produce the highest level of evidence, while professional opinions are 
considered to represent the lowest level of evidence (OCEBM, 2009).
Standard 3.5: Referring to evidence of effectiveness
3. Examples of evidence: In the Standards, examples of how achievement of the 
Standards could be evidenced (i.e. proven, demonstrated) in practice.
Evidence-based drug 
prevention 
Drug prevention work that is based upon a systematic analysis of the best available 
evidence, making use of the evidence, and ensuring correspondence with the 
evidence. The term ‘evidence-based’ is often used interchangeably with terms such as 
‘research-based’ and ‘science-based’ (Kellam and Langevin, 2003, p. 140), but 
differs from ‘effective’ (see Effectiveness) and ‘efficacious’ (see Efficacy).
Experimental design see Randomised controlled trial
Experimental group see Intervention group
External evaluation see Evaluation
Fidelity The degree to which the actual implementation of an intervention corresponds to the 
original plan of the programme developers (or the carefully adapted intervention 
design). Fidelity is reduced if, for example, staff members do not adhere to the 
original protocol and make unplanned modifications, e.g. by reducing the number of 
sessions, changing the content of the intervention. 
Front-line worker see Practitioner
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Gender In the Standards, the set of socially constructed roles, behaviours, etc. that are 
considered appropriate for men and women, e.g. what it means to be a ‘boy’ or a 
‘girl’ in a certain culture. These beliefs can differ between communities. In the 
Standards, culturally defined ‘gender’ is distinguished from ‘sex’ which refers to the 
biological characteristics of men and women. However, some professionals use the 
terms interchangeably, acknowledging their interdependency (e.g. physical ability 
can influence possibility of activities; acceptability of certain activities can influence 
physiological characteristics).
Generalisability The extent to which intervention designs, theoretical models, evaluation findings, etc. 
can be applied to other populations, settings, etc.
Goal In the Standards, a clear statement on the outcome for participants at the completion 
of the intervention. A clear goal definition is necessary for an outcome evaluation. 
Goals are developed from the overall aim by translating it into more specific and 
achievable targets. For example, different goals may reflect different aspects of the 
overall aim. Each goal is then translated into specific objectives. Goals are also 
known as general objectives or global objectives. 
Figure 4 (page 120) gives an example of how an overall aim translates into general 
goals and specific objectives, while Figure 5 (page 151) illustrates the relations 
between specific and operational objectives, evaluation indicators and benchmarks.
Standard 3.3: Defining aims, goals, and objectives
Guidance In the Standards, a general term for written information aimed at directing public 
health actions, such as guidelines and guideline recommendations, quality standards, 
advice, suggestions, etc.
Guideline 1. A set of specific statements to inform the choice and design of the intervention. 
Guidelines are typically based upon systematic reviews of the literature. They often 
contain detailed step-by-step instructions (guideline recommendations) regarding the 
best option for a certain condition (e.g. how to respond to specific needs of the target 
population). Guidelines are also known as practice guidance, practice 
recommendations, etc. The Standards distinguish between guidelines and quality 
standards.
2. General instructions or rules governing (professional) action (e.g. methodological 
guidelines, guidelines for policy makers).
Harmful use see Drug use
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Hazardous use see Drug use
Health determinant see Determinant of health
High quality drug 
prevention
In the Standards, drug prevention work that is: in line with the needs of participants, 
makes reference to policy, and therefore likely to be relevant; underpinned by the 
principles of ethical drug prevention, and therefore likely to be ethical; informed by 
scientific theory and evidence, and therefore likely to be effective; and internally 
coherent, and therefore likely to be feasible.
Drug prevention activities that adhere to the Standards will meet these criteria, and 
will consequently be considered to be of high quality.
Human resources see Staff
Iatrogenic effect Negative outcomes for participants which have been caused by an intervention. 
Iatrogenic effects of drug prevention interventions could be, for example, increased 
drug use, harms for participants, etc. Iatrogenesis can concern main outcomes, such 
as drug use, or increased incidence of other unwanted behaviours (‘side effects’). An 
iatrogenic effect is different from no effect (‘ineffective’) as this would mean that there 
were neither positive nor negative outcomes.
Implementation The process of taking action according to the project plan. In the Standards, 
‘implementation’ usually refers specifically to carrying out the planned intervention 
with participants, while ‘programme implementation’ includes other aspects such as 
participant recruitment, staff training, etc. Implementation is also called ‘delivery’ in 
the Standards.
Standard 6: Delivery and monitoring
Indicated prevention In the context of drug prevention, activities that are targeted at individuals with an 
increased individual risk of (harmful) drug use (adapted from Springer and Phillips, 
2007). This includes those who already use drugs (but are not dependent according 
to DSM-IV or ICD-10) and/or who have an increased individual risk of drug use in 
later life (e.g. due to childhood experiences, mental health or conduct disorders) (see 
Risk factor). Indicated prevention can aim to prevent the onset of drug use, but more 
often aims to reduce existing drug use and to prevent progression to harmful use. In 
practice, there can be an overlap between indicated prevention and selective 
prevention or treatment (EMCDDA, 2009, p. 10).
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Indicator A one-dimensional, substitute measure for a more complex concept that cannot be 
measured or observed directly. Indicators can be used for a range of purposes, e.g. 
to inform needs assessment or evaluations (see Evaluation indicator). Typically, 
several indicators are used to gain a comprehensive understanding of the concept.
Indirect beneficiary A person who does not take part in the intervention but could potentially benefit from 
its positive outcomes. For example, participants’ social environment (e.g. family, 
community) may benefit from the changes in participants’ behaviour (e.g. reduced 
drug use, improved social skills). In addition, participants may pass on their 
knowledge and experiences from the intervention, e.g. to peers, members of the 
target population that did not take part in the intervention. This is utilised in some 
interventions, where participants do not represent the target population, but influence 
the target population indirectly. In such interventions, participants are, for example, 
peers, families, or teachers, while members of the target population are the indirect 
beneficiaries. Indirect beneficiaries are also known as potential beneficiaries.
Instrument see Evaluation instrument
Internal evaluation see Evaluation
Intervention An activity or set of activities carried out in (direct) contact with the target population 
to produce a certain outcome (e.g. prevent or reduce drug use). In the context of drug 
prevention, the term is used in its generic sense and does not imply an actual 
treatment protocol. Service work is included in this definition. In the Standards, the 
term ‘intervention’ focuses on the activities aimed at changing participants, while 
‘project’ refers to all other activities such as planning, participant recruitment, staff 
training, etc. All intervention and project aspects of prevention work are included in 
the overarching term ‘programme’. 
Standard 4: Intervention design
Intervention activity see Activity
Intervention group A group of people who take part in or receive the intervention. In evaluation design, 
the intervention group is distinguished from the control group. The individuals in the 
control group do not receive the intervention, hence providing a reference point to 
interpret changes in the intervention group during the outcome evaluation. The 
intervention group is also known as the experimental group.
Intervention 
materials
see Materials
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Logic model A flowchart or graphical representation of the components of a theoretical model 
(‘theory logic model’) and/or a programme (‘programme logic model’) (CSAP, 2002). 
The theory logic model illustrates the theory of change, i.e. it identifies relevant 
mediators and shows how these achieve outcomes within a given context (e.g. target 
population). The programme logic model illustrates the logical flow of programme 
activities from start to finish, i.e. it identifies essential intervention and project activities 
and demonstrates the internal coherence of the programme. In practice, it is common 
to use only one logic model linking theoretical considerations and practical activities 
(e.g. showing how activities influence mediators).
Long-term outcome see Outcome
Materials In the Standards, all material resources required for the implementation of the 
programme, such as intervention materials, instruments for monitoring and evaluation, 
technical equipment (e.g. computers, DVD players, projectors), physical environment 
(e.g. indoor and outdoor facilities), etc. More specifically, ‘intervention materials’ are 
those materials specific to the intervention, such as workbooks, DVDs, staff training 
manuals, presentations, websites, etc. Materials can relate to participants’ needs 
(e.g. illustrating the content of the intervention) and/or staff members’ needs (e.g. 
providing instructions on delivery).
Standard 5.5: Preparing programme materials
Mediator An intervening variable that explains how an intervention produces a certain 
outcome. Drug prevention interventions cannot usually target participants’ drug use 
directly; instead, they target mediators that have an influence on drug use. Mediators 
can be directly related to drug use, e.g. knowledge about drugs, beliefs about the 
consequences of drug use, attitudes towards drugs, intention to use drugs, etc.; or 
they can be indirectly related to drug use, e.g. life skills, general risk factors and 
protective factors, etc. 
Medium-term 
outcome
see Outcome
Mobilisation of 
resources
The process of activating resources that are already available (e.g. training staff) as 
well as accessing new resources (e.g. recruiting participants, fundraising). 
Standard 5: Management and mobilisation of resources
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Moderator A variable that affects the relationship between the intervention, mediators, and the 
desired outcome, i.e. it has an influence on how effective the intervention is. The 
analysis of moderators frequently focuses on the circumstances of implementation, 
e.g. whether the intervention was carried out as planned (see Fidelity), who delivered 
the intervention (e.g. teacher, researcher), number of sessions, inclusion of booster 
sessions, etc. The choice of moderators can also be determined by the theoretical 
model, e.g. prevailing social norms, differences in family structure, new policies.
Monitoring In the Standards, the continuous gathering and analysis of process and outcome data 
during the implementation of the intervention. It can serve several purposes, such as: 
ensuring that the intervention proceeds according to plan (e.g. fidelity, effectiveness); 
identifying changed or additional requirements (e.g. participant needs, resources); 
improving the intervention while it is being implemented; documenting the 
implementation (e.g. for final report, final evaluations). Monitoring is also known as 
regular review, quality control, reflection, revision, a type of formative evaluation, etc. 
In the Standards, monitoring is distinguished from the process evaluation which 
analyses process data after implementation.
Standard 6.3: Monitoring the implementation
Needs assessment A systematic assessment of the nature and extent of needs, as well as possible causes 
and contributing factors to those needs. Data is typically epidemiological, but can 
also be obtained using focus groups, etc. The aim is to identify unmet needs (e.g. 
gaps in service provision) and to plan activities that fulfil these needs. The Standards 
highlight needs as defined by policy and legislation, the community and its members, 
and, most importantly, the (potential) target population and its social environment. 
Needs assessment is also known as needs analysis. In the Standards, needs 
assessment is distinguished from resource assessment which focuses on assessing 
available resources. 
Standard 1: Needs assessment
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Non-experimental 
design
In outcome evaluation research, a study type where outcomes are measured only in 
the intervention group. If data is collected from the intervention group only after the 
intervention, it is not possible to make any statements about the effectiveness of the 
intervention. If data is collected before and after the intervention, the changes that 
occurred between both points in time can be described. However, it is not possible to 
prove that these changes were caused by the intervention, as this would require the 
use of a control group. This type of non-experimental design is also known as 
naturalistic design or pre-post design without control group. Study types with a 
control group include the quasi-experimental design and the randomised controlled 
trial.
Objective 1. Specific objective: In the Standards, a clear statement on an immediate or 
intermediate change that is necessary to achieve a goal at the end of the 
intervention. It need not necessarily relate directly to drug use. 
Figure 4 (page 120) gives an example of how an overall aim translates into general 
goals and specific objectives.
Standard 3.3: Defining aims, goals, and objectives
2. Operational objective: A clear statement on the output required to achieve the 
specific objectives (e.g. number and type of participant contact) (EMCDDA, 2011).
Figure 5 (page 151) illustrates the relations between specific and operational 
objectives, evaluation indicators and benchmarks.
Objectivity An indicator for the quality of a data collection instrument. An instrument is objective 
if it produces results independently of who uses the instrument to take measurements. 
Other indicators of instrument quality are reliability and validity.
Organisation 1. In the context of drug prevention, an organisation that is active in, or contributing 
to, the field of drug prevention, e.g. provider, local authority, research institute. 
Organisations are also called ‘agencies’ or ‘institutions’ in the Standards.
2. In the Standards, an organisation that is using the Standards to reflect on their 
work, plan their programme, etc. This organisation is likely to be active in, or 
contribute to, the field of drug prevention. Examples include drug prevention charities, 
youth services, schools, local authorities, government, etc.
For specific information on how to use the Standards, please refer to the Introduction.
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Outcome The change that occurs in participants as a result of their exposure to, or involvement 
in, the intervention. In the Standards, outcomes can be distinguished according to 
when they are expected and measured. Immediate and intermediate outcomes occur 
during the intervention, corresponding to the objectives. Post-intervention outcomes 
occur at the end of the intervention, corresponding to the goals. It is also common to 
consider longer term final outcomes which correspond to the programme’s general 
aims.
In outcome evaluation research, follow-up measurements are conducted to test how 
long these outcomes are sustained. The Standards suggest the following intervals for 
follow-up measurements: up to 6 months after the intervention (short-term), >6 to 12 
months after the intervention (medium-term), and >12 months after the intervention 
(long-term).
Outcomes are distinguished from the outputs of a programme.
Figure 6 (page 153) illustrates the relationships between targets, outcomes, and 
measurements.
Outcome data see Outcome evaluation
Outcome evaluation The systematic collection and analysis of outcome data to assess whether goals and 
objectives were achieved and to establish whether the intervention is effective. If the 
evaluation is conducted as a randomised controlled trial, it is possible to attribute 
observed effects to the intervention. The outcome evaluation is distinguished from the 
process evaluation which analyses how the intervention was delivered.
Standards 4.4: If planning final evaluations; 7.1: If conducting an outcome evaluation
Output The products of programme activities, such as deliverables (e.g. sessions held), 
structures created (e.g. community readiness), opportunities given (e.g. number of 
participants), materials published (e.g. final report), etc. (EMCDDA, 2011). Outputs 
are distinguished from outcomes, which concern the changes in participants.
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Participant A person taking part in or receiving the intervention in a direct manner. Participants 
are drawn from the intermediate or the ultimate target population. The ultimate target 
population refers to the people that the intervention wants to produce positive 
outcomes for (e.g. young people at risk of drug use), while the intermediate target 
population describes people who have an influence on that target population (e.g. 
family, peers, teachers). Typically, participants represent only a sample of all eligible 
individuals (e.g. a number of children out of all vulnerable children in the community). 
In evaluation research, some participants do not receive the intervention because 
they have been assigned to a control group. Participants are also known as direct 
beneficiaries.
Pilot intervention A small-scale trial of the intervention prior to its full implementation (e.g. with fewer 
participants). It aims to test the feasibility of the planned intervention (e.g. is the 
resource estimate correct?), its effectiveness (e.g. do outcomes occur as expected?), 
and the appropriateness of the content, intervention materials, evaluation instruments, 
etc. The insights gained from conducting the pilot intervention are used to improve the 
proper implementation. The pilot intervention is also known as a type of formative 
evaluation.
Standard 6.1: If conducting a pilot intervention
Post-test The collection of data from participants at the end of the intervention to inform the 
outcome evaluation. The progress of the intervention is measured by comparing the 
post-test data to the pre-test data. If data is only collected from the intervention group 
after the intervention (non-experimental design), it is not possible to make any 
statements about the effectiveness of the intervention. 
Figure 6 (page 153) illustrates the relationships between targets, outcomes, and 
measurements.
Potential beneficiary see Indirect beneficiary
Practitioner A staff member spending a large amount of time working in direct contact with 
members of the target population, e.g. delivering the intervention. Practitioners are 
also known as field workers or front-line workers.
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Pre-test The collection of baseline data from participants before, or at the beginning of, the 
intervention to inform the outcome evaluation. The progress of the intervention is 
measured by comparing the post-test data to the pre-test data. However, it is not 
possible to prove that changes were caused by the intervention without using a 
control group (see Quasi-experimental design, Randomised controlled trial). 
Figure 6 (page 153) illustrates the relationships between targets, outcomes, and 
measurements.
Prevention see Drug prevention
Process data see Process evaluation
Process evaluation The systematic collection and analysis of process data to understand why outcomes 
were (not) achieved and how the programme can be improved in the future. If an 
existing intervention was implemented, the process evaluation can also demonstrate 
that fidelity was upheld. Process data relates to the outputs of the programme (e.g. 
what activities were carried out, with and by whom). The process evaluation 
documents the outputs; it then analyses why the programme was carried out that way 
and how that might have impacted on the outcomes. Aspects to consider typically 
include: reach and coverage (i.e. how well did participants represent the target 
population?); acceptance of the intervention by participants (e.g. suitability of content 
and materials); fidelity (i.e. was the intervention conducted according to plan?); use 
of resources (e.g. cost-effectiveness). Process evaluations are also known as quality 
assurance reviews, output evaluations, implementation evaluations, programme 
assessments, etc. In the Standards, process evaluations are distinguished from 
monitoring which analyses data during implementation. They are also distinguished 
from outcome evaluations which analyse outcomes for participants.
Standards 4.4: If planning final evaluations; 7.2: If conducting a process evaluation
Programme In the Standards, the sum of one (or several) intervention(s) as well as the 
accompanying research (e.g. needs assessment, monitoring, final evaluations) and 
the surrounding administrative structure (e.g. project management, fundraising, staff 
training, participant recruitment, dissemination, local structures and priorities). Thus, 
the term ‘programme’ is used as an overarching term for all intervention and project 
aspects of prevention work. A governmental strategy for drug prevention can be seen 
as a type of programme. Service work is also included in this definition.
Programme activity see Activity
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Project A time-limited undertaking with a defined purpose. In the Standards, the term is used 
more specifically to refer to administrative work and business matters within a drug 
prevention programme (e.g. resource management). It is distinguished from a strategy, 
which is a broad plan specifying priorities and main activities in drug prevention.
Project cycle see Project stage
Project plan An internal tool to guide implementation, systematically illustrating the main tasks and 
strategies required to deliver the programme. It is produced as soon as the main 
programme elements are defined (e.g. target population, type of intervention). The 
project plan is essential to implement the programme, but also to document and 
review implementation. The project plan is also known as a work plan, action plan, 
or implementation plan. It differs from the programme description which informs 
external parties about the programme.
Standard 5.1: Planning the programme — Illustrating the project plan
Project stage The first level of detail within the Standards. Eight distinct project stages are 
organised chronologically in a project cycle, illustrating the life cycle of a (drug 
prevention) programme from start (needs assessment) to finish (dissemination). The 
centre of the project cycle contains cross-cutting considerations that should be 
reconsidered at each project stage. The project cycle represents a model which, in 
practice, must be adapted to the particular circumstances of projects. The other two 
levels of detail in the Standards are made up of attributes and components.
Programme 
description
In the Standards, a description of the programme with a particular focus on the 
conditions and possible consequences of participation (e.g. price, risks and benefits). 
It is written prior to the start of the intervention to inform external parties about the 
programme (e.g. target population, funders). The programme description is also 
known as a programme outline or a policy (for example, in a school context). The 
programme description differs from the project plan which is an internal tool to guide 
project implementation; it also differs from the final report which summarises the 
programme once it has finished. 
Standard 5.6: Providing a programme description
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Protective factor In the context of drug prevention, a factor that reduces the likelihood of initial drug 
use or the progression to more harmful forms of use. Protective factors can be found 
on different levels, such as individual (e.g. social competence, impulse control, high 
educational attainment), family (e.g. cohesive family unit, care and support, parental 
supervision), peers/community (e.g. norms against drug use), contextual (e.g. high 
socio-economic status). Drug prevention work aims to strengthen protective factors. 
Protective factors are distinguished from risk factors.
Standard 1.4: Understanding the target population
Provider In the context of drug prevention, an organisation that is active in, or contributing to, 
the provision of drug prevention, e.g. drug prevention charity, youth service, school.
Quality standard A benchmark that helps judge whether an activity, a provider, etc. represents high 
quality. Quality standards are typically based upon professional consensus. Their 
main focus is on structural and procedural aspects of quality assurance, e.g. 
evaluation, staff composition and competencies, participant safety, etc. The 
Standards distinguish between quality standards and guidelines.
For specific information about the European drug prevention quality standards, please 
refer to the Introduction.
Quasi-experimental 
design
In outcome evaluation research, a study type where outcomes are measured in the 
intervention group and in the control group before and after the intervention, but 
where participants are not allocated randomly to intervention and control groups. 
Instead, as the intervention group may already be in contact with a service, people 
may be deliberately chosen for the control group to have similar characteristics as the 
people in the intervention group (‘matching’). As allocation is not random, it is more 
likely that (unnoticed) differences between intervention and control groups occur and 
affect the outcomes. This study type is also known as pre-post design with control 
group. Other study types include the non-experimental design and the randomised 
controlled trial.
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Randomisation In outcome evaluation research, the process through which eligible individuals or 
natural groups (e.g. school classes) are randomly assigned to either an intervention 
group or a control group. The assignment is random if each unit (i.e. individual or 
group) has the same chance of being selected for the intervention or the control 
group. This reduces the likelihood of systematic differences between participants in 
the intervention and in the control group. Randomisation is a feature of randomised 
controlled trials.
Randomised 
controlled trial
In outcome evaluation research, a study type involving random allocation of 
individuals or natural groups (e.g. school classes) to intervention groups and control 
groups. Outcomes are measured in both groups before and after the intervention. 
Randomised controlled trials are considered to produce the most robust evidence of 
effectiveness. This study type is also known as experimental design or pre-post design 
with control group and randomisation. A common abbreviation is RCT. Less robust 
study types include the non-experimental design and the quasi-experimental design.
Readiness Stakeholders’ (e.g. target population, community) awareness of drug-related needs, 
and their interest, willingness and ability to support drug prevention activities. Lack of 
target population or community readiness may be a barrier to carrying out 
prevention work. Research has identified distinct stages of community readiness (e.g. 
Plested et al., 1999). 
Standard 2.1: Assessing target population and community resources
Recipient 
organisation
In the Standards, an external organisation (e.g. school, community centre, nightclub) 
within which the intervention is delivered if it is not delivered within the premises of 
the provider. Reasons why an intervention is delivered externally vary, e.g. the 
recipient organisation commissioned the intervention, it provides access to the target 
population on request of the provider, etc. The recipient organisation is also known 
as the host institution.
Recruitment The process of drawing a sample of participants from the wider target population. In 
some interventions, participants are not drawn from the target population, but from a 
group of people who have an influence on members of the target population (e.g. 
family). Recruitment consists of choosing eligible individuals, informing them about 
the programme, inviting them to take part, enrolling them, and ensuring that they 
begin the intervention (e.g. attend the first session). 
Standard 5.4: Recruiting and retaining participants
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Reliability An indicator for the quality of a data collection instrument. An instrument is reliable if 
it produces consistent results, e.g. with the same subjects time after time (‘test-retest 
reliability’), across people who use the instrument (‘inter-rater reliability’), or across 
items within the same instrument (‘internal consistency’). Test-retest reliability is an 
important prerequisite for outcome evaluation; the use of reliable instruments ensures 
that observed changes are due to real changes in participants, and not caused by an 
unreliable evaluation instrument. Other indicators of instrument quality are objectivity 
and validity.
Replication The implementation of an intervention that has already been implemented at least 
once in the past. Replication of existing interventions can be more efficient than 
designing a new intervention, as it utilises existing materials, etc. It is also important 
from a scientific point of view, as it tests whether previously found outcomes can be 
repeated (‘replicated’). If the replication takes place under new circumstances, it also 
tests whether statements about the intervention’s effectiveness can be generalised 
(e.g. to a different target population or setting).
Standard 4.2: If selecting an existing intervention
Resource Money, time, people (e.g. staff members, target population), competencies (e.g. skills, 
knowledge, experience), information, networks, materials (e.g. equipment), etc. that 
are available or required to implement a programme.
Standards 2: Resource assessment; 5: Management and mobilisation of resources
Resource assessment An assessment of all resources that are available to an individual, organisation, 
community, etc., with a particular emphasis on those resources that could be utilised 
in the intended programme (e.g. community readiness). In the Standards, resource 
assessment is distinguished from needs assessment which aims to identify unmet 
needs.
Standard 2: Resource assessment 
Retention The process of ensuring that participants remain in the intervention until it has finished 
or until the goals have been achieved (whichever is more appropriate). 
Standard 5.4: Recruiting and retaining participants
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Risk factor In the context of drug prevention, a factor that increases the likelihood of initial drug 
use or the progression to more harmful forms of use. Risk factors can be found on 
different levels, such as individual (e.g. antisocial behaviour, lack of self-esteem, poor 
school performance), family (e.g. parental drug use, lack of support, lack of parental 
supervision), peers/community (e.g. drug-using peers), contextual (e.g. low socio-
economic status, high drug availability). Drug prevention work aims to reduce risk 
factors. Risk factors are distinguished from protective factors.
Standard 1.4: Understanding the target population
Sample A subset of a population. Participants are a sample of the target population. The 
participant sample should be representative of the target population (i.e. mirror its 
characteristics), so that findings can be generalised to the wider target population. In 
evaluation research, this is best achieved by drawing a random sample so that each 
individual or natural group (e.g. school class) has the same probability of being 
selected into the sample. Random selection can be conducted, for example, by using 
a (computer-generated) table of random numbers. Furthermore, the participant 
sample should be large enough to enable a range of statistical analyses.
Selective prevention In the context of drug prevention, activities that are targeted at individuals with an 
above-average risk of drug use by virtue of their membership in a particular 
population group (adapted from Springer and Phillips, 2007), e.g. school drop outs, 
young offenders, children of drug users, clubbers (see Risk factor). These groups are 
also known as vulnerable populations. 
Service An organisation which is usually commissioned by the government (e.g. local 
authorities) to fulfil people’s needs. For example, social services assist vulnerable 
people with everyday life, such as children in need of support, people with physical 
or mental disabilities, etc. The term can refer both to the organisation itself as well as 
to the work done by this organisation. In Europe, services do not typically implement 
structured, manualised drug prevention programmes. Instead, they are usually 
participant- and needs-led and therefore less structured (e.g. outreach work, drop-in 
centre, brief intervention). Services also often offer generic support in addition to 
specific drug prevention activities, and prevention might not be the primary focus of 
the service. In the Standards, the terms ‘programme’ and ‘intervention’ include service 
work.
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Setting The social and/or physical environment(s) in which the intervention takes place, e.g. 
family, school, workplace, nightclub, community, society. The term can also refer to 
the social and/or physical environment(s) in which people engage in daily activities, 
e.g. work, leisure. The setting is also known as domain, location, environment, or 
implementation level.
Standard 3.4: Defining the setting
Sex In the Standards, the biological characteristics of men and women. ‘Sex’ is 
distinguished from gender which refers to the set of socially constructed roles, 
behaviours, etc. that are considered appropriate for men and women. However, 
some professionals use the terms interchangeably, acknowledging their 
interdependency (e.g. physical ability can influence possibility of activities; 
acceptability of certain activities can influence physiological characteristics).
Short-term outcome see Outcome
Side effect see Iatrogenic effect
Significance see Statistical significance
Staff In the Standards, all individuals working for the organisation that conducts the 
programme, including those working full- or part-time, those who are paid or unpaid 
(e.g. volunteers, interns), and those on permanent or renewable short-term contracts, 
regardless of qualification, experience, or responsibility (e.g. managers, 
administrative staff). In the Standards, the term is also used to refer specifically to 
practitioners, i.e. those in direct contact with the target population. Staff members are 
also known as human resources, personnel, employees, workers, or the workforce.
Standards C: Staff development; 5.3: Setting up the team
Staff development The process of enhancing staff members’ competencies (i.e. knowledge, skills, 
behaviours) through training programmes, regular review, emotional support, 
supervision, encouraging self-reflection, etc.
Standard C: Staff development
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Stakeholder Any individual, group, organisation, etc. who has a vested interest (a stake) in, and/
or who is directly or indirectly affected by, the activities and/or outcomes of the drug 
prevention programme. Examples include: target population, participants, staff 
members, community, recipient organisation, funders, government, media, voluntary 
sector, health and social services, etc.
Standard B: Communication and stakeholder involvement
Standard see Quality standard
Statistically 
significant
A result that is verified by statistical testing to be unlikely to have occurred by chance. 
In outcome evaluation research, the statistical significance of findings is tested to 
understand if, for example, outcomes were really caused by the intervention.
Standard 7.1: If conducting an outcome evaluation
Strategy 1. A broad plan specifying the priorities and main activities of an entire project or 
organisation. In drug prevention, the most important strategies of this type are the 
drugs strategies set up by local, regional, national, and international governments 
(e.g. European Union, United Nations).
Standard 1.1: Knowing drug-related policies and legislation
2. A broad plan specifying the priorities and main activities regarding a particular 
project aspect, such as communication, fundraising, evaluation, documentation, 
dissemination. In the Standards, these strategies are summarised in the project plan.
Standard 5.1: Planning the programme — Illustrating the project plan
Substance see Drug
Supply reduction see Drug demand reduction
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Sustainability 1. The likelihood that a drug prevention programme will continue beyond its initial 
implementation and/or after external funding has stopped, as well as the factors that 
contribute to this likelihood. 
Standards A: Sustainability and funding; 8.1: Determining whether the programme 
should be sustained
2. The likelihood that positive outcomes of the intervention are maintained in 
participants after the intervention has stopped, i.e. that they are found in the long-
term follow-up.
3. The likelihood that the intervention is implemented with high quality once 
programme developers are no longer directly involved (e.g. once the programme has 
been disseminated on a large scale). Sustainability trials seek to determine the 
conditions for continued implementation fidelity (Kellam and Langevin, 2003).
Tailored intervention In the Standards, an intervention that has been adapted to the specific requirements 
of the target population, the setting, etc. in order to maintain or increase its 
effectiveness.
Standard 4.3: Tailoring the intervention to the target population
Target audience In the Standards, people who receive information about the activities and outcomes 
of the programme, e.g. through regular updates during implementation, the final 
report, workshops, etc. Stakeholders such as the target population, funders, the 
professional community, etc. represent common target audiences. 
Standard 8.2: Disseminating information about the programme
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Target population The people towards which the drug prevention intervention is directed, e.g. those 
who are eligible to take part in or receive the intervention, those for who the 
intervention is thought to be effective. The target population may consist of 
individuals, groups, households, organisations, communities, settings, and/or other 
units, as long as they are identifiable and clearly defined. Participants are usually 
drawn from the target population. However, in some interventions, participants are 
not drawn from the target population, but from a group of people who have an 
influence on members of the target population. In these cases, the intermediate target 
population that is eligible to take part in the intervention (e.g. peers, family, teachers) 
is distinguished from the ultimate target population that will be changed indirectly 
(e.g. young people at risk of drug use) (EMCDDA, 1998). The target population is 
also known as the target group. 
Standard 3.1: Defining the target population
Targeted prevention In the context of drug prevention, activities that are targeted at individuals or groups 
with an increased risk of drug use (see Risk factor). There are two types of targeted 
prevention: indicated prevention (increased risk due to an individual characteristic) 
and selective prevention (increased risk due to membership of a certain group). 
Team In the Standards, all staff members working on the programme. Within the team, 
smaller teams can be formed to deal with particular issues, such as fundraising, 
cultural adaptation, evaluation, dissemination, etc. These sub-teams may consist of 
one person only.
Theory see Theoretical model
Theoretical model A set of interrelated assumptions (hypotheses) explaining how and why the drug 
prevention intervention is likely to produce outcomes in the target population. It may 
also explain the rationale behind drug use. The theoretical model helps decide on 
appropriate aims, goals, objectives, mediators, intervention activities, etc. Theoretical 
models are usually based on existing research and theory relating to drug use, health 
promotion, or human behaviour and development in general. Examples of such 
theories include cognitive dissonance theory, social learning theory, normative 
models. The theoretical model is also known as theory, theoretical framework, theory 
of change.
Standard 3.2: Using a theoretical model
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Tiered prevention A prevention approach that gradually progresses from general to more specialised 
interventions. For example, a tiered drug prevention programme may start with a 
universal prevention intervention (e.g. drug education in the classroom). During this 
intervention, individuals with an above-average risk of (harmful) drug use may be 
identified and referred on to take part in an indicated prevention intervention (e.g. 
specialised after-school activity).
Tool see Evaluation tool
Universal prevention In the context of drug prevention, activities that are targeted at groups with an overall 
average risk of drug use (adapted from Springer and Phillips, 2007). Often, such 
interventions will address the entire population within a setting (e.g. school, 
community, society). Universal prevention typically aims to prevent or delay the onset 
of drug use. Individuals or groups with an above-average risk of drug use are not 
singled out (see Risk factor; Targeted prevention).
Validity An indicator for the quality of a data collection instrument. An instrument is valid if it 
actually measures what it is intended to measure. Other indicators of instrument 
quality are objectivity and reliability.
Young people In the Standards, anyone under the age of 18 years, including children. Different age 
ranges may apply where suggested by local, regional, national, or international 
customs, laws, and policies; or where it is more appropriate for the target population, 
setting, intervention, etc.
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